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Abstract 
Myotonic dystrophy type 1 (DM1) is the most common form of muscular 
dystrophy in adults, characterised by multiple tissue involvement and caused 
by an expansion of a (CTG)n repeat within the 3’-UTR of the DMPK gene 
(19q13.3). Normal individuals contain between 5 and 35 CTG repeats, 
whereas the repeats in DM1 patients expand in the range of 50 to several 
thousands. Longer alleles are very unstable and generally always increase in 
size when transmitted from parent to child, explaining the phenomenon of 
anticipation defined by earlier age of onset and an increase in the severity of 
the symptoms.  
Charcot-Marie-Tooth disease (CMT) is a genetically heterogeneous, hereditary 
motor and sensory neuropathy of the peripheral nervous system. To date, 30 
different loci have been mapped and mutations have been identified in more 
than 20 different genes. 
The DM1+CMT++ family is a very unusual three generation family in which all 
patients co-segregate both DM1 and CMT (LOD score = 7.03). It was postulated 
that either a single or two closely linked mutations near the APOC2 marker 
must be the cause of DM1 and CMT.  Southern blot analysis of restriction 
digested genomic DNA revealed a fragment equivalent to a small CTG 
expansion (~200-400) at the DM1 locus, but an expanded allele could not be 
amplified by PCR. We postulated that the expanded repeats may have 
predisposed the repeat tract and the flanking regions to further DNA 
instability, leading to a secondary deletion, insertion and/or rearrangement. 
These novel mutations might modify the expression of DMPK and/or nearby 
genes explaining the unusual clinical presentation.  
To identify the lesion in the DM1+CMT++ family, a variety of molecular 
approaches was performed. The molecular lesion identified was an insertion 
of a GC rich region within the CTG repeats. The allele was comprised of a 
variable number of CTGs at the 5'-end followed by (GGC)3 G (CCG)20 
(CCGCTG)14 (CTG)35. Analysis of single molecule separated alleles revealed 3 
that the interrupted 3'-end of the array was stable, while the CTG repeats at 
the 5'-end were unstable. Postulated mechanisms to explain the DM1 and CMT 
symptoms in the family were: a novel RNA gain-of-function, and/or a novel 
effect on the downstream genes. 
Finding an imperfect CTG repeat allele in the DM1+CMT++ family led us to 
suggest that imperfect CTG repeat alleles may not be unique events and other 
DM1 patients may also contain similar alleles. To investigate this DNA samples 
from 14 DM1 patients with an unusual molecular diagnosis were analysed. The 
majority of these patients presented with an imperfect CTG repeat allele 
containing CCGCTG hexamers and/or CCG repeats. Five patients contained 
two or three higher order repeats containing between 18 and 30 bp such as 
((CTG)5  (CCG)5), ((CTG)2 (CCGCTG)4) and ((CTG)5 (CCG)2 (CCGCTG)). These 
findings further suggest that imperfect CTG repeat alleles might not be as 
rare as was previously believed.  
The results of this project point out the importance of performing a more 
detailed molecular characterisation of the DM1 patients, which could lead to 
the provision of more accurate prognoses and the development of effective 
therapies. 4 
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1  Introduction 
1.1 Dynamic mutations and human diseases 
Dynamic mutations are defined as a change in the mutation rate of the 
product versus the progenitor. In contrast to conventional mutations, which 
are static, these mutations are dynamic and consist of a process of multiple 
steps rather than a single event (Richards and Sutherland 1992). Dynamic 
mutations have been identified in simple tandem repeat sequences 
resulting in variation in the number of repeats. If the repeats are located 
within a gene, an increase in the number might affect the expression of the 
gene or neighbouring genes resulting in disease. A number of human 
disorders have been associated with expanded simple tandem repeats 
including myotonic dystrophy type 1 (DM1), Huntington disease (HD) and 
fragile X syndrome (table 1-1). Additionally, two loci ERDA-1 and CTG18.1 
that are not yet associated with a phenotype have also been associated 
with expanded repeats (Breschel, et al. 1997; Nakamoto, et al. 1997; 
Ikeuchi, et al. 1998). In the general population, the number of repeats is 
usually short (between 5 and 30) and polymorphic. However once the 
repeats reach a certain threshold the alleles become somatically and 
intergenerationally unstable. In the majority of the diseases caused by 
dynamic mutations, longer alleles are associated with an increase in the 
disease severity and decrease in age of onset in successive generations, a 
phenomenon known as anticipation (Cummings and Zoghbi 2000a; Richards 
2001). The expanded repeats are also somatically unstable, with different 
number of repeats arising within different cells and tissues of the same 
individual in a process that is tissue-specific, age-dependant and expansion 
biased. The fact that longer alleles cause more severe phenotype leads to 
the postulate that somatic mosaicism might contribute to the progression 
and severity of the disease (Shelbourne and Monckton 2006).   
Table 1-1. Human disorders caused by dynamic mutations 
              Size of repeats     
Disorder  Type of 
repeat  Normal  Pre-
mutation 
Full 
mutation  Gene  Reference 
Dentatorubral-pallidoluysian atrophy 
(DRPLA)  (CAG)n  7-23  NN  ≥53  ATN1  (Koide, et al. 1994; Nagafuchi, et al. 1994) 
Huntington disease (HD)  (CAG)n  10-34  36-39  ≥40  HTT  (HDCRG, 1993) 
Huntington disease type 2 (HDL2)  (CAG)n  5-18  NN  ≥50  JPH3  (Holmes, et al. 2001b; Stevanin, et al. 2002) 
Spinal and bulbar muscular atrophy, 
X-linked 1 (SMAX1)  (CAG)n  10-36  -  ≥38  AR  (La Spada, et al. 1991) 
Spinocerebellar ataxia 1 (SCA1)  (CAG)n  6-39  -  ≥40  ATXN1  (Orr, et al. 1993) 
Spinocerebellar ataxia 2 (SCA2)  (CAG)n  15-24  -  ≥35  ATXN2 
(Imbert, et al. 1996; Pulst, et al. 1996; Sanpei, et al. 
1996) 
Machado-Joseph disease (SCA3)  (CAG)n  13-44  NN  ≥55  ATXN3  (Kawaguchi, et al. 1994) 
Spinocerebellar ataxia 7 (SCA7)  (CAG)n  7-19  28-35  ≥37  ATXN7  (David, et al. 1997) 
Spinocerebellar ataxia 17 (SCA17)  (CAG)n  25-42  NN  ≥47  TBP  (Fujigasaki, et al. 2001; Nakamura, et al. 2001) 
Spinocerebellar ataxia 12 (SCA12)  (CAG)n  7-45  NN  ≥55  PPP2P2B  (Holmes, et al. 1999; Holmes, et al. 2001a) 
Myotonic dystrophy type 1 (DM1)  (CTG)n  5-35  37-50  ≥80  DMPK 
(Aslanidis, et al. 1992; Brook, et al. 1992; Buxton, et al. 
1992; Fu, et al. 1992; Harley, et al. 1992; Mahadevan, et 
al. 1992) 
Spinocerebellar ataxia 8 (SCA8)  (CTG)n  16-92  NN  ≥100  ATXN8OS  (Koob, et al. 1999) 
Friedreich ataxia (FRDA)  (GAA)n  6-32  33-60  ≥200  FXN  (Campuzano, et al. 1996) 
Myotonic dystrophy type 2 (DM2)  (CCTG)n  up to 26  NN  ~5,000  CNBP  (Liquori, et al. 2001) 
Spinocerebellar ataxia 10 (SCA10)  (ATTCT)n  10-22  NN  ≥800  ATXN10  (Matsuura, et al. 2000) 
Fragile X syndrome *  (CGG)n  5-44  55-200  >200  FMR1  (Fu, et al. 1991; Verkerk, et al. 1991) 
Non-syndromic X-linked mental 
retardation (FRAXE)*  (CCG)n  4-39  31-61  ≥200  AFF2  (Flynn, et al. 1993; Knight, et al. 1993) 
Jacobsen syndrome (JBS) *  (CCG)n  11  80  ≥100  JBS  (Jones, et al. 2000) 
NN (not known); - (not present); *triplet repeats associated with rare folate-sensitive fragile sites (based on OMIM and Entrez gene databases). Claudia Braida, 2008    Chapter 1, 18 
 
The mechanisms involved in the genetic instability of the repeats are not 
clear. It was postulated that the expanded repeats form unusual alternative 
structures that are believed to interfere with the normal process of the cell 
such as replication, recombination and/or repair (Wells 1996; McMurray 1999; 
Sinden, et al. 2002). The mechanisms of pathogenesis vary from disease to 
disease depending on the particular repeat sequence and the location of the 
repeat with respect to the gene. Three main mechanisms have been 
postulated: protein loss-of-function, protein gain-of-function and RNA gain-of-
function (Cummings and Zoghbi 2000b; Galvao, et al. 2001a; Richards 2001).  
1.1.1 Repeat dynamics 
1.1.1.1  Intergenerational instability 
The phenomenon of anticipation was under debate for almost a century. The 
first indication of anticipation in DM1 was reported shortly after the 
description of the disease in 1909. According to Harper, Fleischer reported 
that adult onset patients were often connected to older relatives with 
cataracts, suggesting anticipation in the disease (Fleischer 1918). However, 
Penrose postulated (in 1948) that the anticipation described might not be a 
true phenomenon and in contrast suggested a simple ascertainment bias 
(Penrose 1948). Therefore, anticipation was assumed as an artefact for almost 
forty years until Howeler and colleagues presented enough evidence against 
ascertainment bias (Howeler, et al. 1989). The study comprised the analysis 
of 14 DM families and showed a decrease in the fertility of affected men in 
the second or third decade, the congenital cases were always transmitted 
from affected mothers, and a decrease in the age of onset in the child in 
more than 60 parent-child pairs. These findings demonstrated that 
anticipation in DM was a true phenomenon. 
Sherman postulated that anticipation in fragile X syndrome was also observed 
in families, but not as an increase in the severity and a decrease of age of 
onset as in DM. In contrast, increased penetrance was observed in later 
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men who by their position in the pedigree must have carried the mutant X 
chromosome but did not display the disease. Typically, an asymptomatic male 
carrier transmitted the mutation to his daughters (generally asymptomatic) 
and subsequently the daughters transmitted the mutated allele to affected 
sons. This phenomenon was known as the Sherman paradox. However, at that 
time, there was no molecular explanation available to explain anticipation 
either in DM or in fragile X syndrome (Sherman, et al. 1984; Sherman, et al. 
1985). However, shortly afterwards, first the Sherman paradox was resolved 
in 1991 with the finding that a CGG repeat expansion was responsible for 
fragile X syndrome, and then in 1992, it was found that anticipation in DM1 
was explained by an expansion of CTG repeats (Fu, et al. 1991; Verkerk, et al. 
1991; Aslanidis, et al. 1992; Brook, et al. 1992; Buxton, et al. 1992; Harley, et 
al. 1992). In both cases, the number of repeats increases through generations 
and the repeats must reach a certain threshold to become pathogenic. 
Subsequently, anticipation was considered as one of the characteristics of 
diseases caused by dynamic mutations. 
Intergenerational instability can be modified differently according to the sex 
of the parent transmitting the mutant allele. In some disorders, the repeats 
are more unstable and prone to long expansions when transmitted by the 
mother as in fragile X syndrome (Nolin, et al. 1996).  However, in DM1, short 
expansions are generally more unstable when transmitted by males and long 
expansions associated with congenital cases are almost always transmitted by 
females (Brunner, et al. 1993a; Harley, et al. 1993; Lavedan, et al. 1993; 
Ashizawa, et al. 1994b; Jansen, et al. 1994). The polyglutamine diseases are 
caused by an expansion of CAG repeats within the coding region. In HD in 
particular, the repeats are highly unstable when transmitted from father to 
child, but are generally more stable when transmitted by the mother (Kremer, 
et al. 1995). The mechanism involved in the differential parental origin of 
transmission is not yet fully understood. 
It has been a challenge to model intergenerational instability in DM1 mouse 
models. Small changes in repeat size were widely reproduced in mouse 
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DM1 patients have not been recreated in mouse (Gourdon, et al. 1997; 
Monckton, et al. 1997). However, it was reported recently that the transgenic 
mouse line DM300-328 containing 300 CTG repeats in 45 Kb of human genomic 
sequence from the DM1 locus showed increases in 250-480 CTG repeats trough 
transmissions. This model reproduced the dramatic increases observed in DM1 
patients, but not the parental effects (Gomes-Pereira, et al. 2007). 
Therefore, the validity of this model should be confirmed before it could 
represent a tool to further investigate the underlying mechanisms of 
intergenerational instability.  
1.1.1.2  Somatic mosaicism 
In DM, as well as in other repeat diseases, the expanded alleles are often 
visualised as a diffuse smear by Southern blot of restriction digested genomic 
DNA, suggesting somatic mosaicism (Aslanidis, et al. 1992; Buxton, et al. 
1992; Fu, et al. 1992; Harley, et al. 1992). Subsequently, it was demonstrated 
by small pool PCR (SP-PCR) that the smears could be resolved into individual 
alleles containing different numbers or repeats, revealing the instability of 
the repeats (Monckton, et al. 1995b; Wong, et al. 1995). The rate of 
instability is different amongst the disorders. In DM1, somatic mosaicism has 
been closely examined and it was determined that the expanded alleles in 
skeletal muscle are always larger than in lymphocytes (Anvret, et al. 1993; 
Ashizawa, et al. 1993; Thornton, et al. 1994; Monckton, et al. 1995b). 
Additionally, the expanded repeats increase with the age of the individual. In 
congenital cases sampled at birth, there is practically no heterogeneity and 
the expanded alleles are detected as single bands instead of smears. 
However, as the age at sampling increases the level of heterogeneity 
increases throughout the life of the individual (Wong, et al. 1995; Martorell, 
et al. 1998). Therefore somatic mosaicism has a tendency to be age-
dependant, tissue-specific and expansion-biased.  
Somatic mosaicism has been reproduced in a number of transgenic mouse 
models and in cell culture (Scherzinger, et al. 1997; Lia, et al. 1998; Fortune, 
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DM1 transgenic mouse models, it was shown that the average length in muscle 
was always higher than in lymphocytes, consistent with DM1 patients 
(Fortune, et al. 2000). In HD knock-in mouse models, it was shown that mice 
carrying>72<CAG<80 repeats show high levels of instability in the striatum and 
a low level in peripheral tissues, whereas mice carrying ~150 repeats not only 
show a high level of instability in the striatum but also in other brain regions 
and in peripheral tissues (e.g. liver). These results reveal a striking 
correlation with the disorder phenotype since the earliest and most severe 
defects are seen in the neurons of the striatum, suggesting that somatic 
mosaicism probably contributes towards the progression and severity of the 
disease (Kennedy and Shelbourne 2000; Kennedy, et al. 2003). As a result, it 
was shown that dynamics of the repeats in mouse reproduce the properties 
observed in humans including age-dependance, tissue-specificity and 
expansion-bias.  
1.1.2 Modifiers of repeat dynamics 
The repeat dynamics of simple tandem repeats is a complex process with 
several factors involved. These factors have been classified into two groups: 
factors that are directly associated with the repeats (cis-acting modifiers) and 
factors contributing to the instability through interactions with the repeat 
(trans-acting modifiers)(Richards 2001; Cleary and Pearson 2003; Pearson, et 
al. 2005) 
1.1.2.1  Cis-acting modifiers of genetic instability 
A number of cis-acting factors have been identified to modify the instability 
of triplet repeats: the sequence and the number of repeats, the presence of 
interrupting repeat units and the content of the flanking sequences. Only 
certain specific triplet repeats are unstable and the most common motif is 
(CNG)n. This is probably because these repeats can form stable unusual DNA 
structures which may interfere with normal processes such as replication and 
repair leading to genetic instability (Chen, et al. 1998; Pearson and Sinden 
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than longer ones, and interrupted alleles are more stable than pure repeat 
tracts (Ashley and Warren 1995). However, the repeats become unstable only 
when they reach a critical size threshold. A study revealed that expanded 
repeats at HD, SCA7, SCA1 and DM1 loci are more unstable than repeats at 
the MJD, SBMA, CTG18.1 and DRPLA loci. The difference in the stability was 
correlated with the GC content in the flanking DNA; more unstable loci have a 
higher GC content in the flanking DNA. It is not clear how the level of GC 
content in the flanking DNA affects the instability of the repeats. Possible 
mechanisms involve alterations in the chromatin structure and/or methylation 
status (Brock, et al. 1999). The effect of the flanking DNA on the repeat 
instability was reproduced in DM1 mice models. Monckton and colleagues 
generated five transgenic mouse lines incorporating expanded CTG repeats 
derived from the human DM1 locus. One of the lines (Dmt-D) was significantly 
more unstable than the others. All lines carry similar sizes of CTG repeats and 
the differences were mediated by the site of integration in the mouse 
genome. These results indicated that the genetic instability not only depends 
on the size of the repeats, but also depends on the effects of the flanking DNA 
(Monckton, et al. 1997). 
1.1.2.2  Trans-acting modifiers of genetic instability 
The dynamics of tandem repeats are affected by: sex of transmitting parent, 
tissue specificities and age of the individual. Therefore, there must be 
specific factors responsible for these processes, but these factors have not 
been identified yet (Gomes-Pereira, et al. 2006). Other trans-acting modifiers 
were postulated to be proteins involved in cellular processes such as 
replication, repair and recombination. Until now, the only proteins identified 
to act as trans-acting factors are: MSH2, MSH3 and PMS2. These proteins are 
involved in mismatch repair and it was demonstrated that the absence of 
these proteins in mouse models reduce the level of instability (Manley, et al. 
1999; van den Broek, et al. 2002; Savouret, et al. 2003; Wheeler, et al. 2003; 
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1.1.3 Mechanisms of genetic instability 
The mechanisms involved in the genesis of expanded repeats are not yet 
clear. It has been reported that the triplet repeat regions have sequence 
motifs and symmetry elements that cause an increase in flexibility and the 
formation of a number of novel structures (at least in vitro). The number and 
complexity of potential structures becomes pronounced as the repeats 
increase in number and these unusual structures may alter normal processes 
including replication, recombination and/or repair leading to genetic 
instability (Wells 1996; McMurray 1999; Sinden, et al. 2002).  
Data from humans and mouse models revealed that genetic instability 
generally occurs at different rates in different tissues, and is an expansion-
biased and cell-division-independent process. The instability frequently occurs 
to a higher degree in cells that do not divide such as neurons and muscle 
cells, in contrast with cells that divide frequently such as lymphocytes 
(Anvret, et al. 1993; Ashizawa, et al. 1993; Thornton, et al. 1994; Kennedy, 
et al. 2003). A question arises about the mechanism responsible for the 
variability of the repeats in cells that do not divide or do not undergo 
recombination. The accumulated evidence does not support a role of 
replication slippage and recombination contributing to genetic instability. In 
contrast, a mismatch repair mechanism might be the major mechanism 
responsible for genetic instability (Manley, et al. 1999; van den Broek, et al. 
2002; Savouret, et al. 2003; Wheeler, et al. 2003; Gomes-Pereira, et al. 
2004b).  
1.1.4 Mechanism of pathogenesis 
The pathways leading to the disease phenotype vary from disease to disease 
depending on the particular repeat unit and the location of the repeat with 
respect to the gene. A gain-of-function mechanism was postulated for 
disorders caused by repeats located in coding regions. In contrast, if the 
repeats are in non-coding regions, generally multiple tissue dysfunctions are 
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gain-of-function level and/or modification of chromatin structure (Cummings 
and Zoghbi 2000b; Galvao, et al. 2001b; Richards 2001). Recent evidence 
suggests that more than one mechanism might be involved in diseases such as 
DM1, SCA3, SCA8, SCA10, SCA12 and HDL2 (Gatchel and Zoghbi 2005; Li, et al. 
2008).  
1.1.4.1  Diseases caused by a protein loss-of-function 
In the group of diseases caused by protein loss-of-function, the pathogenesis 
is caused by transcriptional silencing of the gene resulting in a loss of protein 
function. Diseases in this group include: fragile X syndrome, fragile XE 
syndrome and Friedreich ataxia (FRDA). Fragile X syndrome is the most widly 
studied disease in this group and so will be described as an example.  
Fragile X syndrome is the most common cause of inherited mental retardation 
(Morton, et al. 1997). The mutation responsible is an expansion of (CGG)n 
located in the 5’ untranslated region of the fragile X mental retardation 1 
gene (FMR1), which maps to chromosome Xq27.3 (Fu, et al. 1991; Verkerk, et 
al. 1991). The length of the repeat is polymorphic in the general population 
ranging from 6 to 52 repeats, and generally containing 1 to 3 AGG 
interruptions, typically at every tenth repeat. However, when the repeats 
expand to more than 230 repeats (full mutation), the CpG island in the FMR1 
promoter region and the repeats become abnormally hypermethylated and 
generally there is no production of protein, which gives rise to the pathogenic 
phenotype (Bell, et al. 1991; Pieretti, et al. 1991; Eichler, et al. 1994). 
Alleles between 60 and 230 repeats (premutation) are generally unmethylated 
and unstable when they are transmitted through generations (Feng, et al. 
1995). Initially, the intermediate alleles were believed to be non-pathogenic, 
however recently they have been associated with ovarian failure in women 
and fragile X associated tremor ataxia syndrome (FXTAS) in men (Murray 2000; 
Hagerman and Hagerman 2004). Intermediate alleles are associated with an 
RNA gain-of-function mechanism and not a loss-of-function (described in 
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1.1.4.2  Diseases caused by a protein gain-of-function 
The polyglutamine diseases are a group of dominant inherited 
neurodegenerative diseases caused by an expansion of CAG repeats located in 
the coding region of the respective gene.  These include: HD, 
dentatorubralpallidoluysian atrophy (DRPLA), spinal and bulbar muscular 
atrophy, X-linked (SMAX1) and spino-cerebellar ataxia type 1 (SCA1), 2 (SCA2), 
3 (SCA3), 6 (SCA6), 7 (SCA7) and 17 (SCA17) (Zoghbi and Orr 2000; Nakamura, 
et al. 2001). A protein gain-of-function was proposed as the main mechanism 
inducing neurodegeneration in the polyglutamine diseases (Zoghbi and Orr 
2000). Generally, the expansions into the pathogenic range induce a 
conformational change in the protein involved leading to the formation of 
aggregates within the cells in the brain. These aggregates are sequestered in 
inclusions with chaperones and components of the ubiquitin-proteosome 
system. However, there is still controversy regarding the toxicity of these 
inclusion bodies, some lines of evidence suggest they represent a cellular 
protective response (Gatchel and Zoghbi 2005; Ross and Poirier 2005). Recent 
evidence from a SCA3 Drosophila model suggests that the expanded CAG 
repeats in the RNA may also have a pathogenic role in the polyglatumine 
diseases, contributing to the neuronal degeneration (Li, et al. 2008). 
Therefore, as in other diseases caused by dynamic mutations, more than one 
mechanism seems to be involved in the pathogenesis. 
1.1.4.3  Diseases caused by an RNA gain-of-function 
In this group of diseases, the expanded repeats in the RNA are postulated to 
cause disease by titration of specific RNA CNG-binding proteins that are 
normally responsible for regulating the processing of multiple RNAs. The 
diseases included are: myotonic dystrophy type 1 and type 2 (described in 
detail in section 1.2.2.3), FXTAS, spinocerebellar ataxia type 8 (SCA8), 10 
(SCA10), 12 (SCA12) and Huntington disease like 2 (HDL2) (Ranum and Cooper 
2006).  
FXTAS is a disorder that affects more than one third of the adult male carriers 
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involve intention tremor, ataxia, parkinsonism and generalised brain atrophy 
(Hagerman, et al. 2001). Increased levels of FMR1 mRNA were shown in 
individuals with alleles in the premutation range, suggesting an RNA gain-of-
function mechanism to explain the pathogenesis (Tassone, et al. 2000a; 
Tassone, et al. 2000b; Hegde, et al. 2001). Subsequently, intranuclear 
ubiquitin-positive inclusions containing FMR1 mRNA were observed in neurons 
and astrocytes in autopsies of FXTAS patients (Greco, et al. 2002). The 
protein composition of the intranuclear inclusions was investigated by 
fluorescence-activated flow sorting and mass spectrometry analysis (Iwahashi, 
et al. 2006). More than 20 different proteins were identified including: hnRNP 
A2, a number of neurofilaments and lamin A/C (proteins associated with 
different forms of Charcot-Marie-Tooth disease) and MBNL1 one of the RNA 
binding proteins interacting with CUG repeats that is recruited in DM1 and 
DM2 nuclear foci (described in section 1.2.2.3). As a result, it was postulated 
that intermediate alleles might lead to an RNA-mediated neurodegenerative 
phenotype.  
A "knock-in" mouse model previously generated by replacing the endogenous 8 
CGG repeats with 98 CGG repeats was investigated further.  It was observed 
that these mice had increased levels of FMR1 mRNA and intranuclear 
ubiquitin-positive inclusions consistent with those observed in FXTAS patients 
(Willemsen, et al. 2003). Similarly, a Drosophila transgenic line generated 
using the 5'-UTR of the human FMR1 gene containing 90 CGG repeats and ~200 
bp of flanking DNA, reproduced the neuronal degeneration and the formation 
of nuclear inclusions (Jin, et al. 2003). These results indicated that 
intermediate CGG repeats are probably responsible for generating the 
intranuclear inclusions that lead to a neurodegenerative phenotype. 
A similar mechanism seems to be present in patients carrying AFF2 
intermediate alleles. AFF2 is a gene located 600 Kb distal to the FMR1 gene 
and is associated with non-syndromic X-linked mental retardation (Gecz, et 
al. 1996; Gu, et al. 1996; Gecz 2000; Gu and Nelson 2003). The intermediate 
alleles of AFF2 were believed to be non-pathogenic. However, a higher than 
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AFF2 premutation alleles (~40 CCG) (Annesi, et al. 2004). A transgenic 
Drosophila model carrying ~90 CCG repeats was generated to investigate 
whether AFF2 intermediate alleles may also lead to an RNA-mediated 
neurodegenerative phenotype similar to the FXTAS. Indeed a 
neurodegenerative phenotype with nuclear inclusions with similar 
characteristics to the ones detected in FXTAS was observed. Additionally, it 
was demonstrated that the co-expression of both CCG and CGG repeats in 
Drosophila rescues independently their neuronal degeneration by the RNAi 
mechanism. Further investigations are required to explain how the RNA gain-
of-function model could explain the phenotype observed in these diseases, 
and to evaluate the possibility of developing novel therapies using the RNAi 
pathway (Sofola, et al. 2007). 
1.2 Myotonic dystrophy  
Myotonic dystrophy is an autosomal dominant, inherited disease characterised 
by myotonia, muscular dystrophy, cataracts, cardiac conduction defects and 
abnormalities in a number of other organs. DM is a heterogeneous group of 
disorders with two different genetic causes identified so far. These are a CTG 
repeat expansion in the DMPK gene causing myotonic dystrophy type 1 (DM1) 
and a CCTG repeat expansion in the CNBP gene causing myotonic dystrophy 
type 2 (DM2). Both mutations consist of repeat tracts that are transcribed, but 
not translated, suggesting a similar mechanism of pathogenesis based on a 
gain-of-function by toxic RNA containing either expanded CUG or CCUG 
repeats. It could be possible that there are other forms of myotonic dystrophy 
(Ashizawa and Harper 2006). For instance, Le Beer and colleagues identified a 
French family with a phenotype consistent with DM and an additional 
frontotemporal dementia. The patients did not have the DM1 or DM2 
mutations and have been mapped to chromosome 15q21-24 (Le Ber, et al. 
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1.2.1 Myotonic dystrophy type 1 
1.2.1.1  Clinical manifestations 
DM1 is the most common form of muscular dystrophy in adults and is 
characterised by multiple tissue involvement including skeletal myotonia, 
progressive myopathy, cataracts and abnormalities in the heart, brain and 
endocrine systems. Clinical expression of the disorder is variable and the 
patients are classified according to the age of onset as: late-onset, adult-
onset, childhood-onset or congenital (Harper 2001). 
In the late-onset form, the most common finding is a distinctive form of 
cataract characterised by discrete subcapsular opacities that are iridescent 
under slit lamp examination (Harper 2001). 
In the adult-onset form, the symptoms become evident in mid-life, but 
sometimes some signs may become apparent in the second decade. Initially in 
DM1, the distal muscles of the extremities are affected and then the proximal 
musculature. A general weakness and atrophy of the facial muscles causes the 
characteristic haggard appearance. The involvement of the extraocular 
muscles produces ptosis, weakness of eyelid closure. The weakness of facial, 
jaw and palatal muscles generally result in speech disturbances, which are 
sometimes confused with a lower IQ. Myotonia, a delayed ability to relax the 
grip, is commonly observed in the tongue, forearm and hand. Myotonia is the 
most characteristic symptom of DM and can be detected with an 
electromyogram. The central nervous system is also involved and several 
abnormalities can be observed: daytime somnolence (one of the symptoms 
about which relatives complain most), fatigue, depression and personality 
changes. Other systemic features include: cardiac conduction defects, insulin 
resistance and gastrointestinal abnormalities. The gastrointestinal 
involvement could directly or indirectly be the cause of death by aspiration 
due to pharyngo-oesophageal dysfunction. General anaesthesia can be life 
threatening if certain anaesthetics are used (Harper 2001). In males, early 
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In the childhood-onset form, symptoms such as facial weakness, myotonia and 
cardiac conduction defects as in the adult-onset form are also evident. In 
addition, low IQ and other psychological problems are present.  
The clinical features of the congenital form are very severe and include 
generalised hypotonia, respiratory problems, craniofacial abnormalities, 
feeding difficulties and talipes. Those whose survive early childhood will 
develop mental retardation, and the symptoms of the classical form when 
they reach adulthood (Harper 2001). 
1.2.1.2  Genetic features 
In 1992, the DM1 mutation was identified as an expansion of a (CTG)n repeat 
located in the 3’-untranslated region (UTR) of the DM protein kinase gene 
(DMPK) (Aslanidis, et al. 1992; Brook, et al. 1992; Buxton, et al. 1992; Harley, 
et al. 1992) and in the promoter of  the downstream gene SIX5 mapped to 
chromosome 19q13.3 (figure 1-1) (Boucher, et al. 1995). In normal 
individuals, the DM1 locus is highly polymorphic and contains 5 to 35 copies of 
the repeat. In DM1 patients, the repeat is expanded in the range of 50 to 100 
in those mildly affected, 200 to 1000 in those with the adult classical form 
and more than 1000 in those with the congenital form (IDMC, 2000). The 
expanded alleles (with >50 repeats) are genetically highly unstable and nearly 
always increase in length when transmitted from parent to child, resulting in 
anticipation with an increase of disease severity and earlier age of onset in 
successive generations. In the first generation, the affected patients present 
few or no symptoms. In the second generation, the classical adult form is 
observed. In the third generation, a congenital case is expected through 
maternal transmissions (Harper 2001). However, contractions occasionally 
occur through transmissions (less than 10%) (Ashizawa, et al. 1994a), and very 
rarely a reverse mutation (decrease in size to the normal range) can occur 
(Shelbourne, et al. 1992; Brunner, et al. 1993b; Hunter, et al. 1993; O'Hoy, et 
al. 1993; Shelbourne, et al. 1993). Interestingly, a gene conversion event was 
suggested in one of the cases of reverse mutation. The father transmitted his 
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normal range. Haplotype analysis of six markers revealed that at least 7.2 Kb 
of the DM1 chromosome including the CTG repeats were exchanged with the 
normal chromosome (O'Hoy, et al. 1993). Strikingly, the reverse mutation is 
associated with an affected father in all reported cases. Moreover, data from 
small pool PCR analysis comparing somatic and sperm cells give more 
evidence suggesting that this process might be specific to the male germline 
since reversions into the normal range were only seen in sperm samples 
(Monckton, et al. 1995b).To investigate the effects of long CTG repeats in the 
flanking DNA, plasmids containing 17, 98 and 175 CTG repeats adjacent to the 
GFP gene were used to transform different strains of E. coli. The study 
revealed that long repeats promote deletions and inversions in the flanking 
DNA, suggesting that a possible similar mechanism could also be present in 
DM1 patients (Wojciechowska, et al. 2005). 
 
Figure 1-1. Diagram of the DM1 and DM2 loci. A. The gene DMPK is located in chromosome 
19q13.3 in a region of high gene density. The CTG repeats are located in the 3'-UTR of the 
DMPK. The transcription initiation site of SIX5 is located very closed to the polyadenilation site 
of DMPK (less than 300 bp) and the enhancer of SIX5 is located in between (Filippova, et al. 
2001). B. The gene CNBP is located in chromosome 3q.21 in not a very gene dense region. 
The CCTG repeats located in the first intron of CNBP gene are included in a complex repeat 
motif (TG)n (TCTG)n (CCTG)n. The coding regions are indicated in black and the untranslated 
regions in grey (diagram based on Entrez gene database).  
A significant correlation exists between the number of repeats and the 
severity of the clinical symptoms in lymphocytes.  A negative correlation 
exists between the age of onset and the number of repeats. However, these                                  
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information on the severity of the symptoms or the age at onset based on the 
number of repeats (Ashizawa, et al. 1992; Harley, et al. 1993; Lavedan, et al. 
1993; Novelli, et al. 1993a; Redman, et al. 1993). By taking into account the 
progenitor allele and the age at sampling, it was demonstrated that better 
estimation of the severity and age of onset of the disease could be provided 
(Morales 2006).  
1.2.1.3  Population genetics 
The global incidence of DM1 is estimated to be 1 in 8,000 adults. However, in 
certain regions such as in the Sanguenay region of the province of Quebec it is 
as high as 1 in 475 adults, while it is extremely rare among ethnic Sub-Saharan 
Africans (Mathieu, et al. 1990; Ashizawa and Epstein 1991). A founder effect 
was suspected to be the cause of the high prevalence of DM in the Sanguenay 
region. To test the hypothesis, a genealogical reconstruction of 88 DM1 
families was performed. It was demonstrated that all the patients could be 
traced to a unique couple, supporting a founder effect (Mathieu, et al. 1990). 
Subsequently, linkage disequilibrium between the DM1 mutation and a number 
of polymorphisms located in the flanking DNA at both ends of the CTG repeats 
was observed (Harley, et al. 1991). One of the polymorphisms extensively 
studied is the intragenic Alu repeat insertion/deletion polymorphism located 
in intron 8 of DMPK (figure 1-1). The insertion allele (Alu+) was found to be in 
complete association with the DM expansion in Caucasian and Japanese 
populations (Harley, et al. 1992; Mahadevan, et al. 1992; Yamagata, et al. 
1992). The analysis of the structure of the Alu repeat and its presence in 
primates suggested that the ancestral allele is the Alu+ (Rubinsztein, et al. 
1994). Krahe and colleagues described an exception in a Nigerian family, 
where the DM1 mutation was associated with the Alu- allele, suggesting that 
this family probably carries a de novo mutation (Krahe, et al. 1995). Neville 
and colleagues extended the analysis and investigated eight more polymorphic 
sites spanning a region of ~40 Kb. Several haplotypes with different 
frequencies were defined in Caucasian and Japanese populations, but the DM1 
mutation is in linkage disequilibrium with the most common haplotype (A) 
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hypothesis that the DM1 mutation appears to be the result of one or a few 
ancestral mutations.  
DM1 is characterised by low reproductive fitness, affected males frequently 
develop testicular atrophy, adult-onset mothers generally transmit long 
alleles to their children and congenital or child-onset forms occurs. 
Therefore, expanded alleles are generally lost in just three or four 
generations. If there is indeed an ancestral mutation in DM1, there must exist 
a pool of alleles from where new expanded alleles can arise. Imbert and 
colleagues proposed a model to explain the generation of new CTG repeats 
expansion. The authors found that the distribution of the normal alleles in 
Caucasians was trimodal with major frequencies observed in alleles containing 
(CTG)5, (CTG)11-13 and (CTG) 19-30. The  (CTG)5 and (CTG)19-30 were found 
completely associated with the Alu+ allele, whereas (CTG)11-13 was associated 
with the Alu- allele. It was postulated that the repeat expanded from (CTG)5 
to (CTG)19-30 by a small number of events, and that the latter represents the 
pool from where the DM1 mutation now  arises (Imbert, et al. 1993). 
Martorrell and colleagues performed an extensively study in 700 DM1 families 
and provided evidence to support this model. The authors demonstrated: the 
trimodal distribution of normal alleles, small increases in sizes through 
transmissions in alleles containing (CTG)19-33, and dramatic increases in sizes 
through male transmissions in alleles with (CTG)37-54 (Martorell, et al. 1998). 
Even though there still no direct evidence showing the jump from (CTG)5 to 
(CTG)19-30, all the data obtained up to now supports the model of this 
ancestral mutation.  
1.2.1.4  The DMPK protein 
The DMPK gene consists of 15 exons and encodes a serine-threonin protein 
kinase. In the full length protein, five domains can be distinguished: a 
leucine-rich repeat amino terminal region, a catalytic domain with the kinase 
function, VSGGG peptide with an unknown function, a coiled coil domain and 
a carboxy terminal region (Brook, et al. 1992; Fu, et al. 1992; Jansen, et al. 
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six principal mRNA isoforms are generated, differing in the presence or 
absence of the VSGGG motif and the nature of the carboxy terminus (Fu, et 
al. 1993; Groenen, et al. 2000). There is another minor isoform that carries a 
different carboxy-terminus and lacks the CUG repeats, and consequently is 
not retained in the nucleus in DM1 patients unlike the other isoforms 
(Tiscornia and Mahadevan 2000). Analysis of 16 monoclonal antibodies 
revealed that DMPK is expressed almost exclusively in skeletal, cardiac and 
smooth muscle (Lam, et al. 2000). The function of DMPK is not completely 
understood. Potential roles include sodium channel regulation in skeletal 
muscle (Mounsey, et al. 2000), membrane trafficking (Dunne, et al. 1996; Jin, 
et al. 2000), calcium homeostasis (Benders, et al. 1997) and as a regulator of 
the myogenic pathway (Bush, et al. 1996).  
1.2.2 Mechanism of DM1 pathogenesis  
The basis of DM1 pathogenesis is not yet fully understood.  Three models were 
originally proposed to explain how the repeat expansion in a non-coding 
region could result in myotonic dystrophy. The models are: haploinsufficiency 
of DMPK, altered expression of neighbouring genes and a toxic gain-of-
function at the RNA level.  
1.2.2.1  Haploinsufficiency of DMPK 
It was proposed that the expansion of CTG reduces the level of DMPK in cis. 
The levels of mRNA and protein levels were investigated in tissues and cell 
lines from DM1 adult-onset and congenital patients. However, the data is 
contradictory, since some studies detected a decrease in the levels of mRNA 
and protein (Carango, et al. 1993; Fu, et al. 1993; Hofmann-Radvanyi, et al. 
1993; Novelli, et al. 1993b), whereas others show an increase in the mRNA 
levels (Sabouri, et al. 1993; Laurent, et al. 1997). Subsequently, a decrease in 
the levels of poly(A)+mRNA compared to the total RNA was demonstrated, 
indicating that hnRNA containing expanded CUG may not be adequately 
processed into poly(A)+mRNA (Wang, et al. 1995). Furthermore, it was shown 
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periphery of nuclear splicing speckles, preventing its translocation to the 
cytoplasm where it would normally be translated into protein resulting in 
haploinsufficiency of DMPK protein (Taneja, et al. 1995; Davis, et al. 1997; 
Hamshere, et al. 1997; Holt, et al. 2007). This nuclear retention could explain 
why some studies observed a decrease in the levels of mRNA and others found 
an increase. To investigate the biological role and the involvement of DMPK in 
myotonic dystrophy, transgenic mouse overexpressing DMPK and knockout 
mouse models were developed. Initially, only a partial phenotype with mild 
progressive skeletal myopathy and abnormalities in cardiac conduction was 
reproduced in young mice overexpressing DMPK (Jansen, et al. 1996; Reddy, 
et al. 1996; Berul, et al. 1999). However, it was shown subsequently that 
older mice (11-15 months) with 25 extracopies of the human DMPK gene with 
11 CTG repeats developed skeletal and smooth muscle abnormalities together 
with cardiac defects resembling the symptoms observed in DM1 patients. An 
overexpression of DMPK is not observed in DM1 patients, and therefore the 
validity of the model could be questioned. However, the authors postulated 
that the overexpression of DMPK with 11 CTG repeats mimics the effects of 
transcripts containing expanded CTG repeats (O'Cochlain, et al. 2004). 
Despite this evidence, the haploinsuficiency of DMPK is not sufficient to 
explain the multisystemic phenotype of DM1.The overexpression of DMPK 
reproduced many but not all of the aspects of DM1. There are still no DM1 
patients identified with point mutations in the DMPK gene and a second form 
of DM is caused by an expansion of CCTG at another locus. 
1.2.2.2  Effects on neighbouring genes 
The effects on neighbouring genes was suggested by the fact that the CTG 
repeat is a strong positioning element for nucleosomes (known to repress 
transcription) with the efficiency of nucleation increasing with the number of 
repeats (Wang, et al. 1994; Otten and Tapscott 1995; Wang and Griffith 
1995). The expansion of repeats may alter the structure of the local 
chromatin, affecting the expression not only of DMPK but also of the 
contiguous genes. Adjacent to the CTG repeat at the DM1 locus, there is a 
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within a CpG island that regulates the transcription of the adjacent gene sine 
oculis homeobox orthologue 5 (SIX5) (Boucher, et al. 1995). In addition, two 
CTCF binding sites flanking the CTG repeat tract were identified to form an 
insulator (Filippova, et al. 2001). In congenital cases, the CpG island is 
methylated (Steinbach, et al. 1998), the chromatin becomes more condensed, 
the CTCF protein cannot have access to the sites, the activity of the insulator 
is compromised with the consequence that gene expression is altered. It is 
possible that the levels of DMPK are increased whereas the levels of SIX5 are 
decreased, explaining the more severe phenotype of congenital cases 
(Filippova, et al. 2001; Cho, et al. 2005). 
SIX5 encodes for a protein that belongs to a family of homeobox proteins and 
is widely expressed in adult tissue including skeletal muscle, heart, brain and 
eye (Boucher, et al. 1995; Winchester, et al. 1999). Two studies 
demonstrated a significant reduction of the levels of SIX5 mRNA in DM1 
patients (Klesert, et al. 1997; Thornton, et al. 1997), however two other 
studies failed to detect any difference (Hamshere, et al. 1997; Eriksson, et al. 
1999). Cataracts and cardiac conduction deficits were demonstrated in SIX5 
knockout mice (Klesert, et al. 2000; Sarkar, et al. 2000; Wakimoto, et al. 
2002). Kirby and colleagues, from studies with d-Six4 (the SIX5 homologue in 
Drosophila), demonstrated that this is required for the normal development of 
muscle and the mesodermal component of the gonad. Consequently, 
deficiencies in SIX5 may contribute toward cataracts, muscle wasting, 
testicular atrophy and cardiac conduction deficits in DM1 (Kirby, et al. 2001). 
Indeed, Sarkar and colleagues showed in SIX5 knock-out mice that SIX5 is 
required for the viability and maturation of sperm cells and suggest that 
deficiencies in SIX5 expression could cause the reproductive defects in DM1 
males (Sarkar, et al. 2004).  
The other gene located next to DMPK gene is dystrophia myotonica-containing 
WD repeat motif (DMWD), which is located upstream of DMPK and is mainly 
expressed in testis and brain (figure 1-1) (Jansen, et al. 1992; Jansen, et al. 
1995). A reduction in the RNA levels of DMWD was reported in the cytoplasm 
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(Alwazzan, et al. 1999), but other studies showed no differences in the level 
of RNA (Alwazzan, et al. 1999; Eriksson, et al. 1999). Further studies are 
needed to determine if there is a clear reduction in the levels of DMWD and 
subsequently to relate the reduction with the testicular atrophy and/or 
abnormalities in the central nervous system observed in DM1 patients. 
1.2.2.3  RNA-mediated pathogenesis 
The RNA-mediated pathogenesis mechanism postulates that the expanded 
CUG repeats in the RNA cause the disease by titration of specific RNA CUG-
binding proteins that are normally responsible for regulating the processing of 
multiple RNAs. Consistent with this hypothesis, it was shown that the 
transcripts containing expanded CUG repeats accumulate in the nucleus 
(Taneja, et al. 1995; Davis, et al. 1997; Holt, et al. 2007) and the CUG 
repeats fold into stable double-strand RNA hairpin structures in vitro 
(Napieraa and Krzyosiak 1997; Michalowski, et al. 1999), recruiting specific 
RNA CUG-binding proteins and the loss of function of these protein leads to 
myotonic dystrophy (Miller, et al. 2000; Fardaei, et al. 2001). To investigate 
this mechanism, a transgenic mouse model was generated by inserting into 
the final exon of human skeletal actin (HSA) gene either ~250 CTG repeats 
(HSA
LR) or ~5 repeats (HSA
SR). The mouse with the expanded repeats (HSA
LR) 
developed myotonia, myopathy and RNA foci characteristic of DM1, whereas 
those expressing the short repeats (HSA
SR) were normal. These results 
indicated that the expanded CUG repeats are toxic and sufficient to produce 
most of the clinical features of DM1 in skeletal muscle (Mankodi, et al. 2000). 
Similarly, Seznec and colleagues generated another transgenic mouse model 
(DM300) by inserting ~300 CTG repeats plus flanking DNA from DM1 patients. 
The mice exhibit abnormalities in skeletal muscle and abnormal tau 
expression in the brain consistent with symptoms observed in DM1 patients. 
These mice differ from the HSA
LR in that the expression of repeat-containing 
RNA is not limited to skeletal muscle and that the repeats are expressed 
within their natural context. These results provide further evidence for the 
RNA gain-of-function mechanism not only in muscle, but also in brain (Seznec, 
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Two families of proteins were identified as playing a critical role in the 
regulation of alternative splicing. One of these families consists of CUG triplet 
repeat RNA-binding protein 1 (CUGBP1) and ETR3-like factors (CELFs), and the 
other families is the muscle-blind like (MBNL) proteins (Miller, et al. 2000; 
Fardaei, et al. 2001; Ladd, et al. 2001). 
The CELF family is widely expressed in adult tissues with the highest levels in 
skeletal muscle, heart and brain; six genes have been identified in humans 
(Timchenko, et al. 1996b; Lu, et al. 1999; Good, et al. 2000; Ladd, et al. 
2001). CUGBP1 was initially characterised by electrophoretic mobility 
bandshift assay interacting with single stranded RNA containing CUG repeats 
(Timchenko, et al. 1996b). Subsequently, an increase in the levels of CUGBP1 
in the nucleus was observed in lymphoblast cells lines of DM1 patients and in 
homozygous DMPK knockout mice (Timchenko, et al. 1996a; Roberts, et al. 
1997). Similarly, an increased expression of ETR-3 in skeletal and cardiac 
muscle was detected, suggesting that the function could be altered leading to 
defects in alternative splicing (Savkur, et al. 2001; Timchenko, et al. 2001). It 
was shown that the levels of CELF proteins increase, but the proteins do not 
co-localise with the expanded transcripts.  
The other family of RNA-binding proteins involved in DM1 pathogenesis is 
MBNL. Three proteins were identified in humans, namely MBNL1, MBNL2 and 
MBNL3, which all interact in vitro with CUG repeats and co-localise with the 
nuclear foci of DM1 and DM2 patients (Miller, et al. 2000; Fardaei, et al. 2002; 
Mankodi, et al. 2002; Kanadia, et al. 2003). The loss of MBNL protein was 
postulated to play a role in DM1 pathogenesis. To investigate this hypothesis, 
an Mbnl1 knockout model was developed. The mice showed defects similar to 
those seen in DM1 such as myotonia, ocular subcapsular cataracts and 
misregulation of splicing in a number of pre-mRNAs (Kanadia, et al. 2003). 
Furthermore, it was demonstrated that the overexpression of Mbnl1 was 
sufficient to rescue the myotonia and misregulation of splicing in skeletal 
muscle in HSA
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CELF and MBNL proteins might function antagonistically regulating the 
alternative splicing of specific mRNAs. CELF acts during development 
promoting the inclusion of fetal exons, whereas MBNL promotes fetal exon 
skipping and expression of adults isoforms. In DM1 patients, the decrease of 
MBNL, and the increase of CELF cause a misregulation of the alternative 
splicing with the result that fetal isoforms are present in adult tissues (Ho, et 
al. 2004). In DM1, an increasing number of pre-mRNA are shown to present 
defects in alternative splicing including cardiac troponin T (TNNT2) (Philips, 
et al. 1998), insulin receptor (IR) (Savkur, et al. 2001), muscle-specific 
chloride channel (CLCN1) (Charlet, et al. 2002; Mankodi, et al. 2002), brain 
microtubule-associated tau (Sergeant, et al. 2001) and mytoubularin-related 
1 (MTMR1) (Buj-Bello, et al. 2002). Altered expression of one of the isoforms 
of IR has been observed in skeletal muscles from DM1 patients providing an 
explanation for the insulin resistance observed among them (Savkur, et al. 
2001). The alternative splicing of CLCN1 was investigated in skeletal muscle 
from transgenic DM mouse models (HSA
LR) and in muscle tissue from DM1 
patients. A loss of function of CIC-1 due to splicing defects and the 
development of myotonia was correlated with the level of expanded CUG 
repeats (Charlet, et al. 2002; Mankodi, et al. 2002). Alternatively, to 
investigate if the increase in the levels of CUGBP could reproduce the defects 
in alternative splicing observed in DM1, a transgenic mouse-overexpressing 
CUGBP1 in skeletal muscle and heart was generated. The mice developed 
skeletal muscle pathological features similar to DM1 tissues and defects in the 
alternative splicing of at least three pre-mRNAs: CLCN1, TNNT2 and MTMR1 
(Ho, et al. 2005). 
1.2.3 Myotonic dystrophy type 2 
1.2.3.1  Clinical manifestations 
Myotonic dystrophy type 2 was previously known as proximal myotonic 
myopathy (PROMM) and is characterised by: proximal muscle weakness, 
muscle pain and stiffness, cataracts, myotonia, cardiac complications and 
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facial weakness in a number of patients. The symptoms are generally milder 
than in DM1 and there are no congenital cases reported. The clinical 
expression of the disease is highly variable even within families (Day, et al. 
2003). 
1.2.3.2  Genetic features 
In 1998, a DM family that did not carry the DM1 mutation was shown by 
linkage analysis to map to chromosome 3q.21 (Ranum, et al. 1998). It was not 
until 2001 that the mutation was found to be a CCTG repeat expansion 
located in the first intron of the CNBP gene (Liquori, et al. 2001). The CCTG 
repeat is part of a complex repeat motif (TG)n (TCTG)n (CCTG)n (figure 1-1). 
Normal individuals contain up to 26 CCTG that are generally interrupted, 
whereas patients contain uninterrupted expanded alleles with a mean of 
~5,000 repeats (Liquori, et al. 2001). In contrast to DM1, genetic anticipation 
is not clearly demonstrated in DM2 families. A decrease in the age of onset 
through generations is observed, but an increase in the numbers of repeats 
have not been demonstrated due to the high levels of somatic mosaicism that 
complicated the analysis (Day, et al. 2003). 
1.2.3.3  Mechanism of pathogenesis 
The parallels in the clinical and molecular aspects of DM1 and DM2 led to the 
postulation of an RNA gain-of-function model to explain the pathology of DM2 
(Ranum and Cooper 2006). Using patient derived myoblast cells lines and 
skeletal muscle biopsies, it was shown that mutant CNBP pre-mRNA is spliced 
normally, the mRNA is exported from the nucleus and the protein is produced 
normally in the cytoplasm. Nevertheless, the CCUG repeats are retained in 
the nucleus similar to the DM1 repeats indicating that the CCUG expansions 
might cause DM2 (Margolis, et al. 2006). The content and location of the DM2 
foci are different from DM1 foci. DM2 foci are widely dispersed in the 
nucleoplasm and contain just the CCUG repeats, whereas DM1 foci 
accumulate at the periphery of nuclear speckles and contain mutant 
processed DMPK mRNA (Holt, et al. 2007). The RNA gain-of-function 
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however there are some differences between both diseases that cannot be 
explained. DM2 is generally milder and a congenital form is not detected and 
the weakness is mainly proximal. It was postulated that these differences 
could be explained by alternative mechanisms such as effects on neighbouring 
genes and/or haploinsufficiency of DMPK. Further comparisons between DM1 
and DM2 will help to understand the complex mechanism of pathogenesis (Day 
and Ranum 2005). 
1.3 Charcot-Marie-Tooth (CMT) disease 
In 1886, Charcot and Marie in France simultaneously with Tooth in England 
described the clinical features of a hereditary motor and sensory neuropathy 
(HMSN) disorder that was later referred as Charcot-Marie-Tooth disease. CMT 
is a group of genetically heterogeneous, inherited neuropathies affecting 
motor and sensory nerves of the peripheral nervous system (Shy 2004).  CMT is 
the most common inherited neuromuscular disease with an estimated 
prevalence of 1 per 2,500 individuals (Skre 1974). 
1.3.1 Clinical manifestations 
CMT is characterised by progressive distal muscle wasting and weakness 
starting in the lower limb and later affecting also the upper extremities, 
distal sensory loss, decrease or absence of tendon reflexes, and foot 
deformities such as pes cavus (Harding and Thomas 1980). In addition, hearing 
loss is observed in 5% of patients with CMT (Pareyson, et al. 1995). The 
clinical expression of CMT is highly variable, not only between families but 
also within families and only occasionally results in severe impairment 
(Pareyson 1999). 
CMT is classified into two main groups according to the nerve conduction 
velocity (NCV). CMT1 (the demyelinating type) is characterised by motor 
median nerve conduction velocity less than 38 m/s and CMT2 (the axonal 
type) with normal or slightly reduced nerve conduction velocities (≥ 45 m/s). 
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defined (Davis, et al. 1978; Harding and Thomas 1980). Further subdivisions 
depend on the inheritance pattern, which can be: autosomal dominant, 
autosomal recessive or X-linked. The classification is not straightforward, 
because different mutations in the same gene cause different phenotypes 
(Suter and Scherer 2003). 
1.3.2 Genetic features and mechanism of pathogenesis 
In 1982, Bird and colleagues showed by linkage analysis that the mutation in 
some families with CMT1 mapped to chromosome 1 (Bird, et al. 1982). 
Subsequently, studies on DNA polymorphism showed that most patients 
showed linkage to chromosome 17 (Vance, et al. 1989). These results 
provided the first evidence of locus heterogeneity (mutations in different 
genes causing a similar phenotype) for CMT. Furthermore, allelic 
heterogeneity (mutations in the same gene causing a different phenotype) 
was also demonstrated (Suter and Scherer 2003). To date, mutations causing 
CMT have been mapped to 30 different loci and more than 20 different genes 
have been identified. However there are still patients with an unknown 
aetiology, indicating that there are still a number of mutations remaining to 
be identified (http://www.molgen.ua.ac.be/CMTMutations/default.cfm).  
The majority of CMT patients (40%-50%) carry a 1.5 Mb duplication on 
chromosome 17p11.2-p12, including the peripheral myelin protein 22 (PMP22) 
gene (Raeymaekers, et al. 1989; Vance, et al. 1989; Matsunami, et al. 1992; 
Timmerman, et al. 1992; Valentijn, et al. 1992). PMP22 is a small membrane 
protein involved in the correct development of peripheral nerves, 
determination of myelin thickness, and maintenance of axons (Adlkofer, et al. 
1995). Other genes mutated in CMT patients include: myelin protein zero 
(MPZ or PO), gap junction binding 1 (GJB1), glycil-tRNA synthetase (GARS), 
lamin A/C nuclear envelope protein (LMNA) and dynamin2 (DNM2) (Suter and 
Scherer 2003; Pareyson 2004; Barisic, et al. 2008). MPZ is the major 
peripheral myelin protein and mutations may affect Schwann cell-neuron 
interactions causing defective myelination of peripheral nerves (Martini and 
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protein localized at the nodes of ranvier and involved in transportation within 
the cell. GARS is a housekeeping gene encoding an aminoacyl tRNA synthetase 
that plays a role in translation. Mutations in GARS might affect protein 
synthesis necessary for motor neuron maintenance and integrity (Antonellis, 
et al. 2003). Lamins are structural proteins of the nuclear lamina and 
mutations can cause defective nuclear mechanics and impaired mechanically 
activated gene transcription (Lammerding, et al. 2004). DNM2 is implicated in 
vesicular trafficking and endocytosis (McNiven 1998). In summary, the 
mechanisms of pathogenesis identified to date include: Schwann cell function, 
disruption of axonal transport or intracellular trafficking, heat shock proteins 
and ubiquitous housekeeping enzymes.  
1.4 DM1+CMT++ family 
The DM1+CMT++ family is the first reported DM1 family in which all affected 
members also have an intermediate type CMT neuropathy. Co-incidence of 
DM1 and CMT has been observed in a number of patients (Rogoff and Ziegler 
1956; Caccia, et al. 1972; Panayiotopoulos and Scarpalezos 1976; Borenstein, 
et al. 1977; Cros, et al. 1988; von Giesen, et al. 1994), but CMT is not a 
recognized feature of DM1 (Harper 2001). The proband in the DM1+CMT++ 
family was a 65-year-old woman  (II-25, figure 1-2) presenting features of the 
classical adult form of DM1 such as characteristic myopathic fascies, distal 
muscle weakness, percussion myotonia and myotonic discharges on EMG. In 
addition, she presented features of CMT such as reduced motor conduction 
velocity (~60% of normal) and slight sensory loss in the lower limbs. 
Subsequently, her eldest son (III-7) was investigated and he also presented 
symptoms of the classical adult form of DM1 including frontal balding and 
testicular atrophy, together with features of CMT including pes cavus, 
increased lumbar lordosis and slight distal sensory loss in the legs. 
Furthermore, signs of axonal degeneration and regeneration, demyelination 
and remyelination, and many small onion bulbs were detected in a sural nerve 
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A family study was undertaken and 12 more cases were identified (detailed 
information of the DM1 and CMT symptoms are shown in table 1-2 and 1-3 
respectively). Previous generations were also investigated but it seems that 
the disorders have occurred only among the descendants of I-6 and I-9. Both  
I-6 and I-9 were described by their offspring as having no motor disability and 
lived apparently healthy lives until 79 and 85 years of age respectively 
(Spaans, et al. 1986). Taking into account the results of nerve biopsy studies 
in III-7 and III-9 and the values of motor conduction velocity being in the range 
of 25 to 45 m/s, the disease has been classified as an intermediate type CMT 
neuropathy (Spaans, et al. 2008). 
Anticipation is observed in classic DM1 families, however anticipation in the 
DM1+CMT++ family, was not completely detected. Both individuals in the first 
generation were asymptomatic, but one of them probably transmitted the 
mutant allele to five of their daughters who developed late-onset DM1. A 
decrease in the age of onset and an increase in the severity of DM1 symptoms 
were observed between the second and third generation. Nevertheless, no 
congenital cases were detected in the last generation, despite four adult-
onset affected maternal transmissions (Spaans, et al. 1986; Brunner, et al. 
1991). All patients in the fourth generation are intelligent, energetic, 
obtained university degrees and are employed in highly skilled jobs. The first 
generation has not been investigated, however one of them probably carried 
the DM1+CMT++ allele but with the number of CTG at the 5'-end not enough to 
be pathogenic. Unexpectedly for CMT, an increase in the severity of symptoms 
and decrease in the age of onset was observed between the third and fourth 
generation (Spaans, et al. 2008).  
 
Figure 1-2. Pedigree of the DM1+CMT++ family. The symptoms present in the affected members appeared only among the descendants of I-6 and I-9, both 
were described by their offspring as having no motor disability and lived apparently healthy lives until 79 and 85 years of age respectively. I-6 worked as butcher 
and farmer until he died. The individual II-26 refused to be examined but she must be an obligatory carrier. The age of the deceased is indicated (diagram 
obtained from Monckton, unpublished data). Claudia Braida, 2008    Chapter 1, 45 
Table 1-2. Summary of DM1 symptoms 
  Cataract  Myotonic  Weakness  Muscular  Percussion  Cardiac  Age of 
    discharges    atrophy  myotonia  involvement  Onset (years) 
II-24  +  +  NN  -  -  -  NN 
II-25  +  ++  +  +  +  -  50 
II-27  +  ++  -  -  -  -  NN 
II-28  +  +++  +  +  ++  -  55 
III-1  ±  -  -  -  -  -  NN 
III-7  +  +++  ++  ++  +  -  28 
III-9  +  +++  +  +  -  +  25 
III-12  +  +++  ++  ++  +  -  25 
III-16  +  -  +  +  -  -  44 
III-17  +  +  -  -  -  +  35 
IV-19  -  +  +++  +++  +  -  20 
IV-20  -  -  +  +  +  -  24 
IV-21  -  -  +  ±  ±  +  17 
IV-22  +  -  -  -  ±  -  24 
NN (not known), + (present), - (absent), ± (moderate). 
Table 1-3. Summary of CMT symptoms. 
  Distal sensory  Absent  Absent   MNCV  SNCV  Pes cavus  Age of 
  disturbances  knee jerk  ankle jerk  (m/s)  (m/s)    Onset (years) 
II-24  +  +  +  40  NR  -  ND 
II-25  ±  -  +  38  30  -  ND 
II-27  +  -  -  45  NR  -  ND 
II-28  ±  +  +  31  NR  -  ND 
III-1  ±  -  -  48  NR  -  ND 
III-7  +  ±  +  27  NR  +  28 
III-9  +  ±  +  39  NR  +  25 
III-12  +  ±  +  42  NR  -  25 
III-16  +  -  -  44  NR  ±  32 
III-17  -  -  -  33  NR  -  35 
IV-19  ++  -  -  39  NR  ++  10 
IV-20  +  +  +  23  NR  ±  17 
IV-21  -  -  +  27  NR  -  12 
IV-22  -  -  +  44  NR  -  4 
MNCV (motor conduction velocity) normal value >40-45 m/s, SNCV (sensory nerve 
conduction velocity) normal value ≥42m/s. NR (no response with distal nerve stimulation), + 
(present), - (absent), ± (moderate), ND (not determined). 
The mode of inheritance of DM1 and CMT was classified as autosomal 
dominant and complete co-segregation was shown by linkage analyses. Both 
diseases co-segregated with the ApoC2 locus with a maximum LOD score of 
7.04 with zero recombination (Brunner et al. 1991). The molecular Claudia Braida, 2008    Chapter 1, 46 
diagnosis of DM1 was performed in II-27, III-9, III-16, III-17, IV-19, IV-20, IV-
21 and IV-20 by Southern blot analysis of restriction digested genomic DNA 
by PCR and by repeat primed-PCR (RP-PCR). Small expansions (~200-400 
CTG repeats) were detected by Southern blot, but the expanded allele 
could not be amplified either by PCR or RP-PCR. Mutations in genes most 
frequently associated with CMT (PMP22 and in GJB1) were investigated (Shy 
2004). III-7 was screened for a duplication in PMP22 and IV-21 for mutations 
in GJB1, but no abnormalities were detected. Standard cytogenetic studies 
(GTG-banded analysis) and FISH analysis with probes specific for band 
19q13 and the subtelomerics regions of chromosome 19 revealed no 
abnormalities in III-9 and III-16 (Spaans, et al. 2008). As a result, a single or 
two or more closely linked mutations were suggested to be the cause of 
DM1 and CMT.  
A number of patients (II-25, II-26, II-28, III-7, III-9, III-16, III-17 and IV-22) 
were identified as suffering from migraine-like headache attacks. In 
addition, II-28, III-9, III-16 and III-17 from about 50 years of age, developed 
several bouts of acute encephalopathy (figure 1-2). The symptoms observed 
included headache, confusion, fever, encephalographic abnormalities and 
impaired consciousness. II-28 and III-9 developed coma on more than one 
occasion. Disorders presenting similar symptoms include familial hemiplegic 
migraine type 1 (FHM1) and type 2 (FHM2), and cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL). FHM1 can be caused by mutations in the calcium channel gene 
(CACNA1A) (Ophoff, et al. 1996), FHM2 by mutations in a gene enconding 
the alpha-2 subunit of the sodium/potassium pump (ATP1A2) (De Fusco, et 
al. 2003) and CADASIL by mutations in NOTCH3 (Joutel, et al. 1996). 
Screening of these genes in III-9 did not reveal any abnormalities (Spaans, 
et al. 2008). 
Hearing loss at a relatively young age was also observed in most of the 
patients. Apparently, II-26, II-27, II-28 and III-12 developed hearing loss 
before 45 years old as reported by their relatives. Audiologic data of III-9, 
III-16, III-17 and IV-19 revealed severe to profound bilateral sensorineural 
hearing loss in excess for their age (Spaans, et al. 2008). Mutations in more Claudia Braida, 2008    Chapter 1, 47 
than 20 different genes have been associated with autosomal dominant 
impaired hearing (Finsterer and Fellinger 2005). 
The complex symptomatology observed in the DM1+CMT++ family has been 
extensively studied, however the molecular lesion still remains to be 
defined. Additional studies at the molecular level will be required to 
delineate the nature of the mutation or mutations responsible for DM1, 
CMT, acute encephalopathy and hearing loss. 
1.5 Aims of the project 
The molecular diagnosis of myotonic dystrophy type 1, in most of the cases, 
is a straightforward procedure where an expansion of (CTG)n in the DM1 
locus is detected by Southern blot of restriction digested genomic DNA, PCR 
and/or RP-PCR. In the DM1+CMT++ family an expanded allele was detected 
by Southern blot analysis, but PCR and RP-PCR failed to detect an expanded 
allele. It was postulated that an additional lesion might be responsible of 
the complex symptomatology. Taking into account the evidence obtained in 
bacteria carrying long CTG repeats. It was postulated that the expanded 
repeat at the DMPK locus may also predispose the repeat tract and flanking 
regions to further instability, generating a putative break where deletions 
and/or rearrangements might occur. These novel mutations might not be 
identified with the standard techniques and could modify the expression of 
DMPK and/or other genes, explaining the symptomatology observed in the 
DM1+CMT++ family. Additionally, there are a number of DM1 sporadic 
patients with an unusual molecular diagnosis, which might also present 
these novel mutations.  
A series of molecular approaches will be carried out to investigate the 
nature of the molecular lesion responsible for the symptomatology 
observed in the DM1+CMT++ family and in a number of other sporadic DM1 
cases with unusual molecular diagnosis. It is hoped that the definition of 
the mutation in this family will shed light on the pathogenic pathways not 
only in this family but also in classic DM1. A comparison between the 
similarities and/or differences of the findings with the DM1+CMT++ family Claudia Braida, 2008    Chapter 1, 48 
and the sporadic DM1 patients will be necessary to design novel molecular 
diagnostic tools for myotonic dystrophy patients and also for patients with 
a clinical diagnosis of Charcot-Marie-Tooth disease with an unknown 
aetiology. 
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2  Materials & Methods 
2.1 Materials 
Chemicals, molecular biology reagents and plastic ware were obtained from 
standard suppliers such as: Fisher Scientific, Invitrogen, Merck Ltd., 
Promega, Sigma, unless stated otherwise. Oligonucleotides were obtained 
from Sigma-Genosys. 
2.2 Techniques 
All kits and reagents were used following the manufacturer's instructions 
unless stated otherwise. 
2.2.1 DNA extractions 
DNA was isolated from various sources: Nucleon kit (Amersham Biosciences) 
to extract DNA from blood samples; QIAquick PCR Purification Kit and 
QIAquick Gel Extraction Kit (Qiagen) to purify DNA from PCRs and from 
agarose gel slices, respectively; and QIAprep spin miniprep kit and endofree 
plasmid maxi kits (Qiagen) to isolate plasmid DNA. The concentration of 
DNA was determined with a Nanodrop ND-100 Spectrophotometer. 
2.2.2 PCR 
2.2.2.1  Standard reaction 
Genomic DNA (20 ng) was amplified in a 10  µl reaction, with 1 µM of each 
primer, 1U of Taq DNA polymerase (Bioline) and 1X PCR buffer (45 mM 
Tris•HCl pH 8.8, 11 mM ammonium sulphate, 4.5 mM MgCl2, 0.048% 2-
mercaptoethanol, 4.4 µM EDTA, 1 mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM 
dTTP, 0.113 mg/ml BSA). 10% DMSO was added when it was required. The 
reactions were performed in a thermal cycler (Biometra) cycled through 28-Claudia Braida, 2008    Chapter 2, 50 
 
30 rounds of (96°C for 45 sec, annealing temperature (AT) for 45 sec, 70°C 
for 3 min), AT for 1 min and 70°C for 10 min. The sequences of the primers 
and the annealing temperatures are listed in table 2-1 and table 2-2. 
Table 2-1. Forward primers within the DM1 locus 
Name  5'-3' Sequence  Target sequence  AT1/AT2 (°C) 
DM-T*  AGTCCCAGGAGCCAATCAGAG  5'-end of CTG repeat tract  68 
DM-H  TCTCCGCCCAGCTCCAGTCC  5'-end of CTG repeat tract  68/63.5 
DM-A  CAGTTCACAACCGCTCCGAGC  5'-end of CTG repeat tract  68/63.5 
DM-C  AACGGGGCTCGAAGGGTCCT  5'-end of CTG repeat tract  68/63.5 
DM-Cc  GGCTCGAAGGGTCCTTGTAG  5'-end of CTG repeat tract  68 
BAB452  CTGCTGCTGCTGCTGGG  within the repeat tract  66 
DM-GGC  TGCTGCTGCTGCTGGGCGGCG  repeat in DM1+CMT++ family  66 
DM-M  CACGTTTTGGATGCACTGAGAC  3'-end of CTG repeat tract  68 
DMEcoF* ATCTCGTCTGGCAGCAGTTT  EcoRI site in LOC38553 gene   64.5 
* Primers were designed using the Primer3 website (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). AT1 (without DMSO) AT2 (in presence of 10% DMSO) 
Table 2-2. Reverse primers within the DM1 locus 
Name  5'-3' Sequence  Target sequence 
AT1/AT2 
(°C) 
DM-CR  AGGACCCTTCGAGCCCCGTTC  5-end of CTG repeat tract  68 
DM-ER  AAATGGTCTGTGATCCCCCCA  3-end of CTG repeat tract  68 
DM-DR  CAGGCCTGCAGTTTGCCCATC  3-end of CTG repeat tract  68/63.5 
DM-BR  CGTGGAGGATGGAACACGGAC  3-end of CTG repeat tract  68/63.5 
DM-GR  GCAGGGCGTCATGCACAAGAAA  3-end of CTG repeat tract  68 
DM-SR  TCCCCGAAAAAGCGGGTTTGG  3-end of CTG repeat tract  64 
DM-MR  GTCTCAGTGCATCCAAAACGTG  3-end of CTG repeat tract  68 
DM-QR  CACTGTGGAGTCCAGAGCTTTG  3-end of CTG repeat tract  68/63 
3PBR  GGAACGGGCTAGAAAGTTTGCAGC  3-end of CTG repeat tract  68 
3PCR  CCATCGGGACAACGCAGAAGGTAAC  3-end of CTG repeat tract  68 
3PDR  CAGCGTGTGCTTCTGGCTCAG  3-end of CTG repeat tract  68 
SIX-ER*  CAGGCAAGGTAGCCATGTTT  Exon 1 SIX5 gene  61 
SIX-IR*  AGCGCTCCTTGAAGCAGTAG  Exon 1 SIX5 gene  64.4 
DMEcoR* GCCTATGGGACTTTGCACAT  EcoRI site in LOC38553 gene  64.5 
* Primers were designed using the Primer3 website (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). AT1 (without DMSO) AT2 (in presence of 10% DMSO) 
 
2.2.2.2  Repeat Primed-PCR (RP-PCR) 
RP-PCR was performed similarly to standard PCR for 28 cycles with the 
addition of three primers: TAG, a specific flanking primer and the primer Claudia Braida, 2008    Chapter 2, 51 
 
with a target sequence within a repeat tract coupled with a 5'-end tail 
(TAG) used at a final concentration of 0.1 µM. The sequences of the 
primers and the annealing temperatures are listed in table 2-3.  
Table 2-3. Primers selected for RP-PCR 
Name  Sequence (5'-3') 
Target 
sequence 
AT1/AT2 
(°C) 
TAG  TCATGCGTCCATGGTCCGGA  none  68/65 or 67 
TAG-GTC  TCATGCGTCCATGGTCCGGATGCTGCTGCTGCTGC  (CTG)≥5  68/65 
TAG-AGC  TCATGCGTCCATGGTCCGGAAGCAGCAGCAGCAGCAGC  (CTG)≥5  68/65 
TAG-
CCGCTG  TCATGCGTCCATGGTCCGGACCGCTGCCGCTGCCGCTG  (CCGCTG)≥3  68/67 
TAG-
CAGCGG  TCATGCGTCCATGGTCCGGACAGCGGCAGCGGCAGCGG  (CCGCTG)≥3  68/67 
TAG-
CCTGCTG  TCATGCGTCCATGGTCCGGACCTGCTGCCTGCTGCCTG  (CCTGCTG)≥3  68 
TAG-GCC  TCATGCGTCCATGGTCCGGACCGCCGCCGCCGCCGCCG  (CCG)≥5  68/65 
TAG-GGC  TCATGCGTCCATGGTCCGGAGCGGCGGCGGCGGCGGCG  (CCG)≥5  68/65 
AT1 (without DMSO) AT2 (in presence of 10% DMSO) 
2.2.2.3  Small pool PCR (SP-PCR) 
To investigate the dynamics of the DM1 alleles SP-PCR was performed as 
previously described (Monckton, et al. 1995b). The DNA samples were 
digested with HindIII and serially diluted in (1xTE and 0.1 µM of forward 
primer).  A standard PCR was carried out for 28 cycles in the presence of 
10% DMSO with primers DM-A and DM-DR. In the absence of DMSO the 
following modification was carried out: 1 µl of DNA was amplified in a final 
volume of 7 µl containing 0.2 µM of each primer (DM-C and DM-DR), 0.35 U 
of Taq DNA polymerase (SIGMA) in 1X PCR buffer. 
To investigate the degree of somatic mosaicism at least 100 single 
molecules were sized for each sample. To determine the number of input 
molecules two procedures were followed by amplifying a low concentration 
of DNA. If the degree of variation was very high, the different alleles were 
counted directly, assuming that each band arose from a single allele. 
However, if the degree of variation was low and single alleles were not 
resolved the average number of input molecules was estimated according 
to the Poisson distribution. The ratio of positive to negative reactions (f(0)) Claudia Braida, 2008    Chapter 2, 52 
 
was calculated and the average number of input molecules could be 
estimated by 
  
m =  ln f 0 ( ) ( )(Gomes-Pereira, et al. 2004a). 
f(0) = (total number of reactions - number of reactions yielding a product)               
                                 total number of reactions  
 
2.2.2.4  Vectorette PCR 
Genomic DNA (1 µg) was digested overnight with 5U of the restriction 
enzyme of choice in the presence of 1 mM of spermidine in a final volume 
of 20 µl. The enzyme was heat inactivated for 20 min either at 65°C or 
80°C. The doublestranded linker oligo was annealed as follows: 2.5 µg of 
two oligos of choice (table 1-5), 167 mM NaCl, 17 mM MgCl2, 17 mM Tris-HCl 
in 20 µl were placed in a tube and placed in a beaker of boiling water, 
removed and cooled slowly to room temperature. The choice of linker 
oligos depended on the enzyme used to digest the genomic DNA (detailed in 
table 2-5). The digested DNA (1 µg) and 2 µg of linker were ligated at 16°C 
overnight in the presence of 200 U of T4 DNA ligase and 1X T4 ligase buffer 
(50 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 1mM ATP and 25 µg/ml BSA) in 
a total volume of 100 µl. A control ligation was performed by removing 10 
µl of the reaction and adding 500 ng of HindIII digested λDNA. The control 
ligation was resolved on an agarose gel to check the ligation efficiency. 
Excess linker was removed by incubating the ligation reaction at 95 °C and 
performing an ammonium acetate precipitation immediately. The 
remaining ligation reaction (90 µl) were mixed with 1/3 volume of 10 M NH4 
acetate (pH 7) and 1 1/3 volume of isopropanol. The DNA was collected by 
centrifugation in a bench top microcentrifuge (10 min at 13,000 RPM). The 
supernatant was decanted off, the pellet was rinsed with 1ml of 80% 
ethanol and the DNA pellet was recovered as above. The DNA pellet was air 
dried in a laminar flow hood for ~20 min and dissolved in 100 µl of water. A 
volume of 1 µl of each vectorette library was subjected to 30-cycles of PCR 
with a specific primer located in the flanking DNA and the vectorette TAG 
primer (the sequences of the TAG primers are listed in table 2-4). A second Claudia Braida, 2008    Chapter 2, 53 
 
round of 25-cycles hemi-nested or nested-PCR was performed using a 200-
fold dilution of the primary PCR. 
2.2.3 Restriction Digestion 
Restriction digests were performed following the supplier's 
recommendation unless otherwise stated; the enzymes were obtained 
either from Promega or New England Biolabs. 
2.2.3.1  Restriction digest of genomic DNA 
Genomic DNA (5 µg) was digested with 5 U of either EcoRI or PstI in 1X 
recommended buffer and 100 µg/ml of BSA in a final volume of 50 µl. 
Reactions were incubated overnight at 37°C. The EcoRI-digested products 
were resolved on a 0.7% agarose gel and the PstI-digested products on a 1% 
agarose gel. 
2.2.3.2  Restriction mapping to characterise interruptions within the 
CTG repeat tract in the DM1+CMT++ mutant allele 
A 10-fold dilution of the PCR product generated with flanking primers was 
digested with 5 U of Fnu4HI, AciI, HhaI or MspA1I in a final volume of 20 µl 
at 37°C for 1 hour. The products were resolved on a 1.5% agarose gel and 
detected by Southern blot hybridisation either with the DM1 CTG repeat 
probe or the 5'-end probe.  
Table 2-4. Vectorette primers 
Name  Sequence (5'-3')  AT (°C) 
TAG2  TGGTCATCCGGAGGTGTGAG  68 
TAG3  TCCGGAGGTGTGAGCTGATT  68 
TAG4  TCATGCGTCCATGAGTGGCCGGAT  68 
Table 2-5. Oligos used to generate linkers 
Oligo  Sequence (5'-3')  Oligo  Sequence (5'-3')  Enzyme 
V-SU  GATCGGACTTGCTACGGTAATCAG   V-NL-TAG2  TGGTCATCCGGAGGTGTGAGCTGATTACCGTAGCAAGTCC  BamHI, Sau3A1 
V-CG  CGGGACTTGCTACGGTAATCAG   V-NL-TAG2  TGGTCATCCGGAGGTGTGAGCTGATTACCGTAGCAAGTCC  TaqI 
AciI 
V-AATT AATTGGACTTGCTACGGTAATCAG  V-NL-TAG2  TGGTCATCCGGAGGTGTGAGCTGATTACCGTAGCAAGTCC  EcoRI 
V  GGACTTGCTACGGTAATCAG   V-NL-TAG4-ACGT  TCATGCGTCCATGAGTGGCCGGATCTGATTACCGTAGCAAGTCCTGCA  PstI 
V  GGACTTGCTACGGTAATCAG   V-NL-TAG4-GC  TCATGCGTCCATGAGTGGCCGGATCTGATTACCGTAGCAAGTCCCG  HhaI 
V-TA  TAGGACTTGCTACGGTAATCAG   V-NL-TAG4  TCATGCGTCCATGAGTGGCCGGATCTGATTACCGTAGCAAGTCC  MseI 
V-CG  CGGGACTTGCTACGGTAATCAG   V-NL-TAG4  TCATGCGTCCATGAGTGGCCGGATCTGATTACCGTAGCAAGTCC  TaqI 
AciI 
V-AATT AATTGGACTTGCTACGGTAATCAG  V-NL-TAG4  TCATGCGTCCATGAGTGGCCGGATCTGATTACCGTAGCAAGTCC  EcoRI 
V-ANT ANTGGACTTGCTACGGTAATCAG  V-NL-TAG4  TCATGCGTCCATGAGTGGCCGGATCTGATTACCGTAGCAAGTCC  HinfI 
V-SU  GATCGGACTTGCTACGGTAATCAG   V-NL-TAG4  TCATGCGTCCATGAGTGGCCGGATCTGATTACCGTAGCAAGTCC  BamHI, Sau3A1 
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2.2.4 Electrophoresis 
2.2.4.1  Agarose gels 
Depending on the size of the products to be resolved different percentages of 
agarose gels were used in 0.5 X TBE buffer (45 mM Tris, 45mM boric acid, 1 
mM EDTA pH8) with 0.5 µM of ethidium bromide and run at a constant voltage 
(100-130V).  
For the resolution of small fragments with small size differences a 2% (w/v) 
Nusieve, 1% (w/v) agarose gels were used. Before loading the samples in the 
gel 5X Orange G loading dye (0.2 % (w/v) Orange G 15 % (w/v) Ficoll, 1X TBE) 
was added. The DNA fragments were visualised using a UV transilluminator 
and photographed using the UVP ImageStore 7500 system. The bands were 
sized by comparison to molecular weight markers using Kodak Digital Science 
1D 3.5.4 software (Kodak). The molecular weight markers used were 1 kb+ 
ladder (60 ng/µl 1 kb ladder, 1X DNA loading dye in 1X TBE) and λHindIII (10 
ng/µl λHindIII, 1X orange G loading dye).  
2.2.5 Southern "squash" blot  
Southern "squash" blots were performed to transfer DNA from gels to nylon 
membranes. Gels were rinsed in distilled water, incubated with gentle shaking 
in the following solutions: 10 min in depurinating solution (0.25 M HCl), 30 
minutes in denaturing solution (0.5 M NaOH, 1.5 M NaCl) and 30 min in 
neutralising solution (1.5 M NaCl, 0.5M Tris pH 7.5). The gels were rinsed in 
distilled water between incubations. Cling film was placed on the bench 
followed by two sheets of gel blotting paper, the gel inverted, the membrane 
(Hybond-N form GE Healthcare), two sheets of gel blotting paper, a thick 
layer of paper towels, a glass and a weight (~1 kg). The membrane was wet 
first in distilled water and then in neutralising solution; the sheets of gel 
blotting paper were wet in neutralising solution. Any bubbles trapped in each 
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overnight by capillary action. The DNA was fixed to the membrane by 20 min 
baking at 80°C followed by UV crosslinking at 1,200 J/m
2 with a Stratagene UV 
crosslinker 2400.  
2.2.6 Preparation of DNA probes 
Three different probes were used: the DM1 CTG repeat probe, a 5'-end probe 
and p5B1.4, which is a 1.4 Kb BamHI-digested product of cDNA25 (Buxton, et 
al. 1992). The DM1 CTG repeat probe was generated with primers DM-A and 
DM-DR using a template containing 56 CTG repeats. The 5'-end probe was 
generated with primers DM-H and DM-CR, generating a 99 bp product that will 
hybridise at the 5'-end of the repeat tract. The DNA was purified by 
precipitation, PCR products were mixed with 1 volume of 5M NH4 acetate (pH 
7) and 1 1/2 volumes of isopropanol. The DNA was collected by centrifugation 
in a bench top centrifuge (15 min at 13,000 RPM). The pellet was washed with 
1ml 80% ETOH, recovered again as above, air dried and dissolved in water. 
The concentration of DNA was quantified and 10 ng/µl aliquots were made. 
Purified DNA (20-30 ng) and the DNA marker (2.5 ng) were radiolabelled with 
1.85 MBq [α-
32P]dCTP (3,000 Ci/nmol) using Ready-to-go DNA labelling beads  
(GE Healthcare), incubating the reaction at 37°C for 30 min. The probe was 
denatured for 5 min at 100 °C and snap cooled on ice prior to addition to the 
hybridisation buffer. The probe p5B1.4 selected for the analysis of Southern 
blot analysis of restriction digested genomic DNA was purified with G-50 
columns (Microspin G-50, Amersham Biosciences) before addition to the 
hybridisation buffer. 
2.2.7 Southern hybridisation   
The membranes were pre-hybridised for 30 min at 65°C with 10 ml of 
hybridisation buffer (7% (w/v) SDS, 1 mM EDTA, 0.5M Na2HPO4), which was 
then replaced by 5 ml of the same solution containing the radiolabelled 
probe. To block non-specific binding of p5B1.4 probe to the membrane, 22 µg 
of single stranded salmon testes DNA (SIGMA) was added in the pre-Claudia Braida, 2008    Chapter 2, 57 
 
hibridisation step. The membranes were hybridised overnight in a rotating 
oven at 65 °C. Subsequently the blots were washed with washing solution 
(0.2% (w/v) SDS, 0.2X SSC): 2x30 min at 65°C and 1x 30 min at room 
temperature. The membranes were dried at 80°C, exposed to X-ray film and 
developed using an X-Ograph Compact X2 system. 
2.2.8 Genotyping of single nucleotide polymorphisms (SNPs) 
Polymorphisms were genotyped by PCR following restriction digest (detailed 
in table 2-6). The SNPs rs207070736 and rs572634 were analysed as previously 
described (Neville, et al. 1994). To design the analysis of the majority of the 
SNPs DNannotator was used 
(http://bioinfo.bsd.uchicago.edu/SNP_cutter.htm). PCR products were 
digested with the appropriate restriction enzyme in a final volume of 20 µl 
following the supplier's recommendations. The products were resolved on an 
agarose gel and detected by ethidium bromide staining. Allele-specific 
primers were designed for the analysis of rs16980013 and rs635299, since no 
other option was available.  
 
Table 2-6. Polymorphims genotyping assays 
Forward 
primer   5'-3' sequence  Reverse 
primer  5'-3' sequence  refSNP ID  AT 
(°C)   
Product 
size (bp) 
Restriction 
enzyme 
839  AGGGCCCCTCATCAAAGTCCACGGTGT   823  ACGGTTCTGCAGAGTGGAAGT   rs2070736  55*  183  DraIII 
Intron2-For  CTGCCTGTCCAACATGTCAGC   Intron2-Rev CTCCAGAGTGGTGGCATAGGAC  rs657640
§  63  365  NlaIII/TaqI 
463  CCGTCTCCACTCTGTCTCACT   600  GCTCTTGTCCCTCTTCCTAGG   rs572634  55*  334  BanI 
Intron5-For  GGTCATGGAGTATTACGTGGGC  Intron5-Rev AGGGTGGGATAAATGAACCTCC  rs1799894
§  67  397  HinP1I 
I8A  CACCGTGTAACAAGCTGTCATGGC  I8R  ACAGATGTGAGCAGCAGTCGTCAG  rs4646995  64  930/1907  N/A 
HinfI-for  ATTGGCCTACCTGGGACTCT  HinfI-rev  AGCCCTCACCTTTTCTCTCC  rs16939
§/ 
rs527221
§ 
63  333  HinfI/BpmI 
Fnu-For  GAGTCTTCCAGGAGCCACAG  Fnu-Rev  TTGACTGTGGGGAGGTAAGG  rs915915  63  316  Fnu4HI 
490  CTCCGATCGGGTCACCTGTC  505TAG  TCACATGGTCCGGACGCAGCTAAGCGGGTGGCAA  rs635299  61  216  N/A 
491  CTCCGATCGGGTCACCTGTC  506  CGCAGCTAAGCGGGTGGCAC     61  202  N/A 
BAB452  CTGCTGCTGCTGCTGGG  DM-GR  GCAGGGCGTCATGCACAAGAAA  rs10419007  65  186  Sau3AI 
DM-R  GTCCTCCGACTCGCTGACAG  3PDR  CAGCGTGTGCTTCTGGCTCAG  rs3745803
§  68  762  TaqI 
SIX-L  CACACACAAGGGGACAGAGA  SIX-DR  GGGTGGGTAAGAGTAACGGTCA  rs3745802
§  62.5  1378  Sau3AI 
SIX-K  GCCAGCTCTTGCAGACTTTG  SIX-DR  GGGTGGGTAAGAGTAACGGTCA  rs3745802
§  66  1089  Sau3AI 
SIX-J  TGGCGCAGTGGACAAGTAT  SIX-DR  GGGTGGGTAAGAGTAACGGTCA  rs3745802
§  62.5  647  Sau3AI 
SIX-C  CAGGTCAGCAACTGGTTCAAGA  SIX-DR  GGGTGGGTAAGAGTAACGGTCA  rs3745802
§  63  457  Sau3AI 
SIX-O  TCTCCACTTCTCTCTGGCTTGG  SIX-BR  CAGGCAGAAGGATGTGGTGACT  rs2014377
§  60  800  PstI 
SIX-A  CTGGAACTAAGCGCAGGAACAG  SIX-BR  CAGGCAGAAGGATGTGGTGACT  rs2341097
§  63  336  NlaIII 
SIX-P  TTTGGGTTTCCTTCCTAAGCCT  SIX-KR  TCGATGAACTTGTCCCTCCT  rs10775546
§  64  166  AciI 
SIX-N  CCCAGGAGGGACAAGTTA   LOC-AR  CACAACCGCATCGTGAAG  rs16980013  61.6  214  N/A 
TAG-SIX-M  TCATGCGTCCATGGTCCGGACCCAGGAGGGACAAGTTC  LOC-AR  CACAACCGCATCGTGAAG     61.6  234  N/A 
TaqI-For  TCCCCAAGTTACCTCCTGGT  TaqI-Rev  AGGGCCCCTCTAGAACACAT  rs10415988
§  63  167  TaqI 
* Amplification was carried out for 10 cycles (94°C for 1min, 60°C for 1min 30s, 70°C for 3 min), 25 cycles (94°C for 1min, 55°C for 1min 30s,70°C for 3 min), 
55°C for 1min and 70°C 10 min (Neville, et al. 1994). 
§DNannotator was used to design the analysis. N/A (not applicable). Underlined base indicates the error 
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2.2.9 Cloning and sequencing 
Purified PCR products were cloned with TOPO TA Cloning® Kit for 
Sequencing (Invitrogen) with the following modifications: 4 µl of PCR 
product were ligated to the vector (10 ng), the ligation was incubated for 
30 min at room temperature and 4 µl TOPO cloning reaction was added into 
the vial of one shot TOP10 chemically competent cells. Each transformation 
(10-200 µl) was spread on a prewarmed Luria Bertani (1% (w/v) Bacto-
tryptone, 0,5% (w/v) bacto yeast extract, 1% (w/v) NaCl) containing 
ampicillin (100 µg/ml) plate and incubated overnight at 37°C. At least 20 
different colonies were picked with a sterile tip, streaked first onto a fresh 
plate to generate a patch plate and then the tip was resuspended in 20 µl 
of water. After incubation for ~30 min at -70°C, 1 µl of the colony 
suspension was amplified by standard PCR using specific primers to verify 
the presence of the insert. 
Positive colonies were selected and grown overnight in Luria Bertani (LB) 
with ampicillin (100 µg/ml) with vigorous shaking at 37°C. If the volume of 
the culture was between 3 and 5 mls, the cells were harvested by 
centrifugation at 6,800 x g for 3 min and the plasmid DNA isolated with a 
Qiaprep spin miniprep kit. To increase the DNA yield, a starter culture of 2–
5 ml LB medium with ampicillin was inoculated with a single colony and 
incubated for ~8 h at 37°C with vigorous shaking. The starter culture was 
diluted by inoculating 100 ml medium with 100–200 µl of the starter culture 
and grown at 37°C for 12–16 h with vigorous shaking. The cells were 
harvested by centrifugation at 4,800 x g for 20 min at 4°C. The plasmid DNA 
was isolated with endofree plasmid maxi kits (Qiagen). The DNA was sent 
for sequencing to Geneservice, Cambridge Science Park, Milton Road, 
Cambridge, CB4 0FE. The sequences were visualised and analysed using 
ApE-A plasmid editor v1.12.  
2.2.10  Methylation studies 
To investigate the pattern of DNA methylation 60 ng of genomic DNA were 
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choice in a final volume of 20 µl. A control reaction without enzyme was 
also performed for each sample. The reactions were terminated by heat-
inactivation for 20 min at 65°C. The samples were amplified as follows: 30 
cycles (96°C for 45 sec, AT for 45 sec, 70°C for 50 sec), AT for 1 min and 
70°C for 3 min. The PCR products were resolved on a 1.5% agarose gel and 
detected by Southern blot hybridisation.61 
 
 
3  Identifying the nature of the genetic lesion in 
the DM1+CMT++ family using a combination 
of molecular genetic approaches  
3.1 Introduction 
DM1 is the most common form of muscular dystrophy in adults, and is 
characterised by multiple tissue involvement including skeletal myotonia, 
progressive myopathy, cataracts and abnormalities in the heart, brain and 
endocrine systems. The DM1 mutation has been identified as an expansion 
of a pure (CTG)n repeat located in the 3’-untranslated region (UTR) of the 
DM protein kinase gene (DMPK) which maps to 19q13.3 (Aslanidis, et al. 
1992; Brook, et al. 1992; Buxton, et al. 1992; Fu, et al. 1992; Harley, et al. 
1992; Mahadevan, et al. 1992). The DM1 locus is highly polymorphic and in 
normal individuals contains 5 to 35 copies of the CTG repeat. In DM1 
patients this repeat is expanded in the range of 50 to 100 in those mildly 
affected, 200 to 1000 in those with the adult classical form and more than 
1000 in those with the congenital form (IDMC, 2000). Expanded alleles are 
genetically highly unstable and nearly always increase in length when 
transmitted from parent to child, resulting in an increase of disease 
severity and earlier age of onset in successive generations, a phenomenon 
termed genetic anticipation. In the first generation of a classic DM1 family, 
an individual presents a mild form with only a few symptoms such as 
cataracts developed in old age but generally with no muscle symptoms. 
However, an enlarged allele is transmitted to offspring. In the second 
generation, a classical adult form with an age of onset between the third 
and fourth decade often occurs. Once again, the repeat expands on 
transmissions, maternal transmissions will generally result in a congenital 
form with a very severe phenotype including hypotonia and mental 
retardation in the third generation (Harper, et al. 1992).  
CMT is a group of genetically heterogeneous neuropathies affecting motor 
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phenotype is characterised by wasting and weakness of distal limb muscles, 
generally with distal sensory loss, skeletal deformities (usually pes cavus), 
and decrease or absence of tendon reflexes. In addition, hearing loss is 
observed in 5% of patients with CMT. Nerve conduction is one of the 
parameters assessed to define the type of CMT (Pareyson 2003). CMT1 (the 
demyelinating type) is characterised by a motor median nerve conduction 
velocity less than 38 m/s, CMT2 (the axonal type) is characterized by 
normal or slightly reduced nerve conduction velocities (≥ 45 m/s), and 
intermediate CMT is characterized by nerve conduction velocities in a 
range of 25-45 m/s (Davis, et al. 1978; Harding and Thomas 1980). The 
inheritance pattern can be autosomal dominant, autosomal recessive, or X-
linked. To date, 30 different loci have been mapped, and mutations have 
been identified in more than 20 different genes. However, there are still 
patients with an unknown aetiology. CMT1A is the most common type (40-
50 % of all CMT patients) and is caused mainly by duplications of the PMP22 
gene (17p11.2-p12)(Matsunami, et al. 1992; Timmerman, et al. 1992; 
Valentijn, et al. 1992). 
The DM1+CMT++ family is the first reported pedigree with three 
generations in which all the affected patients present clinical and/or 
electromyographic features of both DM1 and intermediate type CMT. 
Although there are other reported cases where co-incidence of DM and CMT 
has been observed (Rogoff and Ziegler 1956; Caccia, et al. 1972; 
Panayiotopoulos and Scarpalezos 1976; Borenstein, et al. 1977; Cros, et al. 
1988; von Giesen, et al. 1994), CMT is not a recognised feature of DM1 
(Harper 2001). Genetic anticipation is only partially observed in this family. 
Even though an increase in the severity of symptoms and a decrease in the 
age of onset are observed between the second and third generation, no 
congenital cases were observed in the fourth generation despite four 
female transmissions. On the contrary, all affected members in the fourth 
generation are intelligent, energetic, obtained university degrees and 
perform skilled jobs despite their physical disability. Unexpectedly, a 
decrease in the age at onset and an increase in the severity of the 
symptoms of CMT were observed between the third and the fourth 
generation. Genetic anticipation is not a common feature of CMT, but there Claudia Braida, 2008    Chapter 3, 63 
 
 
are similar reported cases where genetic anticipation was suspected 
(Hamiel, et al. 1993; Marrosu, et al. 1997; Dupre, et al. 1999; Kovach, et 
al. 2002). The mutations responsible for CMT were point mutations in the 
PMP22 gene (Marrosu, et al. 1997; Kovach, et al. 1999; Kovach, et al. 
2002), point mutations in the Po myelin gene (Bird, et al. 1997), and a 
duplication in the PMP22 gene (Dupre, et al. 1999). The mutation in the 
family described by Hamiel and collaborators is unknown. The cause of 
anticipation is still unknown in these reported families and there is 
insufficient evidence to reject ascertainment bias.  
In addition to the DM1 and CMT symptoms, several affected individuals (II-
26, II-27, II-28, III-9, III-12, III-16, III-17 and IV19) developed early hearing 
loss, a symptom that has been observed in 5% of the patients with CMT 
(Pareyson 2003). Four affected individuals (II-28, III-9, III-16, III-17) have 
also developed recurrent episodes of acute encephalopathy. The episodes 
of encephalopathy were characterised by confusion, headache, 
psychomotor agitation, fever impaired consciousness, and even coma 
resulting in several hospital admissions. Disorders with similar symptoms 
include familial hemiplegic migraine types 1 (FHM1) and 2 (FHM2), cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) and acute confusional migraine (ACM). 
FHM1 can be caused by mutations in the calcium channel gene (CACNA1A) 
(Ophoff, et al. 1996), FHM2 by mutations in a gene encoding the alpha-2 
subunit of the sodium/potassium pump (ATP1A2) (De Fusco, et al. 2003), 
and CADASIL by mutations in NOTCH3 (Joutel, et al. 1996). Screening of the 
most common mutations in these genes was performed in either one or two 
affected members of the DM1+CMT++ family, but was negative. 
Spaans and colleagues showed by linkage analysis that DM1 and CMT co-
segregate with the APOC2 locus on chromosome 19 (~2 cM from the DMPK 
gene) with a maximum LOD score of 7.04 with zero recombination, but do 
not segregate with chromosome 1 or 17 (Spaans, et al. 1986; Brunner, et 
al. 1991). Furthermore, Southern blot analysis of restriction digested 
genomic DNA has revealed a fragment equivalent to a small CTG expansion 
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have not been able to PCR across the expanded allele, nor to visualise the 
expanded allele by repeat primed-PCR (RP-PCR), which allows the 
detection of long expansions (explained in detail in section 3.2.1.3). 
Finally, standard cytogenetic studies and FISH using probes for a pericentric 
or paracentric inversion of chromosome 19, revealed no abnormalities 
(Spaans, et al. 2008). These data suggest that either a single or multiple 
closely linked mutations located near the APOC2 marker cause the DM1 and 
CMT symptoms in this family. There are three different types of CMT that 
have been mapped to chromosome 19.  Dominant intermediate type B (DI-
CMTB) associated with mutation in DNM2 (19q12-13.2), recessive type 3 
(CMT3D or CMT4F) associated with mutation in the PRX gene (19q13.1-13.2) 
and an axonal recessive form, CMT4C3, that maps to 19q13.3 (Delague, et 
al. 2000; Leal, et al. 2001; Zuchner, et al. 2005). The DNM2 gene is 
probably not mutated since it is located ~40Mb distal to the DMPK gene and 
no abnormalities were observed by FISH. However, the ARCMT2B locus or 
the PRX gene located respectively at 2Mb and 5Mb from the DMPK gene 
might be involved. 
The (CTG)n  expansion is the cause of DM1, however the DM1+CMT++ family 
has an unusual molecular diagnosis suggesting that another modification is 
present in addition to this expansion. It is known that once the number of 
CTG repeats passes a certain threshold, the repeats become very unstable 
in the soma and in the germline. Although transmissions from patients 
usually involve expansions, rare reverse mutations into the normal range 
have occurred on transmission to offspring in a number of DM1 families 
(Shelbourne, et al. 1992; Brunner, et al. 1993b; Hunter, et al. 1993; O'Hoy, 
et al. 1993; Shelbourne, et al. 1993). Strikingly, in one case a gene 
conversion event occurred in the father, two regions of the mutated 
chromosome including the CTG repeat tract were exchanged with the 
normal chromosome and the individual inherited an allele within the 
normal range (O'Hoy, et al. 1993). These data suggest that the instability 
within the repeats could also encompass the flanking DNA. A deletion in the 
flanking DNA has not yet been reported in DM1 patients. However in 
bacteria, long CTG repeat tracts inserted into a plasmid promoted the 
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repeats as well as some of the flanking sequence (Wojciechowska, et al. 
2005). Furthermore, in a number of fragile X syndrome and Jacobsen 
syndrome patients, diseases that are both caused by expansion of CGG 
triplet repeats, the expansions predispose to additional DNA instability 
leading to deletions encompassing the repeat tract and the flanking DNA 
(Meijer, et al. 1994; de Graaff, et al. 1995; Jones, et al. 1995; Quan, et al. 
1995).  
It appears logical to speculate that the expanded (CTG)n repeat at the 
DMPK locus may predispose the repeat tract and the flanking DNA to 
further instability, generating a putative break where insertions, deletions 
and/or rearrangements might occur (figure 3-1). These novel mutations 
might not be identified with standard diagnostic techniques, and they could 
modify the expression of DMPK and/or other genes and so explain the 
complex symptomatology observed in the DM1+CMT++ family. A 
combination of molecular approaches was performed to investigate the 
molecular lesion in the DM1+CMT++ family.  
 
Figure 3-1. Three possible novel types of mutation in the DM1 locus.  As observed in 
fragile X syndrome and Jacobsen syndrome, the instability of the expanded repeat at the 
DM1 locus could generate novel mutations such as insertions, deletions and/or inversions 
that might explain the complex symptomatology observed in the DM1+CMT++ family. 
 Claudia Braida, 2008    Chapter 3, 66 
 
 
3.2 Results 
3.2.1 Genotyping the DM1 locus by traditional methods  
In spite of the fact that Southern blot of digested DNA, PCR and RP-PCR had 
already been performed on patient DNA from the DM1+CMT++ family by the 
Spaans group, this project began by genotyping the DM1 locus by PCR in 
order to confirm the previous data. 
3.2.1.1  PCR 
The genotype of the DMPK locus was assessed by standard PCR 
amplification across the repeat array with the primers DM-A and DM-DR 
(figure 3-2). As expected, only normal size alleles were detected in 
unaffected controls (U1 and U10), and both the normal and expanded 
alleles were observed in classic control DM1 patients (A2, A3 and A4). Large 
expanded alleles were only detected after Southern blot hybridisation 
(figure 3-2C). The mutant allele was observed as a heterogeneous smear 
comprised of fragments containing different number of CTG repeats, 
revealing the somatic mosaicism observed at the DM1 locus (Monckton, et 
al. 1995b; Wong, et al. 1995). As expected, individuals IV-11 and IV-12 
from the DM1+CMT++ family, who are both unaffected, present as 
heterozygous (38/5) carrying two normal sized alleles. However, III-9, III-
16, IV-19, IV-20, III-17 and IV-21 appeared as homozygous, since only a 
single band corresponding in size to a normal allele was detected. The band 
detected in III-9 corresponds to an allele containing ~38 repeats. This allele 
is below the pathogenic range but occurs at a very low frequency (0.07%) in 
Caucasian populations (Martorell, et al. 2001), hence it would be extremely 
unlikely (1 in 2 million) to find a homozygous individual for an allele of that 
size. Consequently, a ‘null allele’ (failure to detect the product by the 
technique) was suggested. A 'null allele' could not be confirmed because 
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Figure 3-2. Genotyping of the DMPK locus by standard PCR. A. Schematic diagram of 
the DM1 locus. The location of the primers used to PCR across the (CTG) tract is indicated. 
B. PCR products generated with primers DM-A and DM-DR, which amplified 211 bp of 
flanking DNA, were resolved on a 1.5% ethidium bromide-stained agarose gel. C. The 
products were subsequently detected by Southern blot hybridisation with a DM1 CTG repeat 
probe. U1, U10 (normal individuals), A2, A3, A4 (classic DM1 patients), NC (negative 
control, PCR without DNA). The sizes of the marker are indicated on the right side and the 
estimated number of repeats is indicated on the left side. The expanded allele can be 
visualised as a smear in A2, A3 and A4. Additional bands are also visualised in III-9, IV19, 
IV-20, III-17, IV-21 and U1. However, the intensity is not as strong as in the classic DM1 
patients so they could be either heteroduplex DNA or contamination.  
A ‘null allele’ could be caused by either a technical artefact, a single 
nucleotide variation within the location of the primers in the expanded 
allele, or a putative deletion, insertion or rearrangement in the flanking 
DNA disrupting several priming sites. The affected members in the 
DM1+CMT++ family showed either the late onset form (second generation) 
or the adult form of the disease (third and fourth generations) so the 
number of (CTG)n repeats was not expected to exceed 1,000 repeats in any 
patient. A technical artefact does not seem likely since alleles up to 2,000 
CTG repeats (as observed in the congenital form) can be readily amplified 
by PCR (Monckton, et al. 1995b; Martorell, et al. 1998). To test for a single 
nucleotide variation in the primer site, three different combinations of 
primers (DM-C/DM-DR, DM-A/DM-BR, DM-C/DM-ER) were assessed by PCR, 
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detected (data not shown). Therefore, it seemed reasonable to suggest 
that an insertion within the CTG repeat tract, a deletion or rearrangement 
in the flanking DNA might explain the absence of an expanded allele 
detected by PCR. 
3.2.1.2  Southern blot analysis of restriction digested genomic DNA 
Southern blot analysis of restriction digested genomic DNA was carried out 
with EcoRI and PstI. Both enzymes only have restriction sites in the flanking 
DNA so the length of the repeat array in the DM1 locus can be assayed 
(figure 3-2A). The probe p5B1.4 in EcoRI-digested DNA detects a fragment 
of 8.7 Kb and a larger fragment of 9.6 Kb. Both fragments contain the 
variable polymorphic CTG trinucleotide tract and a 0.9 Kb 
insertion/deletion polymorphism located 4.7 Kb 5'-end distal to the CTG 
repeat tract (figure 3-3A). The 977 bp difference between the fragments 
corresponds to a deletion of three Alu repeats in the smaller fragment  
(Alu-). The analysis of the structure of the two alleles and the presence of 
the Alu+ allele in primates suggested that the ancestral allele is Alu+ whilst 
Alu- is a derived deletion (Mahadevan, et al. 1993b; Rubinsztein, et al. 
1994). The Alu+ allele has been shown to be in complete linkage 
disequilibrium with the DM1 mutation in Eurasian populations (Harley, et 
al. 1992; Mahadevan, et al. 1992; Yamagata, et al. 1992). Although, the 
DM1 mutation was associated with the Alu- allele in one Nigerian kindred 
(Krahe, et al. 1995), this is not usually the case. Therefore, we would 
expect that the DM1+CMT++ mutation would most likely be found on an 
Alu+ 9.6 Kb+ EcoRI fragment. 
Two classic DM1 patients, A7 (~200/13) and A2 (~50/9), were included as 
controls. Southern blot analysis in EcoRI-digested DNA revealed two 
fragments in A7. The larger fragment (>9.6 Kb) contained ~200 CTG repeats 
and the Alu+ allele. The bottom band (8.6 Kb) contained 13 CTG repeats 
and the Alu- allele (figure 3-3B). In A2, only a single band with a size of 9.6 
Kb was observed. This patient was probably homozygous for the Alu+ allele, 
but the resolution of the gel was not sufficient to differentiate the 9 repeat 
allele from the 50 repeat allele. III-16, IV-19 and IV-20 were heterozygous. Claudia Braida, 2008    Chapter 3, 69 
 
 
Two fragments were observed, the 8.7 Kb band that presumably contained 
the normal size allele on an Alu- fragment, and a larger fragment. Only a 
slight increase in size was observed in the larger fragment relative to the 
normal 9.6 Kb Alu+ allele, suggesting a small expansion in the range of 
~150-200 CTG repeats on a Alu+ fragment. Only a single ~9.6 Kb band was 
detected in IV-11 and IV-12, indicating that both individuals were probably 
homozygous (Alu+/Alu+) and the difference in the number of repeats 
between the alleles (38/5) was insufficient to be resolved as two bands in 
this percentage of agarose gel. In III-9 two larger fragments were obtained, 
presumably the bottom fragment contained the normal size allele (38 
repeats) whilst the top fragment contained the expanded allele (~230 
repeats), both on an Alu+ background.  
The probe p5B1.4 detected two fragments in PstI-digested DNA: the top 
one containing the variable polymorphic CTG trinucleotide repeat (1.2 kb), 
and the bottom one of 886 bp without the variable tract. The use of PstI 
increased the resolution of the test by providing smaller fragments to be 
resolved in a higher percentage of agarose gel (1% agarose gel), but the 
level of background was high (data not shown).  Only the fragment 
corresponding in size to the normal CTG allele was visualised in III-9, III-17 
and IV-19. However, two discrete bands were detected in IV-20, the normal 
size allele and the mutated allele. The low level of somatic mosaicism 
present in IV-20, probably because of his young age, may explain this 
result. In III-9, III-17 and IV-19 the level of somatic mosaicism was probably 
higher than in IV-20 and consequently the fragments were spread out in the 
gel preventing their detection.  Claudia Braida, 2008    Chapter 3, 70 
 
 
 
Figure 3-3. Southern blot of restriction digested genomic DNA. A. Restriction map of the 
DMPK locus showing the sites of EcoRI and PstI and the probe p5B1.4. B. EcoRI-digested 
DNA resolved in 0.7% agarose gel and probed with p5B1.4. The large (>9.8-kb) band varies 
in size and defines the DM1 mutation. In A7 (classic DM1 patient) the >9.8Kb and 8.6 Kb 
fragments are detected. A2 (another classic DM1 patient), who is probably homozygous for 
the Alu+ allele, the expanded allele could not be resolved from the normal size allele due to 
the low resolution of the gel and the small size difference between both alleles. Two faint 
bands are present in III-9. The sizes of the marker are indicated on the right, and the 
expected sizes of the Alu+ (9.6 Kb) and Alu- (8.6Kb) alleles on the left. 
3.2.1.3  Repeat primed-PCR (RP-PCR) 
RP-PCR was first described in the context of minisatellite DNA repeat 
amplification (Jeffreys, et al. 1991), and then it was adapted for the 
diagnosis of neurodegenerative diseases when long repeats could not be 
amplified by using flanking primers (Warner, et al. 1996).  The strategy 
involves a PCR containing three types of primers: a specific primer flanking 
the repeat array (P1 or P4), and a second primer (P2+TAG or P3+TAG) 
targeted to the repeat tract containing a 5' tail to be used as an anchor for 
the third primer (TAG) (figure 3-4). The sequence of the tail is carefully 
selected so that it does not contain sequence identity to the genome being 
investigated. The concentration of the primer targeted to the repeat tract 
is used at 1/10 of the other primers so that it is exhausted in the earlier 
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priming in internal sites. In alleles within the normal range, a characteristic 
ladder of fragments corresponding to the number of repeats will be 
obtained, in contrast in expanded alleles the ladder will continue higher up 
(> 50 repeats) allowing a distinguishable pattern. Accurate estimations of 
the number of repeats are not possible. An absence of product at either 
end of the repeat tract (5’-end or 3’-end) could be suggestive of a local 
rearrangement, deletion or insertion.  
 
Figure 3-4. Schematic representation of RP-PCR from both ends. P1 and P4 are the 
primers that give specificity to the reaction. P2+TAG or P3+TAG are targeted to the repeat 
tract and therefore will prime in multiple positions within the repeat tract generating 
fragments of different lengths that will be amplified with TAG. 
When using RP-PCR to investigate the DM1+CMT++ family, a ladder of 
expanded alleles was detected at the 5’-end using multiple flanking 
primers (DM-T, DM-A, DM-H and DM-C) located up to 400 bp from the repeat 
in the affected family members investigated as well as in the classic DM1 
patients (A6 and A8)(figure 3-5). As expected, no expansions were detected 
in the unaffected family members (IV-11 and IV12) and in the normal 
controls (U10 and U11). These data suggest that the 5’-end seems to be 
intact up to ~400 bp. A different scenario was observed at the 3’-end of the 
repeat array. Multiple flanking primers (DM-ER, DM-DR, DM-BR, DM-QR, DM-
3PBR, DM-3PCR and DM-3PDR) up to 1 kb distal from the CTG repeat array 
failed to detect expanded alleles in the DM1+CMT++ patients.  Claudia Braida, 2008    Chapter 3, 72 
 
 
It seemed reasonable to conclude from this data that the expansion at the 
DM1 locus in the affected individuals was coupled with a deletion or a 
rearrangement at least up to 1kb at the 3’-end, since multiple PCR primers 
sites did not appear to be present. If so, the EcoRI fragments detected by 
the probe p5B1.4 on the Southern blot analysis could be generated with 
more distal EcoRI sites.  
 
Figure 3-5. RP-PCR analysis. A. Schematic representation of the DM1 locus showing the 
locations of the different primers (arrows) and the CTG repeat tract (box). The two probes 
used in the analysis are also indicated. B. 5'-end RP-PCR analysis using primer DM-T 
located at 434 bp from the repeat tract (P1 from figure 3-4). C. 3'-end RP-PCR analysis 
using primer 3PDR located at 1093 bp from the repeat (P4 from figure 3-4). The products 
were resolved on a 1.5% agarose gel and subsequently detected by Southern hybridisation. 
The DM1 CTG repeat probe was used to detect the 3'-end products and a 5'-end probe 
(generated with primers DM-H and DM-CR) was used to detect the 5'-end products. Non-
specific products were visualised on the negative control at the 5'-end so a probe was 
designed to hybridise only at the 5'-end of the repeat tract and the problem was solved. A6 
and A8 (classic DM1 patients); U10 and U11, (normal individuals); NC (negative control). 
The sizes of the marker are indicated on the right and the estimated number of repeats is 
indicated on the left.  
Assuming the 5'-end is intact, the next EcoRI site must be very close. 
Indeed, the next EcoRI site is located in the LOC388553 gene (~11Kb). If a 
large deletion or rearrangement occurred, a fragment generated with a 
primer located at the 5'-end of the repeat and a primer located after the 
next EcoRI site (such as DMEcoR) should be obtained (figure 3-6).  Two 
different forward primers (DM-A and DM-C) were used with DMEcoR but a 
product was not obtained in either case. In addition, RP-PCR was 
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allele could not be visualised. These data seemed to argue against a 
deletion or rearrangement of that size.  
 
Figure 3-6. Schematic diagram of a putative deletion at the 3'-end of the (CTG)n. The 
primers selected to investigate the putative deletion are indicated. The EcoRI site indicated 
is located in the LOC388553 gene at ~11Kb distal from the (CTG)n in the reference 
sequence. If a deletion or rearragement occurred in the DM1+CMT++ mutated chromosome 
by using forward primers (DM-A or DM-C) with the reverse DMEcoR primer a product might 
be generated. 
It was possible that the extent of any deletion was not as large as ~11Kb, so 
another attempt at PCR and RP-PCR was performed but using primers 
located in the SIX5 gene. The primer DM-C was used in combination with 
multiple reverse PCR primers (SIX-ER, SIX-IR and SIX-DR) (figure 3-7). Both 
the expanded and normal alleles in the classic DM1 patients were 
amplified. However, in the DM1+CMT++ family only the normal size alleles 
could be detected. In addition, RP-PCR at the 3'-end was performed with 
SIX-DR. The expanded allele in the classic DM1 patients was visualised, but 
only the normal size allele was visualised in the DM1+CMT++ cases. These 
data seem to argue against a deletion of ~1Kb.  
 
Figure 3-7. Schematic diagram of the 3'-end of the repeat tract. The locations of multiple 
reverse primers are indicated. If there is a deletion of ~1Kb at the 3'-end, a product could be 
amplified by PCR using DM-C and a primer located after the deletion. Claudia Braida, 2008    Chapter 3, 74 
 
 
3.2.2 Defining the boundaries of a putative deletion  
In an effort to narrow down the extent of any putative deletion, a loss of 
heterozygosity deletion analysis was performed. All patients should present 
as pseudohomozygous for all markers within a deleted region. Conversely, 
any SNPs that present as heterozygous in any patient will indicate that such 
a marker is not contained within a deletion (figure 3-8). 
 
Figure 3-8. Loss of heterozygosity deletion analysis. Several SNPs located at either end 
of the repeat tract were investigated. If a deletion event is present, the patients should 
present as pseudohomozygous for one or more SNPs depending on the size of the deletion. 
The limit of a deletion event could be defined at the SNP where the individuals present as 
heterozygous. 
The insertion/deletion polymorphism located in intron 8 of the DMPK gene 
was one of the first polymorphisms described in the literature at the DM1 
locus. The Alu+ allele was shown to be in linkage disequilibrium with an 
expanded (CTG) tract. Subsequently, eight more polymorphic sites spanning 
an ~40 Kb region around the DMPK gene were genotyped and 9-11 different 
haplotypes were defined in Caucasian and Japanese populations. However,  
only one of these haplotypes has been shown to be associated with the DM1 
mutation (Neville, et al. 1994; Yamagata, et al. 1998). An exception was 
described in a Nigerian kindred, where the DM1 mutation was not 
associated with the classic DM1 haplotype (Krahe, et al. 1995).  
To determine the extent of a putative deletion and to investigate whether 
the DM1+CMT++ mutation arose in the classic DM1 associated haplotype, 
nine polymorphic sites were genotyped to define the haplotype of each 
individual within a region of ~40 Kb on chromosome 19, extends from the 
3'-end of the DMWD gene to the intron 1 of LOC388553 gene. The 
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The insertion/deletion polymorphism (rs4646995) was detected by PCR 
using primers flanking the insertion site (figure 3-9). As expected, III-16, IV-
19, IV-20, III-17 and IV-21 are heterozygous whilst III-9, IV-11 and IV-12 are 
homozygous for the Alu+ allele. These data confirm the previous data 
obtained by EcoRI-digested DNA and suggest the DM1+CMT++ mutation 
arose on the common Alu+ DM1 haplotype. 
The construction of the haplotypes was performed manually with the data 
obtained from the genotype analysis (table 3-1). Unfortunately, the DNA of 
unaffected individuals was not available so it was not possible to 
unambiguously assign all haplotypes (figure 3-11). III9, IV-11 and IV-12 
present as homozygous for all the SNPs genotyped except for the number of 
CTG repeats so there were only two possible haplotypes. III-9 is 
homozygous for the classic DM1 haplotype so the DM1+CMT++ mutation 
must have arisen in the common DM1 haplotype. At least one DM1 
haplotype could be constructed in the other affected members 
investigated, suggesting that the mutation was also present on the DM1 
classic haplotype.  
Most interestingly, III-16, IV-19, IV-20, III-17 and IV21 were genotyped as 
heterozygous at several SNPs at the 5'-end of the CTG repeat tract 
(rs1799894, rs4646995, rs16939, rs915915 and rs635299) and at the 
rs1045988 located at ~30Kb at the 3'-end. These data indicated the 5'-end 
region was present and presumably intact. Heterozygosity at rs10415988 
appeared to limit a simple 3'-end deletion to less than 40Kb. Claudia Braida, 2008    Chapter 3, 76 
 
 
 
Figure 3-9. PCR based assays which genotype 6 polymorphisms in a region ~40 kb 
around the DMPK gene. PCR products were resolved on 2% Nusieve, 1% agarose gel, 
excluding number 3 that was resolved on 1.5% agarose gel. In each panel, the first lane 
contains the DNA marker followed by PCR products before or after (*) digestion. The sizes of 
the marker, as well as the sizes of the uncut and digested products are indicated. 
Eight more SNPs with a known high value of heterozygosity were selected 
from the Entrez SNP database (http://www.ncbi.nlm.nih.gov/sites/entrez) 
to be genotyped at the 3'-end in an effort to reduce the boundary of a 
putative deletion (figure 3-10). Again several affected individuals were 
genotyped as heterozygous at variable SNPs (table 3-1). The closest 
polymorphic site to the 3’-end of the CTG tract is rs3745802, which is 
located ~2.3 Kb downstream of the CTG repeat in the SIX5 gene and this 
SNP was heterozygous in several patients (figure 3-12A and B). Therefore, Claudia Braida, 2008    Chapter 3, 77 
 
 
the boundary of a putative deletion was reduced even more. However, it 
was not clear from this data if a deletion could be present upstream the 
rs3745802 SNP. The G allele seemed to be associated with the DM1+CMT+ 
mutation since all affected members carried at least one G allele. 
 
Figure 3-10. Diagram of the DM1 locus. Shown are the relative positions of the different 
SNPs investigated, the SNPs, which at least one affected individual from the DM1+CMT++ 
family presented as heterozygous (in blue), the insertion/deletion polymorphism and the 
CTG repeats (in triangles). 
Table 3-1. Genotype of several polymorphisms in the DM1 locus 
refSNP ID  Position (bp)*  H   III-9  IV-11  IV-12  III-16  IV-19  IV-20  III-17  IV-21 
rs2070736  -978  0.408  1/1  1/1  1/1  1/1  1/2  1/2  1/1  1/1 
rs6567640  +378  0.418  1/1  1/1  1/1  1/1  1/1  1/1  1/1  1/1 
rs572634  +3232  0.226  2/2  2/2  ND  2/2  2/2  2/2  2/2  1/2 
rs1799894  +3991  0.495  1/1  1/1  1/1  1/2  1/2  1/2  1/2  1/2 
rs4646995  +6099  0.498  +/+  +/+  +/+  +/-  +/-  +/-  +/-  +/- 
rs16939  +9680  0.498  2/2  2/2  2/2  1/2  1/2  1/2  1/2  1/2 
rs527221  +9760  0.320  2/2  2/2  2/2  2/2  2/2  2/2  2/2  1/2 
rs915915  +10764  0.495  1/1  1/1  1/1  1/2  1/2  1/2  1/2  1/2 
rs635299  +11565  NN  T/T  T/T  T/T  G/T  G/T  G/T  G/T  G/T 
(CTG)n   +12223    38/N  38/5  38/5  14/N  14/N  14/N  14/N  14/N 
rs10419007  +12278  NN  2/2  2/2  2/2  2/2  2/2  2/2  ND  2/2 
rs3745803  +12773  NN  ND  1/1  ND  1/1  1/1  1/1  ND  1/1 
rs3745802  +14559  0.429  1/1  1/1  1/1  1/2  1/2  1/2  1/2  1/2 
rs2014377  +16423  0.260  2/2  1/2  1/2  1/2  1/2  1/2  ND  1/2 
rs2341097  +16834  0.386  1/1  1/2  1/2  1/1  1/1  1/1  1/1  1/1 
rs10775546  +18202  0.303  1/2  1/1  1/2  1/2  1/2  1/2  1/2  1/2 
rs16980013  +18283  0.460  G/G  G/G  G/G  G/G  G/G  G/G  ND  G/G 
rs10415988  +39031  0.500  2/2  2/2  2/2  1/2  1/2  1/2  1/2  1/2 
*distance from the beginning of the DMPK gene. H (heterozygosity), N (null allele), NN (not 
known), ND (not determined). Claudia Braida, 2008    Chapter 3, 78 
 
 
 
Figure 3-11. Possible haplotypes in the DM1+CMT++ family. The name of each SNP 
genotyped is indicated on the left and the alleles are indicated under each individual. DNA 
samples were only available for the individuals genotyped. III-9, IV-11 and IV-12 present as 
homozygous for all the SNPs, except for the number of repeats so only one haplotype was 
possible. In contrast, III-16, IV-19, IV-20, III-17 and IV-21 present as heterozygous in more 
than one SNP, so more than one haplotype could be constructed. The DM1 associated 
haplotype is boxed. N (null allele). 
3.2.2.1  Analysing the integrity of the 3'-end up to intron 1 of the SIX5 
gene   
To investigate the extent of any putative deletion event up to ~2.32 kb 
from the 3'-end of the repeat, the rs3745802 affected heterozygotes were 
genotyped with a series of forward primers located at different positions 
distal to SIX5 and the reverse primer SIX-DR (3-11C). With primers SIX-J, 
SIX-K, SIX-L and SIX-C, the polymorphic site was assayed with Sau3AI, and 
heterozygosity was preserved. However, the direct identification of the 
polymorphic site was not possible with the primers BAB452 and DM-R 
because fragments of similar sizes were obtained from other Sau3AI 
restriction sites located in the amplicon. Performing a nested-PCR with Claudia Braida, 2008    Chapter 3, 79 
 
 
primers SIX-C and SIX-DR solved this problem.  All individuals remained 
heterozygous using primers as distal as BAB452 (targeted to the end of the 
repeat array) (figure 3-12). These data provide evidence that the sequence 
within the first 2.3 kb at the 3’-end of the repeat tract is intact. 
 
Figure 3-12. Investigating the 3'-end. A. Diagram of the amplified region showing the sizes 
of the PCR product and the location of the polymorphic site. B. The products were resolved 
in 2% Nusieve, 1% agarose gel. The size of the marker as well as the size of uncut and 
digested products are indicated. A (*) indicates the products were digested with Sau3AI. C. 
Schematic diagram of the DMPK region and flanking sequence at the 3'-end. The location of 
primers used to analyse the integrity of the 3'-end of the repeat tract up to ~2.32 Kb are 
indicated. 
An alternative approach performed in parallel was to sequence the region 
at the 3'-end. The aims were to search for possible SNPs located before 
(rs3745802) and additionally to analyse the sequence at this end. PCR 
products generated with primers BAB452 and SIX-DR from III-16 and IV-19 
were cloned into the vector pCR®4-TOPO® using the TOPO TA cloning kit 
for sequencing. III-16 and IV-19 were selected because both present as 
heterozygous at rs3745802 and it was possible to identify the different 
chromosomes. The clones obtained were screened by PCR following Claudia Braida, 2008    Chapter 3, 80 
 
 
digestion with Sau3AI.  Clones carrying either the G or T allele were 
selected, plasmid DNA was extracted and sequenced (figure 3-13). The 
sequencing data revealed that the sequence contained within the location 
of the primers BAB452 and SIX-DR was intact in III-16 and IV-19, and no 
additional variants were observed. 
It was clear from this data that a simple deletion event was not present in 
the DM1+CMT++ family. The next step was to determine whether the 
presence of a rearrangement at the 3'-end or an insertion within the (CTG)n 
could explain why an expanded allele was visualised by Southern blot. 
However, it was not possible to amplify by PCR and the 3'-end RP-PCR 
failed. 
 
Figure 3-13. Cloning ~2Kb at the 3'-end of the (CTG)n tract. A. PCR products generated 
with BAB452 and SIX-DR were cloned. Screening was performed by PCR using the primers 
SIX-C and SIX-DR and Sau3AI digestion A. III-16 generated clones B. IV-19 generated 
clones. The white arrows indicate the clones sequenced, one Sau3A+ and one Sau3A- from 
each patient. NC (negative control). Claudia Braida, 2008    Chapter 3, 81 
 
 
3.2.3 Investigating a rearrangement at the 3'-end of the 
(CTG)n  
Vectorette PCR was selected to "walk" across the chromosome to clone a 
putative breakpoint at the 3'-end of the array (figure 3-14). DNA vectorette 
libraries were generated by digesting genomic DNA with a suitable 
restriction enzyme followed by the ligation of a linker containing unique 
PCR primer sites. PCR analysis was carried out using one specific primer 
annealing to the known region, and a vectorette primer identical to a part 
of the linker that will only prime after the first cycle. This strategy 
prevents the amplification of products with a linker at each end so that 
only fragments that are recognised by the specific primer will be amplified 
(Riley, et al. 1990; Arnold and Hodgson 1991). A high level of background 
was observed so, in an attempt to reduce the background, firstly an 
internal primer was designed (TAG3) followed by the design of another 
primer (TAG4). A slight reduction in background was obtained. Claudia Braida, 2008    Chapter 3, 82 
 
 
 
Figure 3-14. Schematic representation of vectorette PCR. Genomic DNA was digested 
with the enzyme of choice; equimolar amounts of the vectorette linker and the digested DNA 
were ligated to generate the vectorette libraries. The sequence of one of the vectorette 
linkers generated is indicated. The vectorette library was amplified with a primer targeted to 
a region within the known region and the vectorette primer (targeted to the vectorette linker). 
Two rounds of PCR were generally performed to obtain single bands. 
Several restriction enzymes were used to generate vectorette libraries from 
III-9, III-16, IV-20, two unaffected controls and two classic DM1 patients. 
Both normal and expanded alleles were distinguished with the DM1 CTG 
repeat probe in all the vectorette libraries screened from the DM1 classic 
patients using either primers located at the 5'-end or 3'-end of the repeat 
tract. However, in the DM1+CMT++ patients, only the normal size allele 
could be identified in the vectorette libraries generated with a variety of 
four, five and six-cutter restriction enzymes: TaqI, Sau3AI, HinfI, BamHI, 
EcoRI, PstI and MseI (figure 3-15). Unexpectedly, the mutant DM1+CMT++ 
allele could not be amplified even with EcoRI or PstI libraries. This result 
was not consistent with the previous data generated by Southern blot of 
restriction digested genomic DNA, where both enzymes generated Claudia Braida, 2008    Chapter 3, 83 
 
 
restriction fragments identified by the probe p5B1.4 (section 3.2.1.2) 
indicating the presence of an EcoRI or PstI restriction site with ~ 200 bp of 
the 3'-end of the repeat.  
 
Figure 3-15. Vectorette PCR. PCR with primers DM-C and TAG-4 were performed on 
Sau3AI vectorette libraries. A. The products were resolved on a 1.5 % agarose gel and 
stained with ethidium bromide (A). The products were detected by DM1 CTG repeat probe 
by Southern blot hybridisation (B).  Strong smears were detected with DM1 CTG repeat 
probe in two classic DM1 patients (A3 and A 14). However, smears similar to those obtained 
in unaffected controls (U12 and U13) were observed in three members of the DM1+CMT++ 
family (III-9, III-16 and IV-20). NC (negative control). The sizes of the marker are indicated 
on the left and the estimated number of repeats is indicated on the right. 
AciI and HhaI, enzymes with high GC rich recognition sequences, were 
selected for a further attempt. Finally, the mutant DM1+CMT++ allele could 
be detected when using a forward primer located at the 5'-end of the CTG 
repeat tract and TAG4. Smears with a length similar to the smears detected 
in the classic DM1 patient were observed with both libraries. Unexpectedly, 
the "38" repeat allele of III-9 was not visualised at the expected size in the 
AciI vectorette library, suggesting that this allele must be digested with 
AciI (figure 3-16C). The normal alleles, but not the expanded alleles were 
detected as discrete bands by ethidium bromide staining with HhaI 
vectorette libraries. Nevertheless, fragments of agarose located on top of 
the normal alleles from III-9, III-16 and IV-20 were cut and the DNA purified Claudia Braida, 2008    Chapter 3, 84 
 
 
(figure 3-16B). The DNA was cloned into the vector pCR®4-TOPO® using the 
TOPO TA cloning kit for sequencing. It should be noted that fragments of 
different sizes were purified together including non-specific products 
generated by vectorette PCR. To identify clones carrying the DM1 expanded 
allele and not other non-specific products, positive clones were detected 
by Southern blot hybridisation using the DM1 CTG repeat probe. Indeed, 
some of the inserts were not detected with the probe. 
Only two clones from III-9 were detected with the DM1 CTG repeat probe 
and both were sequenced (figure 3-17). The sequence revealed that both 
ends (5'-end and 3'-end) of the repeat tract were intact and that vectorette 
PCR was working properly. The sequence of the repeat array consisted of 
38 repeats with the structure (CTG)5-6 (CCGCTG)14 (CTG)5-6, and the HhaI 
site was located at the 3'-end of the array as in the reference sequence. 
However, the sequence obtained probably corresponds to the normal size 
"38" repeat allele previously detected by PCR and not the mutant allele. 
These data explained why a band corresponding in size to the "38" repeat 
allele was not visualised in the AciI library. This allele was digested with 
AciI and only a small smear was amplified containing the 5'-end and 5 CTG 
repeats. The "38" repeat allele from patient III-9 was transmitted to his 
unaffected offspring (IV-11 and IV-12). To confirm the sequence of the 
allele in IV-11 and IV-12, the allele was amplified by PCR, cloned and 
sequenced. The "38" repeat allele in IV-11 and IV-12 was the same as the 
one present in III-9. Interestingly, a similar repeat structure has also been 
observed in a 37 repeat allele from a study of more than 300 sperm donor 
samples (Leeflang and Arnheim 1995). Claudia Braida, 2008    Chapter 3, 85 
 
 
 
Figure 3-16. Vectorette PCR. A. and B. Hemi-nested PCR using a primer located at the 5'-
end of the CTG repeat tract, DM-Cc with AciI vectorette libraries and DM-C with HhaI 
libraries. The products were resolved on a 1.5% agarose gel and stained with ethidium 
bromide. C. and D. The gels were blotted by Southern 'squash' blot and then detected by [α-
32P] dCTP DM1 CTG probe. The sizes of the marker are indicated on the left and the 
estimated number of repeats is indicated on the right side. Although short smears, were 
observed in the two unaffected controls (U12 and U13), long strongly hybridising smears 
similar to those observed in the affected controls were presented in III-9, III-16 and IV-20. 
Strikingly, the "38" repeat allele of III-9 seems to be digested with AciI. The boxes indicate 
the fragments of agarose gel from where DNA was purified and cloned. NC (negative 
control). Claudia Braida, 2008    Chapter 3, 86 
 
 
 
Figure 3-17. PCR screening of clones. PCR using primers DM-C and TAG4 was 
performed to evaluate the presence of the insert in the clones obtained. A. Clones obtained 
from vectorette products generated from III-9 vectorette libraries in A and from III-16 in B. C. 
and D. Auto-radiographs of gels A. and B. respectively. The arrows indicate the clones 
selected for sequencing. The sizes of the marker are indicated either on the left or the right 
side of each panel. NC (negative control). 
The clones obtained from III-16 were comprised of fragments with a wide 
variety of sizes. Only one clone was sequenced just to determine whether a 
sequence could be obtained from it. A partial sequence was read revealing 
that it was comprised of (CTG)31 (CCGCTG)1 (CTG)65 (GGC)2 GC (appendices 
A and B showed examples of sequencing chromatograms). A new type of 
repeat was detected (GGC), and evidence for at least one HhaI site  (GCGC) 
within the CTG array was confirmed. The flanking sequence at the 5'-end of 
the repeat tract was intact. It seemed reasonable to conclude that an 
increase of the GC content within the repeat array may be why a PCR 
product could not be generated by the standard procedure. In addition, it 
also potentially explained why the expanded allele could only be visualised 
from vectorette libraries generated with AciI and HhaI libraries. Both 
restriction enzymes have sites within the CTG repeat tract in the 
DM1+CMT++ allele so a PCR product could be generated by a standard PCR 
because it was not necessary to amplify across the GC rich repeat tract. Claudia Braida, 2008    Chapter 3, 87 
 
 
Presumably, there are no sites for the other restriction enzymes used 
within the CTG repeat tract since no PCR products were obtained. 
3.2.4 Investigating the presence of interruptions within the 
(CTG)n repeat by a modified PCR 
Several additives can be added to a PCR to improve the amplification of 
high GC content regions. Dimethyl sulfoxide (DMSO) is a denaturing reagent 
that it is believed to decrease the melting temperature of the template 
DNA (Chakrabarti and Schutt 2002), and it was selected to be added to the 
PCR. Temperature gradient PCR was performed to obtain the annealing 
temperature to be used with each combination of primers selected (work 
performed by Mahajan Navdeep, MSc project student under my 
supervision).  
Genomic DNA was amplified with primers DM-C and DM-DR in the presence 
of 10% DMSO. The expanded allele was visualised as a heterogeneous smear 
of fragments in all the affected members investigated with an estimated 
size between 200-400 triplets (figure 3-18). These data indicate that the 
molecular lesion in the DM1+CMT++ family seems to be an insertion of a 
GC-rich region into the CTG repeat array. Slight increases in the length of 
the repeat were detected in the offspring of III-16 and III-17 giving 
evidence for the presence of germline mosaicism. SP-PCR analysis is 
required to characterise the degree of somatic and germline mosaicism in 
detail. Characterisation of the interrupted CTG tract would be necessary to 
investigate the effect on somatic and germline mosaicism, and to compare 
it with classic DM1 patients with a pure CTG repeat tract.  Claudia Braida, 2008    Chapter 3, 88 
 
 
 
Figure 3-18. Genotype of the DM1 locus by a modified PCR. A. Products of 28 cycle PCR 
using primers DM-C and DM-DR in the presence of 10% DMSO were resolved on 1.5% 
agarose gel and visualised on UV. B. The products were detected by Southern blot 
hybridisation. The size of the markers is indicated on the left and the estimated numbers of 
repeats is indicated on the right. An extra band is visualised above the band corresponding 
to the "38" repeat allele in IV-11 and IV-12, and probably corresponds to heteroduplex DNA. 
NC (negative control). 
3.3 Discussion 
A combination of molecular approaches was performed to identify the 
molecular lesion in the DM1+CMT++ family. Small expansions were 
visualised by Southern blot analysis of restriction digested genomic DNA, 
but it was not possible to amplify across the array using the standard 
approach. Further investigation of the flanking DNA by RP-PCR showed an 
expanded allele at the 5'-end but was negative at the 3'-end of the CTG 
repeat. As a result, it was postulated that either a deletion, a 
rearrangement or an insertion within the (CTG)n might explain the Claudia Braida, 2008    Chapter 3, 89 
 
 
molecular lesion in the DM1+CMT++ family. The most plausible explanation 
was thought to be a deletion at the 3'-end, which could disrupt one or more 
than one gene causing the complex symptomatology observed in the 
DM1+CMT++ family. Therefore, the investigation was mainly focused on 
finding a deletion at the 3'-end.  
Several SNPs were genotyped in an attempt to determine the extent of a 
putative deletion, but it turned out that several individuals presented as 
heterozygous for many SNPs flanking the repeat providing evidence against 
a deletion. Similarly, the 3'-end of the CTG tract spanning a distance of ~2 
Kb in III-16 and IV-19 was cloned and sequenced, but no differences 
between the normal allele and the DM1+CMT++ allele could be detected. 
Therefore, it was concluded that a deletion was not the molecular lesion in 
the DM1+CMT++ family.  
In an effort to identify a breakpoint at the 3'-end, vectorette PCR was 
performed to walk across the unknown flanking DNA. Both normal and 
expanded alleles were clearly distinguished in classic DM1patients' 
vectorette libraries. However, only the normal allele could be identified in 
the DM1+CMT++ patients' vectorette libraries generated with a variety of 
four, five and six-cutter restriction enzymes (TaqI, Sau3AI, HinfI, BamHI, 
EcoRI, PstI and MseI). Unexpectedly, the mutant allele was not amplified 
from EcoRI libraries, even though a product was visualised by Southern blot 
analysis of restriction digested genomic DNA (section 3.2.1.2). However, 
the mutant DM1+CMT++ allele was finally detected as a smear with 
vectorette libraries generated with AciI and HhaI (enzymes with high GC 
rich recognition sequences). The expanded alleles were cloned and 
sequenced. It was revealed that both ends (5'-end and 3'-end) of the repeat 
tract were intact and that vectorette PCR was working properly. One of the 
sequences revealed the structure of the "38" repeat allele of III-9, which 
consists of (CTG)5 (CCGCTG)14 (CTG)5. Similar interrupted alleles were 
previously obtained (Leeflang and Arnheim, 1995; Monckton et al 
unpublished). Single sperm analysis showed that the instability of the "37" 
interrupted repeat allele was comparable to an allele of 27 repeats without 
interruptions, revealing a decrease of instability in the presence of Claudia Braida, 2008    Chapter 3, 90 
 
 
interruptions (Leeflang and Arnheim 1995). Indeed, the "38" repeat allele 
was transmitted unaltered from III-9 to both his daughter (IV-11) and son 
(IV-12). In addition, an incomplete sequence obtained from a clone from III-
16 revealed that it consists of at least one hexamer (CCGCTG), (GGC)2 and 
a HhaI site within the CTG tract. Subsequently, it was clear that the failure 
to PCR across the repeat tract might be due to an increase of the GC 
content within the CTG tract.  By adding DMSO to the PCR, the mutant 
allele was detected and expansions between 200-300 triplet repeats similar 
to those obtained by EcoRI-digested DNA were visualised. Additional bands 
were previously obtained in IV-19 and III-17 by standard PCR (figure 3-2), 
and these bands were interpreted as heteroduplex DNA and/or 
contamination.  However, the bands probably corresponded to the 
expanded allele that was not being efficiently amplified because of the 
high GC content. Only slight changes in the number of (CTG) were observed 
through transmissions (figure 3-18) giving molecular evidence for the 
absence of genetic anticipation observed between the third and fourth 
generations.  
In conclusion, the molecular lesion in the DM1+CMT++ family seems to be 
the insertion of several interruptions, which increases the level of GC 
content in the region preventing the amplification by standard PCR. Even 
though the ARCMT2B locus or PRX or DNM2 genes associated with three 
forms of CMT were not investigated, it would be extremely unlikely that 14 
affected members carry an imperfect CTG allele together with a mutation 
in one of these loci. Further investigations would be necessary to identify 
the nature of the insertion before any conclusion could be drawn about the 
pathogenesis of the CTG repeat tract with insertions. Meanwhile, we could 
speculate about possible mechanisms a novel RNA gain-of-function and/or a 
novel effect on the downstream genes. The evidence obtained so far 
indicates that at least one GGC repeat is present. If several repeats are 
present a novel RNA gain-of- function might explain the CMT symptoms by 
analogy to what happens in fragile-X associated tremor/ataxia syndrome 
(FXTAS).   Claudia Braida, 2008    Chapter 3, 91 
 
 
FXTAS is a neurodegenerative disorder that affects more than one third of 
the adult male carriers of premutation alleles (55<CGG<200) in the FMR1 
gene. The phenotype and the pathogenesis are completely different to 
fragile X syndrome (Hagerman, et al. 2001; Berry-Kravis, et al. 2003; 
Jacquemont, et al. 2003; Leehey, et al. 2003; Hagerman and Hagerman 
2004). An RNA gain-of-function model similar to the one postulated for DM1 
and DM2 seems to be the cause (Willemsen, et al. 2003). Ubiquitin-positive 
intranuclear inclusions containing FMR1 mRNA were observed in neurons 
and astrocytes of FXTAS patients (Greco, et al. 2002; Tassone, et al. 2004). 
The protein composition of the intranuclear inclusions was investigated, 
and more than 20 different proteins were identified. Some of these 
proteins identified such as hnRNP A2, a number of neurofilaments and 
lamin A/C proteins have been associated with different forms of CMT. In 
addition, MBNL1, which is one of the RNA binding proteins interacting with 
the CUG repeat that is recruited in DM1 and DM2 nuclear foci was also 
found co-localised in the intranuclear inclusions (Iwahashi, et al. 2006). 
Therefore, if several CGG repeat are present inside the (CTG)n tract, one or 
several of these proteins could be recruited explaining the CMT symptoms 
observed in the DM1+CMT++ family. 
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4  Defining the imperfect CTG repeat allele in 
the DM1+CMT++ family and quantifying germ 
line and somatic instability 
4.1 Introduction 
Several factors have been shown to affect the stability of simple repeat 
loci. These factors are the sequence and the number of repeats, the 
presence of interrupting repeat units, the content of the flanking 
sequences, and trans-acting elements. Only some specific triplet repeat 
sequences are unstable. The most common motif is (CNG)n, and this is 
probably because these repeats can form unusual stable DNA structures 
that may interfere with normal processes such as replication and repair 
leading to genetic instability (Chen, et al. 1998; Pearson and Sinden 1998; 
McMurray 1999; Sinden, et al. 2002). Shorter alleles are more stable than 
longer ones, and interrupted alleles are more stable than pure repeat 
tracts (Ashley and Warren 1995). High GC content in the flanking DNA has 
been associated with more unstable alleles (Brock, et al. 1999). However, 
it is still not clear how the level of GC content in the flanking DNA affects 
the instability of the repeats. Possible mechanisms involve alterations in 
the chromatin structure and/or methylation status.  A number of proteins 
participating in DNA repair pathways were identified as trans-acting 
elements. The absence of Msh2, Msh3 and Pms2 (proteins involved in 
mismatch repair) has been shown to reduce the levels of instability in 
several mouse models (Manley, et al. 1999; van den Broek, et al. 2002; 
Savouret, et al. 2003; Wheeler, et al. 2003; Gomes-Pereira, et al. 2004b).  
Normal interrupted repeat alleles are commonly observed at the FRAXA 
(Eichler, et al. 1994), SCA1 (Chung, et al. 1993), SCA2 (Choudhry, et al. 
2001), SCA3 (Kawaguchi, et al. 1994), SCA8 (Moseley, et al. 2000; Silveira, 
et al. 2000), SCA10 (Matsuura, et al. 2006), SCA17 (Koide, et al. 1999; 
Nakamura, et al. 2001), FRDA (Cossee, et al. 1997; Montermini, et al. 
1997) and DM2 loci (Liquori, et al. 2001). Generally, expanded alleles have Claudia Braida, 2008    Chapter 4, 93 
 
 
lost the interruptions and become unstable. At the SCA17 and SCA2 loci, 
pure expanded CAG repeats were associated with germline instability, but 
uninterrupted alleles of equal size are stably transmitted through the 
generations (Gao, et al. 2008). At the SCA1 locus, interrupted intermediate 
alleles are stable and non-pathogenic, in contrast to pure repeat alleles of 
similar sizes that are unstable and associated with the SCA1 phenotype 
(Chong, et al. 1995; Zuhlke, et al. 2002). In SCA2, intermediate size 
interrupted CAG alleles are associated with autosomal dominant 
parkinsonism, while pure alleles are associated with cerebellar ataxia 
(Charles, et al. 2007). Similarly, in SCA10, differences in the pathogenesis 
were observed between expanded uninterrupted and interrupted alleles. In 
addition, absence of anticipation was observed in a family carrying an 
interrupted SCA10 expanded allele. It was postulated that the sequence 
configuration of the repeat tract could be a disease modifier not only in 
SCA10 but also in other repeat diseases associated with an RNA gain-of-
function (Matsuura, et al. 2006). 
An imperfect CTG allele at the DM1 locus was demonstrated to be the 
molecular lesion in the DM1+CMT++ family. This finding was unexpected 
since in myotonic dystrophy type 1 it was assumed that the expanded CTG 
repeat tract-causing disease was pure. Nevertheless, an imperfect CTG 
repeat tract within the normal size was found in a study of 383 sperm 
donors (Leeflang and Arnheim 1995) and Cockburn and colleagues 
presented data at the International Myotonic Dystrophy Consortium (IDMC4) 
of at least three patients with an interrupted CTG repeat allele. Kang and 
collaborators showed that interrupted CTG repeats are more stable than 
pure repeats in E. coli (Kang, et al. 1996).  It is not known if the 
interruptions within the CTG repeat tract at the DM1 locus will affect the 
instability of the tract and/or have an effect on the pathogenesis. It could 
be postulated that the CTG repeat at the DM1 locus will probably show the 
same behaviour as the other types of repeats associated with diseases.  
Here we present the combination of approaches performed in order to 
characterise the nature and extent of the interruptions in the DM1+CMT++ 
allele. The stability of the imperfect CTG repeat allele was investigated Claudia Braida, 2008    Chapter 4, 94 
 
 
and compared to the stability of CTG repeats in classic DM1 patients. In a 
preliminary attempt to investigate whether the interruptions modify the 
activity of the DMPK and/or SIX5 gene, the methylation pattern of the 
repeat tract on the DM1+CMT++ allele was also investigated. 
4.2 Results 
4.2.1 Cloning and sequencing the imperfect CTG allele in the 
DM1+CMT++ cases  
To identify the type and number of interruptions at the imperfect CTG 
allele in the DM1+CMT++ family, cloning and sequencing was performed. 
Genomic DNA from DM1+CMT++ cases was amplified with primers DM-A and 
DM-DR in the presence of 10% DMSO.  The expanded alleles were visualised 
as smears with a size range from ~850 bp up to ~1.6 Kb (figure 4-1). DNA 
from the smears was purified with the Quiaquick gel extraction kit and 
cloned into the pCR®4-TOPO® vector using the TOPO TA cloning kit for 
sequencing. The kit has a very high efficiency, but only a few colonies were 
obtained. An increased efficiency was obtained by increasing the ligation 
reaction time and the amount of ligated-vector used to transform the cells. 
The clones obtained were screened by PCR. A heterogeneous population of 
fragments of different sizes was obtained due to the fact that the DNA was 
purified from a smear and not from a single band (figure 4-1). 
Unexpectedly, two main fragments were constantly obtained even within 
each clone: an expected large fragment containing ~213 triplets (~ 850 bp) 
and a smaller fragment of ~40 triplets (~330 bp). The smaller fragments 
probably correspond to large deletions generated by E. coli as Kang and 
colleagues previously observed. The authors showed that long pure CTG 
repeat tracts in bacteria are very unstable with a bias towards large 
deletions reducing the size of the repeats down to 20-40 repeats which are 
stable (Kang, et al. 1995).   Claudia Braida, 2008    Chapter 4, 95 
 
 
 
Figure 4-1. Amplifying expanded alleles by a modified PCR. Genomic DNA was 
amplified with primers DM-A and DM-DR in the presence of 10% DMSO. The products were 
resolved on a 1.5% agarose gel and detected with ethidium bromide staining. The expanded 
alleles were visualised as a smear. DNA from the smears (indicated with white boxes) were 
purified and cloned using the TOPO TA cloning kit for sequencing. NC (negative control). 
The position of the molecular weight marker is indicated on the right and the estimated 
number of triplets is indicated on the left.  
Two clones, 2.17 (figure 4-2A) and 5.19 (data not shown), were selected to 
sequence with vector primers flanking the insert (T3 and T7F). In both 
clones, the flanking DNA at both end was intact. In 5.19, (CTG)30 was read, 
which corresponded in size to the smaller insert. Only a partial sequence 
was obtained from 2.17 but, very interestingly this sequence contained two 
copies of a variant CCGCTG repeat:(CTG)35 (NNN)? (CCGCTG)2 (CTG)35. The 
sequence beyond the CTG repeats was not possible to read from the 5'-end. 
Only two CCGCTG hexamers were read after the CTG repeats at the 3'-end. 
A complete sequence was probably not read because the sample contained 
a heterogeneous population of inserts and/or due to the complexity of the 
insert. DNA from the fragment containing ~213 triplets was purified from 
the gel (figure 4-2A), but a cleaner sequence could not be obtained. 
In an attempt to obtain clones with a more homogeneous population of 
plasmids, a number of selected clones (containing the large insert) were 
streaked on LB plates. The population was still very heterogeneous in these 
primary subclones so a second round of single colony subcloning was Claudia Braida, 2008    Chapter 4, 96 
 
 
performed. Unfortunately, the fragment with ~213 triplets was constantly 
lost and only the fragment with ~40 triplets remained (figures 4-2B and C). 
Plasmid DNA from four secondary subclones was sequenced. Once again the 
flanking DNA at both ends was intact. One clone (indicated in figure 4-2C) 
contained just (CTG)33. Two clones had the following structure: (CTG)13 
(CCGCTG)6 (CTG)34. In the last clone, 57 and 58 CTG repeats were read 
from both ends, but again the sequence beyond the CTG repeats was 
impossible to read. The sequence of these collapsed subclones appear to 
confirm the presence of variant CCGCTG hexamers within the array. 
In an attempt to generate clones with longer inserts, the cloning was 
carried out using Max efficiency Stbl2 competent cells, which are more 
suitable for cloning some unstable inserts (Trinh 1994). These cells were 
previously used to clone an insert containing ~162 CTG repeats and flanking 
DNA of the DMPK gene. The yield was low but stable clones were generated 
(Colm Nestor personal communication). Nevertheless, the attempt in our 
case was unsuccessful; only one clone from 20 colonies investigated 
contained just the smaller fragment with ~40 triplets.  
Another attempt at direct sequencing was performed with single molecule 
separated expanded alleles obtained by SP-PCR analysis. The use of single 
molecule separated alleles removes both the complicating factor of starting 
with a heterogeneous population of fragments and the cloning step. HindIII-
digested genomic DNA from III-9, III-16, IV-19 and IV-20 was serially diluted 
and amplified with primers DM-A and DM-DR. The products were resolved 
on agarose gels and detected by Southern blot hybridisation with the DM1 
CTG repeat probe. Single molecule separated alleles containing an 
expanded allele were selected for sequencing.  PCR products from three 
single molecules (two from III-16 and one from IV-20) were sequenced 
directly with primers DM-A and DM-DR. However, once again a clear 
sequence from within the repeat array was not obtained, presumably 
because of sequence misalignment within the array caused by Taq 
polymerase mediated slippage events within the PCR product. These data 
highlight the technical difficulties in cloning and sequencing large repeat 
tracts. Nonetheless, the sequence data from the collapsed subclones Claudia Braida, 2008    Chapter 4, 97 
 
 
suggest the array is primarily comprised of CTG repeats with some CCGCTG 
hexamers. 
 
Figure 4-2. Representative data from PCR screening. A. Expanded alleles amplified with 
primers DM-A and DM-DR of III-16 were purified from the gel and cloned with TOPO TA 
cloning kit. The clones were screened by PCR using primers DM-A and DM-DR. The size of 
the expected insert is indicated with a black arrow. The white arrows indicate the clones 
selected for the primary subcloning. The white box indicates the DNA that was purified and 
sequenced. B. Screening of clones from the first streaking. The white arrows indicate the 
clones that were selected for the secondary subcloning. C. The repeats are quite stable but 
the correct insert was lost. The arrow indicates the clone that was selected for sequencing. 
Both ends of the repeat tract were intact and the clone contained (CTG)33. NC (negative 
control). The sizes of the molecular weight markers are indicated either on the right or the 
left side of the panels. 
4.2.2 Restriction site mapping  
Vectorette PCR data and sequence data from vectorette library fragments 
(in section 3.2.3) revealed that the expansion is comprised of at least one 
HhaI site (GCGC), a number of hexamers (CCGCTG), and two (GGC). 
Restriction site mapping was performed in an attempt to define the array. 
Four different restriction enzymes were selected: HhaI, MspA1I, AciI and 
Fnu4HI. MspA1I (CMGCKG) recognizes and cleaves the CCGCTG hexamers; 
AciI (CCGC) recognizes and cleaves the CCGCTG hexamers as well as GGC; Claudia Braida, 2008    Chapter 4, 98 
 
 
and Fnu4HI (GCNGC) recognizes and digests CNG repeats.  Diluted PCR 
products generated with primers DM-A and DM-DR were digested 
independently with one of the restriction enzymes of choice. The products 
were resolved on an agarose gel and detected with either the DM1 CTG 
repeat that detects fragments containing the CTG repeat tract and the 
flanking DNA, or a 5'-end probe that will only detect fragments containing 
the 5'-end flanking DNA. By sizing the generated fragments, the location of 
the different restriction sites, the size and type of interruptions could all 
be estimated. 
Analysis of PCR products derived from the genomic DNA of III-16, IV-19 
showed that Fnu4HI digested the repeat tract completely so the repeat 
tract must be comprised primarily of runs of CNG (figure 4-3). The 
expanded allele was digested with AciI and MspA1I and two products were 
obtained: a small band of ~170 bp (denominated PB) and a smear. PB was 
detected only with the DM1 CTG repeat probe so it must be comprised of 
the 3'-end flanking DNA (72 bp) plus ~35 CTG. The smear must contain the 
5' flanking DNA plus a number of repeats that were not digested with either 
AciI or MspA1I. The sizes of the smears obtained with AciI are smaller than 
the smears obtained with MspA1I. The difference must be due to the 
presence of a series of CCGCM (M represents C or A) digested with AciI but 
not with MspA1I. More than one site of both AciI and MspA1I must be 
present because the size of PB and the smear is less than the size of the 
undigested expanded allele. HhaI digested the expanded allele into a band 
of ~330 bp (denominated PA) and a smear. The PA band was only detected 
with the DM1 CTG repeat probe indicating that it must contain just the 3' 
flanking DNA, whereas the 5' flanking DNA must be in the smear that is 
detected with both probes. There is only one HhaI site because if we add 
the size of the smear plus the size of PA, the size of the undigested 
expanded allele is reproduced. By subtracting the size of the 3'-flanking 
DNA (72 bp) from the size of PA, we can postulate that the HhaI site is 
located at ~258 bp. Similar data including PA and PB was obtained from 
samples III-9, IV-20, III-17, IV-21 and IV-22 (data not shown), suggesting 
that the structure of the 3'-end of the repeat tract seemed to be very 
similar in all the DM1+CMT++ cases. In contrast, the 5'-end of the repeat Claudia Braida, 2008    Chapter 4, 99 
 
 
tract appeared to be the variable part. Therefore, instead of obtaining 
discrete bands, a smear was visualised revealing the presence of somatic 
mosaicism.  
Somatic mosaicism gives rise to variant allele length within the samples 
complicating the estimation of the location of the restriction sites, and 
consequently the structure of the interruptions could not be more 
accurately postulated. Claudia Braida, 2008    Chapter 4, 100 
 
 
 
Figure 4-3. Restriction site mapping. A. Diagram illustrating the location of the restriction 
sites of each enzyme in the flanking DNA of a PCR product generated with the primers DM-
A and DM-DR. There are no HhaI restriction sites in the flanking DNA. K (represents G or T), 
M (represents A or C). B. Representative autoradiographs. Genomic DNA was amplified with 
DM-A and DM-DR, following restriction digest. The products were resolved on a 1.5% 
agarose gel detected with the DM1 CTG probe (B) or with the 5'-end probe (C). UD 
(undigested product), NC (negative control). The size of the marker is indicated on the right 
side. PA band detected constantly with HhaI digestion, PB band detected constantly with 
AciI and MspA1I digestions. Claudia Braida, 2008    Chapter 4, 101 
 
 
4.2.2.1  Analysing single molecule separated alleles 
To decrease the complexity of the analysis, single molecule separated 
alleles containing expanded alleles from III-9, III-16, IV-19 and IV-20 were 
obtained by SP-PCR and assessed by restriction mapping following the 
procedure described previously. The analysis reproduced the data 
generated with bulk genomic DNA, but mainly single bands were obtained 
instead of the smears, except PA which remained as a smeary blob (figure 
4-4). An estimation of the number and types of repeats was made possible 
by sizing the fragments (table 4-1). The number of CCGCM repeats was 
estimated by the difference between the top fragment from AciI and 
MspA1I. By adding the size of the top MspA1 fragment and the size of PB 
minus the size of the undigested product, we estimated the number of 
CCGCKG repeats. The number of CTG repeats at the 5'-end was estimated 
by subtracting the flanking DNA (43 bp) from the AciI top fragment. The 
number of CTG repeats at the 3'-end was estimated by subtracting the 
flanking DNA (72 bp) from the size of PB (table 4-1). The structure of the 
expanded allele of III-16 was estimated to consist of (CTG)120-140 (CCGCM)21-
25 (CCGCKG)29-32 (CTG)38. Similar data was obtained with single molecule 
separated alleles of III-9, IV-19 and IV-20 (table 4-1). The difference 
between the single molecule separated alleles was the number of CTG at 
the 5'-end. Slight changes in the numbers of CCGCM (± 6 repeats), CCGCKG 
(± 6 repeats) and the 3'-end CTG (± 6 repeats) were obtained in different 
single molecule separated alleles, both within the same patient and 
between different patients. The length of 9C (single molecule separated 
allele from III-9) was more than 2 Kb, so the resolution of the digested 
products on 1.5% agarose gel was not as good as the other alleles. 
Therefore, it was not considered in the comparisons. 
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Figure 4-4. Restriction site mapping using single molecule separated alleles. Three 
single molecule separated alleles of III-16 obtained by SP-PCR were investigated. Diluted 
PCR products generated with primers DM-A and DM-DR were digested independently with: 
Fnu4HI, AciI, HhaI and MspA1I. The products were resolved on a 1.5% agarose gel and 
detected with either the DM1 CTG probe (A) or the 5'-end probe (B). The size of the marker 
and the estimated number of triplets are indicated. PA product was generated with HhaI, PB 
product was generated with AciI and MspA1I. 
Table 4-1. Sizing the different type of repeats in single molecule separated alleles 
  III-16 
8G 
III-16 
8H 
III-16 
12D 
III-9 
9D 
9D 
III-9 
9C 
IV-19 
11E 
IV-19 
10A 
IV-20 
6C 
5' CTG  121  140  133  395  617*  267  169  147 
CCGCM  25  23  21  18  17*  16  12  20 
CCGCKG  29  35  32  26  65*  37  35  28 
3' CTG  38  38  38  35  35*  36  30  36 
 
*Estimates might not be accurate. The length of the digested products from 9C was more 
than 1.65 Kb so the resolution on a 1.5% agarose gel was very low.  Claudia Braida, 2008    Chapter 4, 103 
 
 
4.2.3 RP-PCR  
4.2.3.1  Detecting CCGCTG 
To investigate if runs of the CCGCTG hexamer are located within the CTG 
repeat tract, CCGCTG repeat specific primers were designed to perform 
RP-PCR (figure 4-5). The CCGCTG repeat specific primer contains three 
CCGCTG hexamers, and the CTG repeat specific primer contains five CTG 
repeats. If the primers were highly specific, the ladders obtained with CTG 
and CCGCTG primers should have different sizes and partially 
complementary gaps should be expected in the ladders. The "38" repeat 
allele of IV-11 and IV-12 has previously been confirmed by sequencing to 
contain 14 copies of the CCGCTG hexamer, so these alleles were used as 
positive controls. A ladder with a size corresponding to 14 CCGCTG 
hexamers was obtained in IV-11 and IV-12 from both ends with the CCGCTG 
repeat specific primers (figure 4-6).  Two discrete bands were obtained 
with the CTG repeat specific primers. The gap between those two bands 
coincides with the CCGCTG hexamer smear. These data indicated that each 
primer detected each type of repeat with a high specificity. 
 
Figure 4-5. 3'-end RP-PCR designed to detect two different types of repeats. A. 
Possible structure of the DM1+CMT++ allele. Assuming there is an insertion of a number of 
copies of CCGCTG hexamers within the CTG repeat tract, two different types of primers 
could be used: one targeted to the CTG and another targeted to the CCGCTG. B. Products 
generated with the CTG repeat specific primer. C. Products generated with the CCGCTG 
repeat specific primer.  
A long run of CTG repeats were visualised at the 5'-end in III-9, III-16, IV-19, 
IV-20, III-17 and IV-21, but only small faint smears around 650-850 bp were 
obtained with the CCGCTG specific primers. At the 3'-end, a smear was Claudia Braida, 2008    Chapter 4, 104 
 
 
obtained with a size between 200-300 bp, detected in all cases with the 
CCGCTG specific primer. Two ladders with a gap in the middle were 
detected with the CTG repeat specific primer (figure 4-6). Most of the gap 
complemented the ladder detected with the CCGCTG repeat specific 
primer except the top, indicating that another type of repeat must be 
present. By sizing the bottom and the top part of the ladders, the number 
of repeats was estimated. The DM1+CMT++ allele was estimated to 
comprise of (CTG)X (NNN)x(CCGCTG)14 (CTG)35. The CTG repeats at the 5'-
end seemed to be the variable part of the repeat tract.  
 
Figure 4-6. RP-PCR. A. DNA was amplified by RP-PCR using primers DM-A and primers 
TAG-CAGCGG (to detect the CCGCTG hexamer) or TAG-AGC (to detect CTG). The 
products were resolved on a 1.5% agarose gel and detected with the 5'-end probe. B. DNA 
was amplified by RP-PCR using primers DM-DR and primers TAG-CCGCTG (to detect the 
CCGCTG hexamer) or TAG-GTC (to detect CTG). The RP-PCR products were resolved on 
a 1.5% agarose gel and detected with the DM1 CTG repeat probe. The estimated sizes of 
triplets are indicated on the right. Note a gap between 300-400 bp where a ladder was not 
detected with either the CTG repeat specific primer or the CCGCTG repeat specific primer, 
so other type of repeats should be present. NC (normal control). 
Given that small products were generated by RP-PCR at the 3'-end with the 
CCGCTG specific repeat primer, it appeared logical to clone and sequence 
those fragments. The DNA from the top part of the CCGCTG hexamer RP-
PCR ladder was purified from an agarose gel and cloned into pCR®4-TOPO® 
using a TOPO TA cloning kit for sequencing. Relatively stable clones were 
obtained and plasmid DNA from two clones for each sample was sequenced. Claudia Braida, 2008    Chapter 4, 105 
 
 
Slight differences were observed between the sequences of the clones 
corresponding to the same patient. Nevertheless, the sequences confirmed 
the estimated sequence previously postulated by sizing the smears 
(CCGCTG)10-15 (CTG)35 (data generated by Navdeep Mahajan MSc student 
project under my supervision). 
4.2.3.2  Cloning the gap 
A gap between 300 bp to 400 bp was detected in 3'-end RP-PCR when using 
the CTG repeat specific primer, suggesting that another type of repeat 
must be present in the DM1+CMT++ allele. GGC repeats were observed by 
sequencing vectorette clones, so it could be possible that the gap 
corresponds to the presence of GGC repeats. In order to investigate the 
presence of GGC by RP-PCR, specific primers were designed containing five 
GGC repeats. Unexpectedly, a ladder for the variant GGC repeats was not 
obtained, but in contrast the complementary repeat CCG was detected. 
Ladders at the 5'-end and 3'-end were detected in III-9, III-16, IV-19 and IV-
20 using CCG specific primers; as expected IV-11 and IV-12 were negative 
(figure 4-7). The ladder coincides with the gap previously detected with the 
CTG repeat specific primer. By sizing the top and bottom part of the 
ladder, the number of CCG repeats was estimated. The sequence of the 
repeat seemed to be comprised of (CTG)x (CCG)20 (CCGCTG)14 (CTG)35. 
Similar data was obtained with III-17, IV-21 and IV-22 (data not shown).  
DNA from the top part of the RP-PCR ladder obtained with the CCG repeat 
specific primer at the 3'-end was purified cloned and sequenced. Four 
clones were sequenced, even though slight differences between the 
different clones were observed, the sequence confirmed the estimated 
sequence. In addition, DNA from the top part of the RP-PCR ladder at the 
5'-end with the CCG repeat specific primer was also purified, cloned and 
sequenced. One clone was sequenced and the following structure (CTG)X 
(GGC)3 G (CCG)5 (CCA)1 (CCG)7 was read. The HhaI site within the CTG tract 
was revealed, together with GGC and CCG. Unexpectedly, a new type of 
CCA repeat was also observed. The presence of this novel variant could be 
either a mutation generated during PCR or by E. coli or even a sequencing Claudia Braida, 2008    Chapter 4, 106 
 
 
error, and so it should be verified. The GGC repeats were not detected by 
RP-PCR but this could be because the primer contained five repeats and the 
alleles appear to contain only three repeats.   
 
Figure 4-7. Representative RP-PCR autoradiographs. The specific primer was targeted to 
the 5'-end (A) or to the 3'-end (B). CTG (CTG repeat specific primer), CCGCTG (CCGCTG 
repeat specific primer) and CCG (CCG repeat specific primer). The products were run on a 
1.5% agarose gel and detected with either the 5'-end probe (A) or the DM1 CTG repeat 
probe (B). Estimated sequences of the repeat tract are indicated on the right and the position 
of the molecular weight marker is indicated on the left. 
4.2.3.3  Single molecule separated alleles investigated by RP-PCR 
Single molecule separated alleles were used to test which repeat was 
responsible for somatic mosaicism observed when amplifying bulk genomic 
DNA. Ladders with different lengths located at different positions were 
visualised. By sizing the top and bottom part of each smear, the number of 
each type of repeat was estimated. The sequence of the repeat seemed to 
be comprised of (CTG)x (CCG)20 (CCGCTG)14 (CTG)35. The numbers of CCG, 
CCGCTG and CTG at the 3'-end seemed to be very similar between single 
molecule separated alleles containing the expanded allele of the same 
patient and between different patients. In contrast, the CTG tract at the 
5'-end seemed to be the variable part of the array (figure 4-8). This data 
indicates that the different number of CTG repeats at the 5'-end causes the 
somatic mosaicism detected in each patient. Claudia Braida, 2008    Chapter 4, 107 
 
 
 
Figure 4-8. Representative RP-PCR autoradiographs. Single molecule separated alleles 
were investigated by RP-PCR. The specific primer was targeted to the 5'-end (A) or to the 3'-
end (B). CTG (CTG repeat specific primer), CCGCTG (CCGCTG repeat specific primer) and 
CCG (CCG repeat specific primer). The products were run on a 1.5% agarose gel and 
detected with either the 5'-end probe (A) or the DM1 CTG repeat probe (B). Estimated 
sequences of the repeat tract are indicated. The size of the molecular weight marker is 
indicated on the left. Claudia Braida, 2008    Chapter 4, 108 
 
 
4.2.4 Amplifying the 3'-end of the DM1+CMT++ allele by PCR 
Three GGC triplets seemed to be at the end of the CTG repeat at the 5'-
end. The primer DM-GGC (TG CTG CTG CTG CTG GGC GGC G) was designed 
to detect the boundary. DM-GGC was used in combination with DM-DR in an 
effort to amplify the 3'-end of the repeat tract, which seemed to be similar 
in all the patients. Single molecule separated alleles containing expanded 
alleles were amplified with primers DM-GGC and DM-DR and a product of 
~350 bp was constantly obtained. The products were digested with HhaI 
and a single site was detected in all the single molecules investigated. The 
DNA from the bands was purified, cloned and sequenced. The sequence 
revealed that the product consisted of: GCG (CCG)20 (CCGCTG)14 (CTG)35 
(worked performed by Rhoda Stefanatos, undergraduate student project 
under my supervision).   
Slight differences in the sequence obtained from the independent single 
expanded alleles were obtained. To test if these differences were real or 
cloning errors, genomic DNA from the DM1+CMT++ cases was amplified with 
DM-GGC and DM-DR and resolved by agarose gel electrophoresis. Two 
rounds of PCR were needed to detect amplification products.  The first 
round was performed with primers DM-C and DM-DR in the presence of 10% 
DMSO. A hemi-nested PCR was performed with primers DM-GGC and DM-DR 
using 100-fold dilution of the first PCR. The size of the band was estimated 
in each patient. The average size of the band was 344 bp ± 5 bp (figure 4-
9). These data along with the results described above, indicated that the 
3'-end of the repeat tract is the same in all the DM1+CMT++ cases 
investigated. Therefore, the 3'-end was transmitted unmodified from the 
third to the fourth generation. The only difference between the 
DM1+CMT++ alleles was the number of CTG repeats at the 5'-end, which is 
also responsible for somatic mosaicism present in the patients. 
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PCR with DM-GGC and DM-DR 
 
Figure 4-9. Amplifying the 3'-end of the repeat tract. Genomic DNA was amplified with 
primers DM-C and DM-DR in the presence of 10% DMSO. Hemi-nested PCR was performed 
with primers DM-GGC and DM-DR using 100-fold dilution of the primary PCR reaction. The 
products were resolved on a 2% nusieve, 1% agarose gel. NC (negative control), U1 (normal 
individual), A2 (classic DM1 patient). The size of the marker is indicated on the left. The 
bottom band is a non-specific band that was not detected by Southern blot hybridisation with 
the DM1 CTG repeat probe. 
In summary, the combination of cloning and sequencing, RP-PCR, 
restriction mapping and the PCR performed with the DM-GGC primer were 
necessary to obtain the best-estimated structure of the DM1+CMT++ allele. 
The allele is comprised of three novel repeat types and a HhaI site (figure 
4-10). The CTG repeats at the 5'-end are unstable and responsible for both 
somatic and germ line variation. In contrast, the interrupted 3'-end is 
somatically and intergenerationally stable. 
 
Figure 4-10. Structure of the DM1+CMT++ allele. The best estimated sequence of the 
imperfect CTG repeat tract is shown. The variable tract of the structure is the CTG run at the 
5'-end, followed by (GGC)3 G (CCG)20 (CCGCTG)14 (CTG)35.  
4.2.5 Investigating the dynamics of the DM1+CMT++ allele by 
SP-PCR 
The expanded CTG repeat at the DM1 locus has been demonstrated to be 
somatically and intergenerationally unstable. The somatic instability is 
expansion-biased, age-dependant and tissue specific (Monckton, et al. Claudia Braida, 2008    Chapter 4, 110 
 
 
1995a Martorell, 1998; Wong, et al. 1995 Martorell, 1998). Given the 
stabilising effect of variant repeats at other loci, we thought it likely that 
the presence of interruptions could affect the stability of the CTG repeat. 
4.2.5.1  Analysing the degree of somatic mosaicism  
To investigate in detail the dynamics of the DM1+CMT++ allele, SP-PCR was 
performed with DNA derived from blood cells. SP-PCR has been 
demonstrated to be a powerful technique to resolve and amplify products 
derived from single molecules, allowing a detailed analysis of repeat length 
variation to be performed (Monckton, et al. 1995). 
HindIII-digested genomic DNA was serially diluted and amplified with 
primers DM-A and DM-DR. The products were resolved on 1.5% agarose gels 
and detected with the DM1 CTG repeat probe. The progenitor allele 
(inherited allele transmitted by the father or the mother) was estimated as 
the lower boundary of the distribution when amplifying ~150 genomic 
equivalents. To measure the somatic mosaicism, an average of 3 genomic 
equivalents per reaction were amplified and more than 100 molecules were 
sized for each patient (figure 4-11). The degree of somatic mosaicism was 
estimated as the difference between the 90
th percentile and the 10
th 
percentile in the distribution (figure 4-12). The CTG repeats at the 5'-end 
of the DM1+CMT++ allele was somatically unstable and biased toward 
expansions; alleles of different sizes were visualised in each DM1+CMT++ 
patient.  
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SP-PCR with primers DM-A and DM-DR 
 
 
Figure 4-11. Repeat length variation in blood cells from the DM1+CMT++ cases. SP-
PCR was used to assess the repeat length variation. Representative SP-PCR 
autoradiographs derived from ~3 genomic equivalents. The scale on the right displays the 
molecular weight marker converted into number of triplets. The age at sampling is indicated 
above each panel. Claudia Braida, 2008    Chapter 4, 112 
 
 
 
 
Figure 4-12. Distribution of the imperfect CTG allele in blood cells of seven 
DM1+CMT++ cases. More than 100 expanded molecules were sized for each individual. 
The somatic mosaicism of samples with similar progenitor allele and similar age at sampling 
was very similar as expected (III-16 and III-17, IV-21 and IV-22). PA (total length of the 
progenitor allele), DSM (degree of somatic mosaicism). The size of the interruptions at 3'-
end for all the DM1+CMT++cases was 84 triplets. Claudia Braida, 2008    Chapter 4, 113 
 
 
4.2.5.2  Understanding the intergenerational dynamics of the 
DM1+CMT++ allele  
Slight increases in the length of the CTG repeats were observed through 
maternal transmissions, for example the mutant allele of III-16 increased 
~43 CTG repeats when transmitted to the offspring. Similar increases in 
size where observed in the DM1+CMT++ allele of III-17 (table 4-2). These 
data indicated the interrupted CTG repeat allele was intergenerationally 
unstable and explained the slight anticipation observed in the DM1 
phenotype between the two generations. Nevertheless, these changes are 
far smaller than those observed in classic DM1 patients. For instance, 
combining the data generated in two studies of 66 mother-child pairs, the 
average size of the inherited allele in affected children was 496 CTG 
repeats ranging from 65 to 1760. The average size of the progenitor allele 
in the mother was 75 ranging from 56 to 95 (Barcelo, et al. 1993; Redman, 
et al. 1993).  
The imperfect CTG repeats seemed to be more intergenerationally stable 
than the pure CTG repeat, consistent with what was previously observed 
with the "38" repeat allele in sperm (Leeflang and Arnheim 1995). 
Strikingly, in the DM1+CMT++ family, patients with similar length of the 
progenitor allele presented similar age of onset of DM1 symptoms (table 4-
2). 
Table 4-2. Comparison of the progenitor allele length with the age of onset of DM1 and 
CMT observed in the DM1+CMT++ cases 
  Progenitor 
allele  
Transmitted 
allele  
Length 
change (CTG)  
Age of onset 
of DM1 (yrs) 
III-9  225 (141)  -  -  25 
III-16  170 (86)  213  43  44 
IV-19  213 (129)  -  -  20 
IV-20  213 (129)  -  -  24 
III-17  179 (95)  220/25  41/46  35 
IV-21  220 (136)  -  -  17 
IV-22  225 (141)  -  -  24 
The total length of the progenitor allele is displayed in number of triplets; the length of the 
CTG repeats at the 5'-end is shown in brackets. The age of onset is quite difficult to define 
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4.2.5.3  Age effects on the level of somatic mosaicism  
The repeat length of CTG repeats in blood cells of classic DM1 patients 
increases in size over the lifetime of an individual (Martorell, et al. 1995; 
Wong, et al. 1995; Martorell, et al. 1998). A detailed study of 111 DM1 
patients over a period of time from one to seven years showed that when 
the size of the progenitor allele was >200 repeats an increase in average 
repeat length was detected in a period of more than two years. However, if 
the number of repeats was < 200 repeats, an increment in the modal allele 
size was not generally detected. From 34 patients with <200 repeats, only 
one showed a detectable change in average repeat length (Martorell, et al. 
1998). 
To investigate if the somatic mosaicism of the DM1+CMT++ allele changes 
over time, repeat blood samples from III-9, III-16 and IV-21 taken with time 
intervals ranging from 3 to 8 years were investigated by SP-PCR. A 
statistically significant increase in the allele length was observed in IV-21 
over 8 years (Mann-Whitney, p<0.0001), with an increase of 34 CTG repeats 
in the median (figure 4-13 and 4-14). In contrast, no obvious differences in 
the repeat length distributions were observed between the two samples 
obtained 3 and 4 years apart from III-9 and III-16 respectively. IV-21 was 
sampled very young, while III-9 and III-16 were sampled after 55 years of 
age so this could explain the differences. Additionally, probably the age 
effects are not as dramatic as in pure CTG repeat tracts. 
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SP-PCR with primers DM-A and DM-DR 
 
 
Figure 4-13. SP-PCR analysis of the repeat length in repeat samples from the same 
patient. Each panel shows 5 lanes of SP-PCR derived from ~15 genomic equivalents. The 
scale on the right displays the molecular marker converted into number of triplets. The age at 
sampling is indicated above and the median of the total repeat length below each panel. 
 
Figure 4-14. Somatic mosaicism of the DM1+CMT++ allele in repeat samples. The 
histograms represent the frequencies of allele lengths at two different time points. A statically 
significant variation in the allele lengths was observed in IV-21 over 8 years (Mann-Whitney, 
p<0.0001).    Claudia Braida, 2008    Chapter 4, 116 
 
 
4.2.5.4  Comparison of the level of somatic mosaicism in the 
DM1+CMT++ family with classic DM1 patients 
The progenitor allele length and the age at sampling were identified as the 
major modifiers of somatic mosaicism in DM1 in an extended study, which 
comprised the analysis of samples from Costa Rica (50), Texas (30), 
Scotland (23) and Uruguay (4). Individuals in the extreme of the 
distribution as congenital cases and individuals with the mild form 
investigated later in life were not included in the analysis of that study. 
Linear regression analysis showed that the age at sampling and the 
progenitor allele length presented significant positive correlations with the 
degree of somatic mosaicism. To clarify further these interrelationships, 
the data was analysed using a General Linear Model ANOVA with interaction 
between the age at sampling and the progenitor allele length. The model 
revealed that ~66% of the variation in somatic mosaicism is caused by 
complex interactions between the progenitor allele length and the age at 
sampling (GLM ANOVA, r = 0.81, p =0.005). The model was: log SV = 
2.2228log PA + 3.4945 log AS - 1.0206 log PA x log AS, where SV is somatic 
variation, PA is progenitor allele in number of CTG repeats and AS is age at 
sampling in years (Morales 2006). 
To determine if the DM1+CMT++ allele affects the degree of somatic 
mosaicism, the data from the DM1+CMT++ cases was compared with the 
previous study. The level of somatic mosaicism in the DM1+CMT++ cases 
was always lower than the expected level for the age at sampling (figure 4-
15A) and for the progenitor allele length (figure 4-15B), except for IV-19 
and III-9 who both presented a level of somatic mosaicism slightly higher 
than expected for the length of the progenitor allele. The values of somatic 
mosaicism calculated with the formula predicted by the General Linear 
Model were almost all noticeably higher than the observed values (table 4-
3). These data strongly suggest that the presence of interruptions at the   
3'-end of the repeat tract decreased the instability of the CTG repeats at 
the 5'-end.  
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Figure 4-15. Age at sampling and progenitor allele effects on the degree of somatic 
mosaicism. A. Linear regression analysis between the age at sampling and somatic 
variation. B. Linear regression analysis between the progenitor allele and somatic variation. 
Black dots represent data from classic DM1 patients (Morales 2006) and red dots represent 
the DM1+CMT++ cases. Half of the points should be expected to be located above the 
tendency line and the other half below. However, all the points from the DM1+CMT++ cases 
were located below the tendency line in the analysis of age at sampling versus somatic 
variation. By Fisher exact test, it was shown that the points were statistically different from 
the tendency line obtained with the DM1 classic patients (p=0.0017), giving evidence for a 
reduced instability of the DM1+CMT++ alleles. 
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Table 4-3. Comparing the degree of somatic variation 
  Progenitor 
allele 
Age at sampling 
(years) 
Somatic variation 
observed 
Somatic variation 
estimated 
III-9  225 (141)  58  325   511 (419) 
III-9  223 (139)  55  344   480 (389) 
III-16  170 (86)  61  102   483 (367) 
III-16  168 (84)  57  38   442 (328) 
IV-19  213 (129)  37  306   302 (221) 
IV-20  213 (129)  34  101   275 (197) 
III-17  179 (95)  58  100   464 (355) 
IV-21  220 (136)  30  158   244 (173) 
IV-21  217 (133)  22  103   172 (113) 
IV-22  225 (141)  28  189   230 (163) 
The total length of the progenitor allele is displayed in number of triplets, with the length of 
the CTG repeats at the 5'-end shown in brackets. The somatic variation observed was 
calculated as the difference between the 90
th percentile and the 10
th percentile. The 
estimated somatic variation was calculated using the model generated with a GLM (log SV = 
2.2228log PA + 3.4945 log AS - 1.0206 log PA x log AS), where SV is somatic variation, PA 
is progenitor allele in number of CTG repeats and AS is age at sampling in years. The 
estimated somatic variation taking into account only the CTG repeats at the 5'-end is 
indicated in brackets. 
4.2.6 Investigating DNA methylation in the DM1+CMT++ allele 
The CTG repeat at the DM1 locus cannot be methylated as it does not 
contain any CpGs. However, the repeat is in a CpG island and is flanked by 
multiple CpG sites in the vicinity. Methylation of these flanking CpGs may 
affect the chromatin structure and gene expression. Steinbach and 
colleagues analysed part of the CpG island at the 3'-end of the DMPK gene 
for methylation status using methylation-sensitive restriction enzymes and 
Southern blot. In the expanded alleles containing ≥1,000 CTG repeats in 
congenital cases, the CpG island was hypermethylated, whereas it was 
unmethylated in normal alleles or expanded alleles of adult onset cases 
(Steinbach, et al. 1998). The interruptions present in the DM1+CMT++ allele 
provide new CpG methylation sites within the repeat tract; methylation of 
the repeat tract may similarly affect chromatin structure and gene 
expression so we investigated whether those sites were methylated. Claudia Braida, 2008    Chapter 4, 119 
 
 
To determine the pattern of methylation in the DM1+CMT++ allele, genomic 
DNA of the DM1+CMT++ cases was digested with two methylation sensitive 
enzymes, either AciI or HhaI. The digested DNA was amplified by PCR with 
specific primers to detect whether the site of interest was methylated or 
not. If the site was methylated, the enzyme will not recognize the site and 
a PCR product could be amplified. In contrast, if the site was unmethylated 
the enzyme will recognize and digest the site and in consequence no PCR 
product will be generated. Several controls are needed including a no 
enzyme control. Ideally, three pair of primers should be used: one pair 
targeted to a region where there is no restriction site; a second pair to 
amplify a product only in the undigested control; and a third to generate a 
product only if the restriction site under study is methylated. The first pair 
will act as an internal control of the PCR, the second will act as an internal 
control of the digestion and the third is to investigate whether the site is 
methylated or not.  
The AciI sites and the HhaI site located within the CTG repeat tract in the 
DM1+CMT++ allele were investigated by amplifying the digested products 
with primers DM-C and DM-DR. In our case, it was not necessary to use 
three pairs of primers because the normal allele does not have a 
methylation site so it will act as an internal control of the PCR. The HhaI 
site seemed to be unmethylated in the majority of the expanded alleles. 
The expanded alleles were not detected when the DNA was digested, and 
the normal alleles always amplified as expected (figure 4-16). In contrast, 
the majority of the AciI sites seemed methylated, and several expanded 
alleles were detected when the DNA was digested. It should be pointed out 
that analysis with AciI enzyme requires a control of the digestion reaction. 
This data was generated at the end of the project and there was 
insufficient time left to perform the digestion reaction control. 
Several AciI sites within the CTG repeat tract in the DM1+CMT++ allele were 
methylated. Consequently, the activity of SIX5 and DMPK genes might be 
altered. It will be interesting to test whether the pattern of methylation in 
the flanking CpG sites at either end of the repeat tract is also modified. Claudia Braida, 2008    Chapter 4, 120 
 
 
 
Figure 4-16. Methylation pattern of the DM1+CMT++ allele. Genomic DNA was digested 
either with HhaI or AciI, and amplified with primers DM-C and DM-DR. The digested 
products and the undigested controls were resolved on a 1.5 % agarose gel and detected by 
Southern blot hybridisation with the DM1 CTG repeat probe. The position of the molecular 
weight marker is indicated on the right. There are several non-specific bands with sizes 
between 250-350 bp with a weak signal, which are probably just contamination. 
4.3 Discussion 
It has been demonstrated that the combination of cloning and sequencing, 
restriction mapping and RP-PCR together with the use of single molecule 
separated alleles has been extremely successful in defining the structure of 
the imperfect CTG allele in the DM1+CMT++ family. It should be noted that 
each technique has advantages and disadvantages, and it is necessary to 
use a combination of the techniques to obtain a reliable structure due to 
the instability of the repeat structures. The 3'-end of the repeat was 
amplified by PCR using the primer DM-GGC and DM-DR, and it was verified 
that the 3'-end of the repeat tract was practically unchanged in the 
different patients. The structure of the DM1+CMT++ allele has been 
characterised. It is comprised of a variable number of CTG repeats at the 
5'-end followed by: GGC, CCG, CCGCTG and 35 CTG repeats at the 3'-end.  Claudia Braida, 2008    Chapter 4, 121 
 
 
The dynamics of the CTG repeat at the 5'-end of DM1+CMT++ allele was 
investigated by SP-PCR analysis. It was shown that the CTG repeats at the 
5'-end were somatically unstable and biased toward expansions, but to a 
lower degree than the CTG repeats in classic DM1 patients. This gives a 
molecular explanation for the mild DM1 phenotype observed in the 
patients. The presence of interruptions within the CTG repeats at the DM1 
locus seemed to stabilise the repeat tract.  
Generally, expanded CTG repeats increase in size when transmitted. For 
instance, a mother with 100 repeats has a 62% risk of transmitting a 
congenital allele (Redman, et al. 1993). However in the DM1+CMT++ family, 
only small changes in the number of CTG repeats at the 5'-end were 
observed through maternal transmissions. The small increases in size in the 
CTG repeats explain the reduced anticipation in the DM1 phenotypes 
observed in the DM1+CMT++ family. An increase in the severity of symptoms 
and a reduced age of onset was observed in the CMT phenotype through the 
generations in the DM1+CMT++ family. If CMT is caused by the presence of 
interruptions, the anticipation could be explained by the small changes in 
the number of CTG repeats at the 5'-end. The CCG repeats are more toxic 
than the CTG repeats, since only 55 repeats are enough to express a 
phenotype in FXTAS (Hagerman and Hagerman 2004). Therefore, the small 
changes in the number of CTG repeats at the 5'-end could be enough to 
retain more alleles in the nucleus and consequently more proteins would be 
retained, explaining the anticipation in CMT. In order, to probe this 
hypothesis, it will be necessary to demonstrate first that the interruptions 
are definitely the cause of CMT. 
The presence of imperfect CTG alleles has not been taken into account 
before, and it could be one of the factors responsible for the variability 
observed in the DM1 patients. It will be interesting to investigate the 
presence of interruptions in patients with a phenotype not as severe as 
expected for the number of CTG repeats. In addition, a similar mechanism 
may explain the CMT phenotype in families with an unknown aetiology.  Claudia Braida, 2008    Chapter 4, 122 
 
 
The expansion of CTG repeats in the DM1 locus has been shown to alter the 
adjacent chromatin structure establishing a region of condensed chromatin 
(Otten and Tapscott 1995). In vitro studies showed that the CTG repeats 
are strong nucleosome positioning elements and the efficiency of the 
formation increased with the number of triplets, indicating that the 
expansion may repress the transcription of the DMPK gene and/or 
neighbouring genes (Wang, et al. 1994). Furthermore, the CTG repeats in 
the DM1 locus are inserted in a CpG island that controls the activity of the 
downstream gene SIX5 (Boucher, et al. 1995). Two CTCF binding sites flank 
the CTG repeat tract and form an insulator element between DMPK and 
SIX5 (Filippova, et al. 2001). In congenital DM1 cases, the CpG island is 
methylated so the enhancer element of SIX5 is lost. In addition, the CTCF 
protein cannot have access to the sites and consequently the activity of the 
insulator is compromised. Reduced levels of SIX5 transcript were observed 
in DM1 patients (Klesert, et al. 1997; Thornton, et al. 1997). The 
interruptions in the DM1+CMT++ allele provide new CpG sites, of which at 
least some seemed to be methylated (section 4.2.6). It will be interesting 
to investigate the methylation pattern in the 5' and 3' flanking DNA of the 
repeat tract in the DM1+CMT++ allele. Two possible outcomes can be 
envisioned. The first possible outcome is that the CpG island is methylated 
as in congenital DM1 cases. Alternatively, by analogy to the mechanism 
observed in FXTAS, the CpG island may remain unmethylated and the level 
of SIX5 increased (Tassone, et al. 2000b). If indeed the level of SIX5 
increased, it could be a possible explanation for the complex phenotype 
observed in the DM1+CMT++ family. Furthermore, the CTG repeats are 
strong nucleosome positioning elements (Wang, et al. 1994) in contrast to 
CCG repeats, which are strong inhibitors (Wang and Griffith 1996). It will 
be interesting to investigate the structure of the chromatin at the 
DM1+CMT++ allele where CTG repeats are next to CCG repeats, and to 
analyse whether the activity of the DMPK and SIX5 genes may be altered. 
Future investigations will focus on trying to explain how the other 
symptoms in the DM1+CMT++ family can be explained by the presence of 
this novel repeat. As was postulated in the previous chapter, the most 
plausible explanation is by a mechanism similar to FXTAS. The presence of Claudia Braida, 2008    Chapter 4, 123 
 
 
interruptions in the DMPK transcript probably alters its secondary structure 
and consequently novel proteins may be trapped and a novel phenotype 
could be expressed. 124 
5  Investigating the molecular lesion in a 
number of sporadic DM1 cases with an 
unusual molecular diagnosis 
5.1 Introduction 
The DM1 mutation was identified as an expansion of a CTG repeat at the 3'-
end of the DMPK gene in 1992. Evidence obtained from cloning and 
sequencing 50-80 repeat alleles and hybridisation with CTG probes revealed 
that the expanded allele was comprised of pure CTG repeats (Brook, et al. 
1992; Fu, et al. 1992; Mahadevan, et al. 1992). An imperfect CTG repeat 
allele within the normal range (37 repeats) was identified in a sperm 
sample while studying the male germline mutation rate of triplet repeats 
(Leeflang and Arnheim 1995). The sequence of the "37" repeat allele 
revealed that it consisted of (CTG)4 (CCGCTG)16 (CTG). The presence of the 
CCGCTG hexamer can be easily identified by restriction digestion with AciI 
(CCGC). The presence of the AciI sites was also investigated in 71 
individuals carrying between 30 and 54 CTG repeats in the DM1 locus, but 
no other imperfect CTG repeat alleles were identified (Martorell, et al. 
2001). These data suggested that imperfect CTG repeat alleles must not be 
common within the premutation alleles. Nevertheless, the Cockburn group 
presented preliminary data at the International Myotonic Dystrophy 
Consortium (IDMC4) that three DM1 patients presented an interrupted CTG 
repeat allele detected by RP-PCR (Cockburn, et al. 2003). We had 
demonstrated in chapter four that the molecular lesion in the DM1+CMT++ 
family consisted of an imperfect CTG allele at the DM1 locus. Therefore, it 
could be possible that the presence of interruptions within the CTG repeats 
at the DM1 locus might not be such a rare event. 
Interestingly, our collaborators Jean-Louis Mandel and his colleagues had 
identified a number of sporadic DM1 patients, who were referred for 
genetic testing and then presented with an unusual molecular diagnosis. 
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group (DM1-UC1, DM1-UC2, DM1-UC3, DM1-UC4, DM1-UC5, DM1-UC6, DM1-
UC7 and DM1-UC8) presented an interrupted pattern on RP-PCR, and by 
partially sequencing the 3'-end CTG repeat tract a number of interruptions 
(CCGCTG or CCTGCTC) were detected. Two patients are related, DM1-UC1 
is the mother of DM1-UC2. DM1-UC7 has two normal alleles, with one large 
interrupted allele containing "40" repeats. In the second group of patients 
(DM1-UC9, DM1-UC10, DM1-UC11, DM1-UC12, DM1-UC13, DM1-UC14 and 
DM1-UC15), discrepancies between Southern blot of restriction digested 
genomic DNA and 3’-end RP-PCR studies were found. In DM1-UC9, a 
deletion of 10 bp was sequenced at the 3'-end of the repeat tract. DM1-
UC10 was the father of DM1-UC11 (a foetus). It was postulated that 
probably a large deletion occurred between the father and foetus.  An 
expanded allele was detected by Southern blot of restricted digested 
genomic DNA in both patients, but the expanded allele was only detected 
in the father (DM1-UC10) by 3'-end RP-PCR. In the patient DM1-UC12, two 
alleles within the normal range were detected by PCR but only one allele 
was detected by RP-PCR. 
In this chapter, the series of molecular analyses performed to further 
characterise the DM1 mutation in these unusual DM1 cases are presented. 
The dynamics of the DM1 alleles was investigated by SP-PCR analysis to test 
whether the instability of the CTG repeats was modified in the unusual 
cases. To gain an insight into the possible effects of the unusual mutation 
on the pathogenesis, the pattern of DNA methylation at the 3'-end flanking 
DNA was also investigated.  
5.2 Results 
5.2.1 Genotyping the DM1 locus by traditional methods 
5.2.1.1  PCR 
PCR, Southern blot digested genomic DNA and RP-PCR was previously 
performed by Mandel's group, however the analysis of the unusual cases Claudia Braida, 2008    Chapter 5, 126 
 
began by genotyping the DM1 locus by a standard PCR to confirm the 
previous results. 
To genotype the DM1 locus, a standard PCR was performed with primers 
DM-C and DM-DR (figure 5-1). DM1-UC7, DM1-UC12 and DM1-UC15 presented 
as heterozygous carrying two normal alleles. One normal allele and an 
expanded allele were detected in DM1-UC3, DM1-UC5, DM1-UC6, DM1-UC8 
and DM1-UC9. The expanded alleles were smeary, consistent with somatic 
mosaicism as is generally observed in classic DM1 patients. In DM1-UC1, 
DM1-UC2, DM1-UC4, DM1-UC10, DM1-UC11, DM1-UC13 and DM1-UC14, the 
expanded allele was not detected and only one normal allele was 
identified. A polymorphism within the primer site could be one reason why 
an expanded allele was not detected in the latter patients. However, three 
independent combinations of primers (DM-C/DM-DR, DM-A/DM-BR and DM-
C/DM-ER) failed to detect an expanded allele (figure 5-1A). Alternatively, 
an additional lesion such as an insertion within the CTG repeats, a deletion 
or a rearrangement at the flanking DNA might explain why an expanded 
allele was not detected by the standard PCR. Taking into account the 
information given previously, an interruption seemed to be the cause in 
DM1-UC1, DM1-UC2 and DM1-UC4, whereas a deletion at the 3'-end was 
assumed to be most likely in DM1-UC11. 
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Figure 5-1. Genotype of the DM1 locus by standard PCR. A. Schematic diagram of the 
DM1 locus indicating the position of the primers tested. B. PCR products were resolved on a 
2% Nusieve, 1% agarose gel.  C. Representative autoradiograph. PCR products were 
resolved on a 1% agarose gel, transferred by Southern blot hybridisation and detected with 
the DM1 CTG repeat probe. The sizes of the marker are indicated on the right side and the 
estimated number of repeats is indicated on the left side. NC (negative control), A6 and A8 
(two classic DM1 patients), U10 and U11 (two normal controls). Additional bands with sizes 
of >1 Kb were detected in U10 and U11. The intensity is not as strong as the normal bands 
so it was probably contamination. Similarly, the additional bands detected in DM1-UC4, 
DM1-UC10 and DM1-UC15 could represent contamination. 
5.2.1.2  RP-PCR 
RP-PCR was performed with the CTG5 repeat specific primer from each end 
of the repeat tract both to analyse if an expanded allele could be amplified 
in DM1-UC1, DM1-UC2, DM1-UC4, DM1-UC10, DM1-UC11, DM1-UC13 and 
DM1-UC14, and to characterise further the DM1 mutation in the other 
unusual patients. 
In DM1-UC3, DM1-UC5, DM1-UC6, DM1-UC8 and DM1-UC9, an expanded 
allele was visualised with multiple primers at both ends (figure 5-2). In 
DM1-UC9, the expanded allele was not detected at the 3'-end when using 
the primer DM-ER. This result was consistent with the 10 bp deletion at the 
3'-end detected by sequencing, which removed part of the DM-ER priming 
site. In DM1-UC7, DM1-UC12 and DM1-UC15, only ladders corresponding in 
size to the normal alleles were detected by RP-PCR consistent with the 
standard PCR. In DM1-UC1, DM1-UC2, DM1-UC4, DM1-U10, DM1-UC11, DM1-
UC13 and DM1-UC14, an expanded allele was detected at the 5’-end of the Claudia Braida, 2008    Chapter 5, 128 
 
repeat tract with multiple primers (DM-T, DM-A, DM-H and DM-C), but was 
negative at the 3'-end of the array even with primers located up to 1 Kb 
distal to the repeat tract.  From this data, it could be postulated that the 
5'-end of the CTG repeat tract seemed to be intact in all the unusual cases. 
However, an additional lesion at the 3'-end must be present in DM1-UC1, 
DM1-UC2, DM1-UC4, DM1-U10, DM1-UC11, DM1-UC13 and DM1-UC14. 
 
Figure 5-2. RP-PCR studies. A. Diagram of the DM1 locus indicating the position of the 
different primers and the two probes used in the analysis. B. 5'-end RP-PCR with primer DM-
T. The products were run on a 1.5% agarose gel and detected with the 5'-end probe by 
Southern blot hybridisation. The DNA from DM1-UC12 and DM1-UC13 did not amplify well; it 
was probably a pipetting error while setting up the PCR. The samples were repeated and 
normal alleles were detected in DM1-UC12 and an expanded allele in DM1-UC13. C. 3'-end 
RP-PCR with primer 3PCR. The products were resolved on a 1.5% agarose gel and 
detected with the DM1 CTG probe. A faint ladder corresponding to the expanded allele was 
detected in DM1-UC3. NC (negative control), A6 and A8 (two classic DM1 patients), U10 
and U11 (two normal individuals). The size of the marker is indicated on the right and the 
estimated number of CTG repeats is indicated on the left side of each panel. 
The DNA samples from DM1-UC12 and DM1-UC15 were genotyped as both 
having two normal alleles of 5 and 17 CTG repeats at the DM1 locus. It was 
suspected these might be two samples from the same patient, so three 
highly polymorphic loci ERDA-1, CTG18.1 and MSH3 were genotyped in both 
samples. In all loci investigated, both samples were heterozygous 
presenting alleles of the same size (data not shown). The probability of 
finding a heterozygous individual carrying the same sizes of repeat alleles 
at the three loci was calculated by the product of the probabilities of each 
allele size. It was estimated to be approximately 1:59 x10
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both samples almost certainly corresponded to the same patient probably 
arising from a mistake made when the samples were sent. Consequently, 
sample DM1-UC15 was not included in further analyses. 
5.2.2 Genotyping the DM1 locus by a modified PCR  
A modified PCR was performed to investigate the possibility that an 
imperfect CTG allele with a high GC content might prevent the detection of 
the alleles by a standard PCR.  
The genomic DNA was amplified with primers DM-C and DM-DR in the 
presence of 10% DMSO. Expanded alleles were amplified in DM1-UC2, DM1-
UC3, DM1-UC4, DM1-UC5, DM1-UC6, DM1-UC8, DM1-UC9, DM1-UC10, DM1-
UC11 and DM1-UC13. In DM1-UC13, the expanded allele was still only 
detected as a faint interrupted smear. This result indicated that the 
expanded allele in DM1-UC13 did not amplify as effectively as the normal 
allele and/or the sequence of the expanded allele did not contain pure CTG 
repeats, consequently the DM1 CTG repeat probe did not hybridise 
properly. Two alleles within the normal range were amplified with DM1-
UC7 and DM1-UC12, verifying the data obtained by the standard technique. 
Nevertheless, an expanded allele was still not amplified in DM1-UC14 
(figure 5-3). The expanded alleles were all smeary, consistent with somatic 
mosaicism. An expanded allele was also identified in DM1-UC1 (data not 
shown). The expanded allele of DM1-UC11 (a foetus) was detected as a 
discrete band. The DM1 expanded allele in foetuses and newborns show 
practically no repeat length heterogeneity and are detected as single bands 
on the gels when amplified by PCR. The alleles become more 
heterogeneous in size with increasing age (Wong, et al. 1995; Martorell, et 
al. 1998). Therefore, the absence of somatic mosaicism of the expanded 
allele of DM1-UC11 was expected. 
The "41" repeat allele of DM1-UC7 was cloned and sequenced to determine 
the structure of the interrupted allele. The sequence revealed that the 
allele consisted of (CTG)6 (CCGCTG)15 (CTG)5. The CTG repeats were 
interrupted by a series of CCG, in a very similar manner to the structure Claudia Braida, 2008    Chapter 5, 130 
 
sequenced in the "38" repeat allele of III-9, IV-11 and IV-12 (chapter three, 
section 3.2.3). It is not known yet how many people were screened to 
identify these unusual cases so the frequency of that allele cannot be 
estimated. However, it should be pointed out that an interrupted allele of 
that size is not a unique event, as was previously believed. 
The expanded allele in DM1-UC1, DM1-UC2, DM1-UC4, DM1-UC10, DM1-UC11 
and DM1-UC13 was not visualised by the standard PCR. Therefore, the most 
likely explanation is an imperfect CTG repeat allele with a high GC 
content. 
 
Figure 5-3. Genotyping the DM1 locus by a modified PCR. Genomic DNA was amplified 
with primers DM-C and DM-DR in the presence of 10% DMSO. A. The products were 
resolved on a 1.5% agarose gel and stained with ethidium bromide. B. The gels were 
detected with the DM1 CTG repeat probe by Southern blot hybridisation. A2, A3 and A4 
(classic DM1 patients), U1 and U10 (normal individuals). The top bands of DM1-UC7 and 
DM1-UC12, which were not as strong as the other two bands probably corresponded to 
heteroduplex DNA. A faint interrupted smear extending up to the top of the gel was detected 
in DM1-UC13, although it is not visible here. The size of the marker is indicated to the left of 
each panel and the estimated sizes of repeats are shown on the right.  Claudia Braida, 2008    Chapter 5, 131 
 
5.2.3 Investigating interruptions by RP-PCR assays 
Mandel's group have identified CCGCTG interruptions in some unusual 
cases, so the CCGCTG3 specific primer was used in RP-PCR in order to gain 
an insight into the number and the location of the interruptions. The 
patients were investigated with RP-PCR from both ends of the CTG repeat 
tract using either the CCGCTG3 specific primer or the CTG5 specific 
primers. The "41" repeat allele of DM1-UC7 contained 15 CCGCTG repeats 
and was used as an internal control. 
In DM1-UC7, a ladder was detected from both ends when using the 
CCGCTG3 repeat specific primer. By measuring the top and the bottom of 
the ladder, 15 copies of the CCGCTG hexamer were estimated. Two small 
ladders and a gap in the middle were detected with CTG5 specific primer 
(figure 5-4). The gap corresponded to the ladder of CCGCTG repeats, and 
the small ladders corresponded in size to the CTG repeats located at either 
end of the CCGCTG hexamers. The structure of the "41" repeat allele 
detected by RP-PCR was consistent with the sequence. In a similar way, the 
structure of the other unusual cases was postulated. At the 5'-end using the 
CTG5 repeat specific primer, a large uninterrupted tract of CTG repeats 
was observed in DM1-UC2, DM1-UC3, DM1-UC4, DM1-UC5, DM1-UC6, DM1-
UC8 and DM1-UC11. In DM1-UC11, the ladder detected with the CTG repeat 
specific primer goes up to ~450 bp so it could be determined that the allele 
contained ~105 CTG repeats at the 5'-end. The numbers of CTG repeats in 
the other unusual cases could not be determined because the ladder 
extended all the way up to the top of the gel. In addition, a ladder with the 
CCGCTG3 specific primer was detected at the 5'-end in DM1-UC11, starting 
at the end of the CTG repeat ladder. The other unusual cases were 
negative with the CCGCTG3 repeat specific primer at this end. 
At the 3'-end, DM1-UC2, DM1-UC3, DM1-UC4, DM1-UC5, DM1-UC6 and DM1-
UC8 presented ladders of different sizes with the CCGCTG3 repeat specific 
primer. The ladder detected with the CTG5 repeat specific primer 
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ladders. By sizing the top and bottom part of each ladder, the structure of 
the repeat tract was estimated for each patient.  
The DNA from the top part of the ladders obtained with the CCGCTG3 
repeat specific primers from DM1-UC2, DM1-UC3, DM1-UC4, DM1-UC5, DM1-
UC6 and DM1-UC8 at the 3'-end was purified and cloned. The inserts were 
quite stable in E. coli so it was possible to obtain a reliable sequence (work 
performed by Stefanatos Rhoda, an undergraduate project student under 
my supervision). The sequences verified the majority of the estimated 
sequences obtained by sizing the ladders obtained by RP-PCR. In DM1-UC2, 
DM1-UC5, DM1-UC6 and DM1-UC8, a number of CCGs were detected in the 
sequences.  
 
Figure 5-4. RP-PCR in the presence of 10% DMSO. A. 5'-end RP-PCR analysis using 
primer DM-A. The products were resolved on a 1.5% agarose gel and detected by Southern 
blot hybridisation with the 5'-end probe. B. 3'-end RP-PCR using primer DM-DR. The 
products were detected with the DM1 CTG repeat probe. The white boxes show the DNA 
that were extracted from agarose gel, cloned and sequenced. The size of the DNA molecular 
weight marker is indicated either on the left of each panel. NC (negative control). Claudia Braida, 2008    Chapter 5, 133 
 
The presence of CCG sequenced in some of the clones was verified by RP-
PCR using the CCG5 repeat specific primer, designed previously to 
investigate the DM1+CMT++ cases (chapter four). Bands were detected by 
RP-PCR only from the 3'-end in DM1-UC2, DM1-UC5, DM1-UC6, DM1-UC8 
(figure 5-5), and DM1-U13 and DM1-UC14 (figure 5-6). Taking together the 
information obtained by RP-PCR and sequencing, an estimated structure 
has been postulated for almost all of the unusual cases investigated (figure 
5-7). Most of the unusual cases contained a number of CCGCTG hexamers 
and CCG repeats. It should be pointed out that in DM1-UC2, DM1-UC3, DM1-
UC5 and DM1-UC6, higher order repeats units, containing subrepeats 
seemed to be present (indicated with black arrows in figure 5-7). For 
example in DM1-UC2, a higher order repeat unit comprised of 5 CTG repeats 
and 5 CCG repeats is repeated 3 times. Similarly in DM1-UC3, a higher order 
repeat containing 2 CTGs and 4 CCGCTGs is repeated two times, and 
another higher order repeat containing 4 CTGs and 1 CCGCTG is repeated 
three times. 
In DM1-UC9, the ladder detected with the CTG5 specific primer at both 
ends was continuous, and no bands were detected either with the CCGCTG3 
repeat or with the CCG5 repeat specific primers (figure 5-5). This data 
indicated that the CTG repeats in the expanded allele are pure. A deletion 
of 10 bp was sequenced at the 3'-end, which seemed to be the only unusual 
feature of this DM1 allele.  
The structure of the expanded allele of DM1-UC10 seemed to be 
interrupted with ~31 CCGCTG hexamers. Nevertheless, the allele inherited 
by DM1-UC11 (a foetus) was quite different. The number of CTG repeats 
was reduced, whereas the number of CCGCTG hexamers increased in size. 
The CCGCTG increased by ~88 repeats, whereas the CTG reduced by ~50 
repeats at the 3'-end and by ~23 repeats at the 5'-end. These data revealed 
that the CCGCTG hexamers and the CTG repeats at both ends were 
unstable.  
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Figure 5-5. Representative 3'-end RP-PCR. Genomic DNA was amplified by RP-PCR 
using the primer DM-DR. Three different repeat specific primers were used independently: 
the CTG5 repeat specific primer, the CCGCTG3 repeat specific or the CCG5 repeat specific. 
The products were resolved on a 1.5% agarose gel and detected by Southern blot 
hybridisation with the DM1 CTG repeat probe. Bands were detected with the CCG5 repeat 
specific primers only in DM1-UC5, DM1-UC6 and DM1-UC8. The sizes of the DNA 
molecular weight marker are indicated on the left and the number of estimated repeats on 
the right. 
The structure of the expanded alleles of DM1-UC13 and DM1-UC14 was not 
determined completely (figure 5-7 and table 5-1). In DM1-UC13, a long run 
of CTG repeats was detected at the 5'-end. From the other end, two 
ladders with a big gap in between were detected with the CTG5 repeat 
specific primer. Part but not the entire gap corresponded with the CCG 
repeat ladder and with two bands detected with CCGCTG. Additionally, the 
smear detected with the CTG5 repeat specific primer at the 3'-end was 
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arrangements are present. This result is consistent with the PCR analysis 
where a faint interrupted smear was detected. The expanded allele of 
DM1-UC14 did not amplify by PCR, and a short ladder was detected by RP-
PCR with the CTG5 repeat specific at the 5'-end and at the 3'-end with the 
CCG5 repeat specific primer. Taking into account all these data, it could be 
postulated that the expanded allele must contain a large interruption of 
either a novel repeat unit or arrangement of repeats (figure 5-6). 
 
Figure 5-6. RP-PCR analysis in the presence of 10% DMSO. Genomic DNA was amplified 
by RP-PCR. Three different repeat specific primers were used independently: the CTG5 
repeat specific primer, the CCGCTG3 repeat specific primer and the CCG5 repeat specific 
primer. The products were resolved on a 1.5% agarose gel and detected by Southern blot 
hybridisation with the 5'-end probe (A) or the DM1 CTG repeat probe (B). The position of the 
molecular weight marker is indicated on the left side of the panels and the estimated number 
of repeats is indicated on the right side. Claudia Braida, 2008    Chapter 5, 136 
 
 
Figure 5-7. Structure of several imperfect CTG repeat alleles detected in DM1 patients 
with an unusual molecular diagnosis. The structure of each allele was constructed taking 
into account the data obtained with RP-PCR and sequencing some clones. All unusual 
cases except DM1-U12 and DM1-UC9 present an imperfect CTG allele at the 3'-end of the 
repeat tract. The 5'-end seemed to contain long runs of pure CTG repeats. The black arrows 
indicate higher order repeats containing two different repeat units. The structure of the 
DM1+CMT++ allele is also indicated. DM1-UC10 and DM1-UC11 are related and the 
symbols on the left side indicate the relationship (father and foetus). 
Table 5-1. Best progenitor allele estimated sequence  
Patient  Estimated structure of the DM1 progenitor allele 
DM1-UC1  (CTG)48 (CCGCTG)17 (CTG)14    
DM1-UC2  (CTG)222(CCG)5((CTG)5 (CCG)5)2 (CCGCTG)22 (CTG)14 
DM1-UC3  (CTG)425 (CCGCTG)4 ((CTG)2(CCGCTG)4)2 ((CTG)4(CCGCTG))3 (CTG)14 
DM1-UC4  (CTG)318 (CCGCTG)19 (CTG)13 
DM1-UC5  (CTG)412 (CCG)5 (CTG)5 (CCGCTG)(CCG)5(CTG)5 ((CCGCTG)3(CTG)4)3 ((CCGCTG)(CTG)5)3 
DM1-UC6  (CTG)516  ((CCG)2 (CCGCTG))2 (CCG)2 ((CTG)5(CCGCTG))2 ((CTG)5 (CCG)2 (CCGCTG))4(CTG)31 
DM1-UC7  (CTG)5 (CCGCTG)15 (CTG)5 
DM1-UC8  (CTG)225 (CCGCTG) (CTG)7 ((CCGCTG) (CTG)7 (CCG)2)4  (CCGCTG) (CTG)9 (CCGCTG)(CTG)8 
DM1-UC9  (CTG)396  
DM1-UC10  (CTG)285 (CCGCTG)31 (CTG)58 
DM1-UC11  (CTG)128 (CCGCTG)119 (CTG)8 
DM1-UC12  Two normal alleles 
DM1-UC13  (CTG)x (NNN)x(CCG)10(NNN)11(CTG)9 
DM1-UC14  (CTG)50 (CCG)5(NNN)x(CCG)10(NNN)8(CTG)4 
DM1-UC1 was not assessed by RP-PCR using the CCG5 repeat specific primer, because there was no DNA left. However, a number of CCG are probably 
present as in DM1-UC2, suggested by a gap in the CTG5 repeat specific RP-PCR that is not filled with CCGCTG.  In DM1-UC12, two normal alleles with sizes 17 
and 5 were genotyped by PCR. Both expanded alleles seemed to amplify well by RP-PCR. It should be investigated why this individual was considered unusual 
and if this individual presents the DM1 phenotype. The only oddity in DM1-UC9 seemed to be a small 10 bp deletion in the flanking DNA at the 3'-end. DM1-
UC13 and DM1-UC14 present other repeat types or arrangements, which remain to be investigated. DM1-UC1 and DM1-UC10 were not investigated by SP-PCR 
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5.2.4 Investigating the degree of somatic mosaicism 
The structure of the DM1 expanded alleles in the unusual cases has been 
characterised in all except for DM1-UC13 and DM1-UC14, for which several 
regions remain to be characterised. The majority of the patients presented 
imperfect CTG repeat alleles, except for DM1-UC9, which contains a 10 bp 
deletion at the 3'-end flanking DNA of the CTG repeats. Taking into account 
the data obtained in other repeat diseases and in the DM1+CMT++ family, it 
could be postulated that the presence of interruptions in the unusual cases 
might also stabilise the CTG repeats. However, could the type and/or 
number of interruptions have a different effect?  
To gain an insight into the dynamics of repeats in different imperfect CTG 
repeat alleles, SP-PCR was performed. More than 100 molecules were 
amplified and sized for each patient.  The length of the progenitor alleles 
and the degree of somatic mosaicism were determined (figure 5-8 and 5-9). 
All the different DM1 expanded alleles were somatically unstable and 
biased toward expansions. DM1-UC13 and DM1-UC14 were investigated by 
SP-PCR analysis, but the dynamics of the expanded alleles was not 
quantified. The expanded alleles in both cases did not amplify as well as 
the normal alleles or the DM1 CTG probe did not hybridise properly. 
Therefore, it was necessary to optimise the technique, but this 
optimization was not initiated due to a lack of time. 
In an attempt to assess the level of somatic variation of the unusual DM1 
expanded alleles, the data was compared with the linear regression 
analysis between the progenitor allele and the somatic mosaicism in classic 
DM1 patients (Morales Montero 2006). However, no obvious differences 
were detected (figure 5-10). It should be pointed out that the age at 
sampling also has an effect in the degree of somatic mosaicism. Due to the 
fact that the age at sampling was not available, no further conclusion could 
be drawn.  
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SP-PCR with DM-A and DM-DR  
 
 
 
SP-PCR with DM-C and DM-BR 
 
Figure 5-8. Somatic mosaicism of several imperfect CTG repeats alleles. For each 
sample, 6 representative SP-PCRs each containing ~15 genomic equivalents of DNA are 
shown. The scale on the right shows the position of the molecular weight marker converted 
into the number of triplets. Claudia Braida, 2008    Chapter 5, 140 
 
 
 
Figure 5-9. Distributions of imperfect CTG repeat alleles in unusual DM1 patients. The 
progenitor allele (PA) and the degree of somatic mosaicism (DSM) are indicated in each 
panel. At least 100 expanded molecules were sized for each patient. In DM1-UC2 two 
different populations of alleles are clearly distinguished. It will be interesting to determine the 
structure of each allele. Claudia Braida, 2008    Chapter 5, 141 
 
 
Figure 5-10. Linear regression analysis between the progenitor allele and the somatic 
variation. Data from classic DM1 patients (Morales 2006) shown in black, data from the 
DM1+CMT++ cases shown in red and data from the unusual cases shown in green. No 
obvious differences were observed between the classic DM1 patients and the unusual 
cases.  
5.2.5 Investigating DNA methylation at the DM1 locus 
All the unusual DM1 cases provide new additional CpG methylation sites 
within the repeat tract, so maybe those sites are methylated. A preliminary 
attempt to investigate DNA methylation in the flanking DNA at the 3'-end of 
the repeat tract was performed with the methylation sensitive enzyme 
HhaI. The first HhaI site located at the 3'-end of the repeat tract is located 
at 218 bp distal to the end of the repeat (figure 5-11A). Genomic DNA was 
digested overnight with HhaI enzyme, following PCR amplification with 
primers DM-C and DM-SR. The HhaI site in the normal allele was expected 
to be unmethylated, so a PCR product should not be detected because the 
enzyme will be able to digest the site.  
As expected, the normal alleles were digested with HhaI and an allele was 
not amplified by PCR. However, it should be pointed out that the normal 
allele of DM1-UC2, DM1-UC3, DM1-UC6, DM1-UC7 and DM1-UC8 was 
amplified slightly in the digested sample. The gels were detected by 
Southern blot hybridisation, which is a very sensitive protocol such that the 
presence of one molecule would be enough to visualise a band on the 
autoradiograph. The expanded alleles of DM1-UC2, DM1-UC3, DM1-UC4, Claudia Braida, 2008    Chapter 5, 142 
 
DM1-UC5 and DM1-UC6 seemed to be methylated, since no difference was 
observed in the intensity of the bands visualised between the digested and 
undigested control. In contrast, the majority of the expanded alleles of 
DM1-UC8 and DM1-UC9 seemed to be unmethylated, since the smear 
present in the undigested control is not reproduced in the digested sample 
(figure 5-11B). It was expected that the expanded alleles of DM1-UC9 would 
not be methylated since the size of the CTG repeats is within the adult 
onset range and the only oddity was a small deletion at the 3'-end. This 
data was consistent with the study of Steinbach and collaborators, where 
only the expanded alleles with sizes ≥1,000 repeats were found to be 
methylated in the flanking DNA (Steinbach, et al. 1998). It would be 
interesting to extend the study and analyse the pattern of DNA methylation 
both within the repeat tract and at more sites at the 3'-end in the flanking 
DNA. The expanded alleles of DM1-UC11, DM1-UC13 and DM1-UC14 failed to 
amplify in the undigested samples. Due to lack of time, these samples were 
not further investigated. Claudia Braida, 2008    Chapter 5, 143 
 
 
Figure 5-11. Methylation pattern at the 3'-end of the repeat tract. A. Schematic diagram 
of the DM1 locus indicating the position of the primers and the HhaI site investigated. B. 
Genomic DNA was digested overnight with HhaI. The digested and undigested products 
were amplified with primers DM-C and DM-SR. The products were resolved on a 1.5% 
agarose gel and detected with the DM1 CTG repeat probe. The size of the marker is 
indicated on the right of the panel.  
5.3 Discussion 
The modified PCR in the presence of 10% DMSO was successful in amplifying 
the expanded alleles, which previously were not amplified by the standard 
reaction, except for the expanded allele of DM1-UC14. The combination of 
RP-PCR with specific primers and sequencing was extremely successful in 
characterising the structure of the DM1 expanded allele in a number of Claudia Braida, 2008    Chapter 5, 144 
 
unusual DM1 patients. The sequencing data verified the sequence 
estimated from the RP-PCR gels, indicating that the primers were 
extremely accurately. The majority of the patients presented with an 
imperfect CTG repeat allele containing a long tract of CTG repeats at the 
5'-end, followed by CCGCTG hexamers and/or CCG repeats, and ending 
with a small number of CTG repeats at the 3'-end. Additionally, DM1-UC2, 
DM1-UC3, DM1-UC5 and DM1-UC6 contained two or three higher order 
repeats units. It would be interesting to investigate the mechanism 
responsible for generating these higher order repeat units. Two patients, 
DM1-UC13 and DM1-UC14, seem to present another type of repeat unit 
and/or arrangement of repeats that still remains to be investigated.  
The intergenerational instability in the imperfect CTG repeat allele from 
DM1-UC1 and DM1-UC10 was investigated. The expanded allele of DM1-
UC10 consists of (CTG)128 (CCGCTG)31 (CTG)58. The foetus of DM1-UC10 
inherited an increased number of CCGCTG from 31 to 119, but a reduction 
in the CTG repeats from 58 to 8 at the 3'-end and from 128 to 105 at the 5'-
end. It should be noted that the increase in CCGCTG is very dramatic in 
comparison to what was observed in the DM1+CMT++ allele, where the 
CCGCTG repeats were stably transmitted. Moreover, it is not comparable to 
what is observed in pure CTG repeats alleles of the same size. Martorell 
and colleagues investigated 700 DM1 families and found that alleles up to 
25 repeats were always stably transmitted (in 1,043 transmissions), 26-37 
repeats gain 1 to 3 repeats (in 84 transmissions), while repeat alleles 
between 38-54 repeats showed dramatic increases in size in the majority of 
males transmissions with gains between 45 to 1120 repeats. Small changes 
were observed in females transmissions (gains of 3 to 7 repeats) and in 
some male transmissions (gains of 3-15 repeats) (Martorell, et al. 2001). 
The fact that DM1-UC10 is a male and the CCGCTG repeats are surrounded 
by CTG repeats could explain the instability of that allele. It may be that 
the threshold is 31 repeats and not 38 repeats as in pure CTG arrays. The 
structure of the imperfect CTG repeat allele of DM1-UC1 has not been 
completely determined, however the level of intergenerational instability 
seemed to be similar to the DM1+CMT++ allele. An increase in the CTG 
repeat at the 5'-end was detected, while the interrupted 3'-end seemed to Claudia Braida, 2008    Chapter 5, 145 
 
be only slightly modified (gain of 5 CCGCTG repeats). A more in depth 
interpretation could be performed once the structure for DM1-UC1 is 
studied in detailed.  
The level of somatic mosaicism was investigated in DM1-UC2, DM1-UC3, 
DM1-UC4, DM1-UC5, DM1-UC6, DM1-UC8 and DM1-UC9. In all cases the 
alleles were somatically unstable. However, no investigation was 
undertaken into which part of the repeat tract was unstable. From the RP-
PCR, it could be suggested that the interruptions seem to be quite stable 
since discrete bands are detected, while the CTG repeats at the 5'-end 
were detected as smears as is consistent with somatic mosaicism. 
Therefore, the CTG repeats at the 5'-end seemed to be unstable as in the 
DM1+CMT++ allele. This interpretation could be easily verified by using 
single molecule separated alleles and RP-PCR analysis.  
Investigation of the mutation mechanisms of minisatellites revealed a gain 
of few repeats units at one end of the tandem array, suggesting a polarity 
effect. The authors postulated that the polarity effect could be caused by 
an element outside the array (Jeffreys, et al. 1994). It is of interest to 
consider that the interruptions identified in the DM1 unusual cases and in 
the DM1+CMT++ allele were always detected at the 3'-end of the repeat 
tract and the unstable part of the array seem to be at the 5'-end. These 
results suggest a mutational polarity as observed in minisatellites. Further 
investigations on the flanking DNA at both ends of the repeat array will 
help to identify putative cis-acting modifiers. 
The pattern of methylation at the 3'-end seemed to depend on the number 
and type of interruptions. Only one single site was investigated at the 3'-
end, but differences were observed. The expanded alleles of DM1-UC2, 
DM1-UC3, DM1-UC4, DM1-UC5 and DM1-UC6 were methylated, whereas the 
expanded alleles of DM1-UC8 and DM1-UC9 were unmethylated. Further 
investigations of the methylation pattern at the 3'-end flanking could reveal 
possible effects on the stability of the repeats.  Claudia Braida, 2008    Chapter 5, 146 
 
A correlation with the genotype and the clinical symptoms in the unusual 
cases would be extremely interesting to determine the effect of 
interruptions on the pathogenesis. It could be postulated that the 
interruptions might decrease the severity of the symptoms. From an 
extended study performed by Morales and colleagues, it was estimated that 
the average progenitor allele associated with adult-onset patients is ~324 
repeats, while progenitor alleles with 485 repeats or more would be 
associated with child-onset or congenital forms. If the unusual cases had 
pure CTG repeat tracts, we could predict that DM1-UC3, DM1-UC4, DM1-
UC5, DM1-UC6, DM1-UC8 and DM1-UC9 have either the child-onset or 
congenital onset forms of the disease since all of them presented 
progenitor alleles with more than 485 repeats. However, the presence of 
imperfect CTG alleles in these patients might decrease the severity of 
symptoms and they might have an adult-onset form of the disease instead. 
Alternatively, it could be postulated that the presence of interruptions 
might alter the phenotype of the disease. In SCA2, intermediate size 
interrupted alleles are associated with Parkinsonism, while pure alleles are 
associated with cerebellar ataxia (Charles, 2007). Similarly, in the 
DM1+CMT++ family, the imperfect CTG allele seemed to be the cause of 
CMT and the other symptomatology. Therefore, it could be postulated that 
a modified phenotype should be expected in the unusual cases with 
interruptions.  
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6  Discussion 
Myotonic dystrophy type 1 is the most common form of muscular dystrophy 
in adults and is caused by an expansion of a (CTG)n repeat located in the 
3’-untranslated region (UTR) of the DMPK gene (Aslanidis, et al. 1992; 
Brook, et al. 1992; Buxton, et al. 1992; Harley, et al. 1992). Normal 
individuals contain between 5 and 35 CTG repeats, which are polymorphic 
and relatively stable. However, if under certain circumstances the number 
of repeats increases, the repeats become dramatically unstable showing a 
higher mutation rate. Longer alleles generally always increase in size when 
transmitted from parent to child, and consequently the child will present 
anticipation characterised by earlier age of onset and an increase in the 
severity of the symptoms (Harper 2001). Nevertheless, in a small 
percentage (< 10%) of transmissions, contractions occur (Ashizawa, et al. 
1994a) and occasionally these contractions can result in reverse mutations 
(Shelbourne, et al. 1992; Brunner, et al. 1993b; Hunter, et al. 1993; O'Hoy, 
et al. 1993; Shelbourne, et al. 1993). Interestingly, in one of the cases of 
reverse mutation, a gene conversion event was suggested (O'Hoy, et al. 
1993). The effects of long CTG repeats on the flanking DNA were 
investigated in E. coli and it was demonstrated that long repeats promote 
deletions and inversions in the flanking DNA, suggesting that similar 
mechanisms could also be present in DM1 patients (Wojciechowska, et al. 
2005).  
The DM1+CMT++ family is a very unusual three-generation family in which 
all the patients co-segregated both DM1 and CMT with the APOC2 on 
chromosome 19 with a maximum LOD score of 7.03 and zero 
recombination. However, both disorders failed to segregate with 
chromosome 1 or 17. It was suggested that DM1 and CMT might be caused 
by a single or two closely linked mutations near the APOC2 marker (Spaans, 
et al. 1986; Brunner, et al. 1991). A fragment equivalent to a small CTG 
expansion (~200-400) at the DM1 locus was detected in the patients by 
Southern blot analysis of restriction digested genomic DNA, but not by PCR. 
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developed hearing loss, migraine and recurrent episodes of acute 
encephalopathy (Spaans, et al. 2008). We postulated that in these patients 
the expanded repeats may have predisposed the repeat tract and the 
flanking regions to further DNA instability, leading to a secondary deletion, 
insertion and/or rearrangement. The expression of DMPK and/or nearby 
genes might be modified by these novel mutations explaining the unusual 
clinical presentation observed in the DM1+CMT++ family. In order to 
identify the molecular lesion in the DM1+CMT++ family, a variety of 
molecular approaches were performed.  
6.1 The molecular lesion in the DM1+CMT++ family  
Previously, it was shown that in the DM1+CMT++ family small expansions 
were detected by Southern blot analysis of restriction digested genomic 
DNA, but it was not possible to amplify across the array using the standard 
approach. This data was confirmed and further investigation of the flanking 
DNA by RP-PCR showed an expanded allele at the 5'-end, but was negative 
at the 3'-end. These data suggested that the additional modification must 
be located at the 3'-end. The most likely explanation was a deletion, which 
could have disrupted one or more genes causing the complex 
symptomatology observed in the DM1+CMT++ family. Therefore, the 
investigation was mainly focused on finding a deletion at the 3'-end. 
However, genotyping several polymorphisms flanking the CTG repeat 
revealed that several individuals presented as heterozygous for many SNPs 
giving evidence against a deletion. Additionally, haplotype analysis 
revealed that the DM1+CMT++ allele was found on the classic DM1 
haplotype. 
At this point, either a rearrangement or an insertion were the two 
remaining possibilities. A breakpoint at the 3'-end was investigated by 
vectorette PCR. Patients' vectorette libraries generated with a variety of 
four, five and six-cutter restriction enzymes failed to detect an expanded 
allele in the DM1+CMT++ family, however the technique was working 
successfully with classic DM1 patients. An attempt with AciI and HhaI, 
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expanded alleles were detected as smears in the DM1+CMT++ family, 
consistent with somatic mosaicism. The DNA from the smear was cloned 
and sequenced. The sequence of the "38" repeat allele (non-pathogenic) of 
III-9 was obtained and consisted of (CTG)5-6 (CCGCTG)14 (CTG)5-6 . Further 
investigations with IV-11 and IV-12 revealed that they both inherited the 
same allele. Additionally, an incomplete sequence of an expanded allele 
from III-16 revealed that it consisted of at least one hexamer (CCGCTG), 
(GGC)2 and a HhaI site within the CTG tract. These results suggested that 
the failure to PCR across the repeat tract might be due to an increase of 
the GC content within the CTG tract. To test this possibility, a modified 
PCR in the presence of 10% DMSO was performed. The expanded alleles 
were finally visualised, confirming that the additional modification was 
indeed an insertion and not a rearrangement. 
6.2 The structure of the DM1+CMT++ allele 
The next step in the project was the characterisation of the interruptions 
in the DM1+CMT++ allele. It was not an easy task, but at the end the 
combination of cloning and sequencing, restriction mapping and RP-PCR 
together with the use of single molecule separated alleles helped us reveal 
the structure of the DM1+CMT++ allele. The allele was comprised of a 
variable number of CTGs at the 5'-end followed by (GGC)3 G (CCG)20 
(CCGCTG)14 (CTG)35. Analysis of single molecule separated alleles revealed 
that the interrupted 3'-end of the array was stable in blood cells of both 
the same patients and between the patients investigated. In contrast, the 
CTG repeats at the 5'-end were unstable. These results suggested the 
interrupted 3'-end was stable, while the CTG repeats at the 5'-end were 
unstable in the soma and in the germline.  
Imperfect CTG repeat alleles were previously reported in four individuals, 
but the presence of those alleles were considered an unique event in DM1 
(Leeflang and Arnheim 1995; Cockburn, et al. 2003). Therefore, finding 
imperfect CTG repeat allele in the DM1+CMT++ family was not expected. 
These results led us to suggest that imperfect CTG repeat alleles may not 
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contain imperfect alleles. Jean-Louis Mandel and colleagues identified a 
number of DM1 sporadic patients with an unusual molecular diagnosis, 
which could also be carriers of imperfect CTG repeats alleles. 
6.3 Imperfect CTG repeat alleles present in several 
DM1 patients with an unusual molecular 
diagnosis 
DNA samples from 14 DM1 patients with an unusual molecular diagnosis 
were investigated in order to further characterise the mutation. The 
majority of the patients presented with an imperfect CTG repeat allele 
containing CCGCTG hexamers and/or CCG repeats (figure 5-7). Two 
patients, DM1-UC13 and DM1-UC14, seem to present another type and/or 
arrangement of repeats, which still remains to be investigated. DM1-UC7 
presented a "41" repeat allele consisting of  (CTG)6 (CCGCTG)15 (CTG)5, a 
structure very similar to the "38" repeat allele of III-9, IV-11 and IV-12. 
DM1-UC2, DM1-UC3, DM1-UC5 and DM1-UC6 contained two or three higher 
order repeats containing between 18 and 30 bp such as ((CTG)5  (CCG)5), 
((CTG)2 (CCGCTG)4) and ((CTG)5 (CCG)2 (CCGCTG))  (table 5-1). DM1-UC9 
presented a pure CTG repeat array with a small deletion of 10 bp at the 3'-
end flanking DNA. These findings further suggest that imperfect CTG repeat 
alleles might not be a rare event, as was believed. It is not known yet how 
many people were screened to identify these unusual cases so the 
frequency of imperfect CTG repeat alleles was not estimated.  
6.4 The repeat dynamics of CTG repeat alleles  
The repeat dynamics of pure CTG repeats have been extensively studied in 
humans and in DM1 mouse models. Normal alleles containing up to 37 CTG 
repeats are generally stable, however alleles with more than 50 CTG 
repeats are highly unstable. Increases in the length of these unstable 
alleles are observed when transmitted from parent to child, resulting in 
anticipation (Harper 2001). As the number of CTG repeats increases, the 
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the instability; short expansions are generally more unstable when 
transmitted by the father, while long expansions are more unstable when 
transmitted by the mother. The congenital cases are almost always 
transmitted by adult-onset mothers (Brunner, et al. 1993a; Harley, et al. 
1993; Lavedan, et al. 1993; Ashizawa, et al. 1994b; Jansen, et al. 1994).  
Somatic mosaicism has been investigated in different tissues and in repeat 
samples obtained over one and seven years. Expanded alleles are always 
longer in skeletal muscle than in lymphocytes (Anvret, et al. 1993; 
Ashizawa, et al. 1993; Thornton, et al. 1994; Monckton, et al. 1995) and 
always increase in length with the age of the individual (Wong, et al. 1995; 
Martorell, et al. 1998). Therefore, it was postulated that the somatic 
mosaicism in pure CTG repeats is expansion-biased, age-dependant and 
tissue-dependant.  
6.4.1 Germline instability of imperfect CTG repeat alleles 
There was no previous knowledge regarding the repeat dynamics of 
imperfect CTG repeat alleles, so our next aim was to investigate the 
dynamics of imperfect CTG repeats by SP-PCR.  
III-16 and III-17, both adult-onset mothers, transmitted the DM1+CMT++ 
allele to their sons and daughters, providing an opportunity to investigate 
the germline instability of imperfect CTG repeat alleles. Adult-onset 
mothers carrying 100 CTG repeats have a 62% chance of transmiting a large 
expansion to their child resulting in the congenital form of the disease 
(Redman, et al. 1993). Despite the high risk of transmitting long alleles, 
both III-16 and III-17 transmitted small increases in the number of CTG 
repeats (~43 CTG repeats) at the 5'-end on two occasions (IV-19, IV-20 and 
IV-21 and IV-22, respectively). These results provided the molecular 
explanation for the slight anticipation observed between the third and 
fourth generation.  
Both individuals (I-6 and I-9) in the first generation were asymptomatic. 
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DM1 and CMT. A decrease in the age of onset and a reduction in the 
severity of the DM1 symptoms were observed between the second and third 
generations. Unfortunately, there is no DNA available to investigate the 
DM1 locus in the second or first generation. However, it could be 
postulated that the number of CTG repeats must have increased between 
the first, second and third generations, respectively. The progenitor alleles 
of III-9, III-16 and III-17 had different sizes.  III-9 inherited 225 repeats, III-
16 inherited 170 repeats, and III-17 inherited 179 repeats. These data 
suggest that the alleles were not stably transmitted. It could be postulated 
that either I-6 or I-9 must have carried an intermediate size allele. 
Although the size may have been insufficient to cause a phenotype, the 
allele could have been unstable in the germline. Assuming that the 
dynamics of imperfect CTG repeat alleles are similar to the dynamics of 
pure alleles, probably the father (I-1) carried an interrupted 3'-end allele 
containing less than 50 CTGs at the 5'-end, since shorter alleles are more 
unstable when transmitted by males.  
A polarity effect has been observed; the CTG repeats at the 5'-end of the 
repeat array were always unstable, whereas the interrupted 3'-end was 
stable through transmissions. Similar polarity effects were described for 
fragile X syndrome (Eichler, et al. 1994; Zhong, et al. 1995; Kunst, et al. 
1997), SCA2 (Choudhry, et al. 2001) and on minisatellites (Jeffreys, et al. 
1994). In fragile X syndrome, the polarity is observed at the 3'-end of the 
repeat tract (relative to transcription orientation), while the instability in 
SCA2 is observed at the 5'-end. In this project, the polarity effect was 
observed at the 5'-end as in SCA2. A flanking element was suggested to 
cause a polarity effect. Two possible mechanisms could mediate the effect. 
One of these mechanisms postulates that the flanking effect is mediated by 
an element that causes  double strand breaks at a distal site (Jeffreys, et 
al. 1994). The second mechanism postulates that the position of the 
nearest replication origin is the flanking effect, which causes a difference 
in the mutation rates between the leading and lagging strand containing 
long repeat arrays during replication (Richards and Sutherland 1994). In the 
DM1+CMT++ allele, the presence of interruptions at the 3'-end are probably 
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repeats at the 5'-end. Recently, we obtained a sperm sample from IV-21, so 
investigations into the repeat dynamics in the sperm DNA will provide a 
better understanding of the characteristic of germline instability in 
imperfect CTG repeat alleles. 
A primary characterisation of the dynamics of germline instability in two 
unusual cases was performed. The expanded allele of DM1-UC10 consists of 
(CTG)128 (CCGCTG)31 (CTG)58, however DM1-UC11 inherited a different allele 
(CTG)105 (CCGCTG)119 (CTG)8.The CTGs at both ends were reduced and the 
CCGCTG repeats increased dramatically. This finding is in contrast to the 
DM1+CMT++ allele, where the interrupted end was stably transmitted and 
only slight increases in the CTG repeats at the 5'-end was observed. Pure 
CTG repeat alleles containing 31 repeats are relatively stable, however it 
could be possible that the threshold for CCGCTG repeats is lower. 
Alternatively, the presence of CTG repeats surrounding the CCGCTG 
repeats could have an effect on the instability. DM1-UC1 contains an 
imperfect CTG repeat allele, which probably consist of (CTG)48 (CCGCTG)17 
(CTG)14. The structure of the imperfect CTG repeat allele of DM1-UC1 has 
not been completely verified because there was no more DNA left. DM1-
UC1 is the mother of DM1-UC2 and she transmitted an imperfect allele to 
her son. The expanded allele of DM1-UC2 consist of (CTG)222 (CCG)5 ((CTG)5 
(CCG)5)2 (CCGCTG)22 (CTG)14. It could be suggested that the level of 
intergenerational instability is similar to the DM1+CMT++ allele. Apparently, 
the CTG repeat at the 5'-end increases, while the interrupted 3'-end 
seemed to be only slightly modified (a gain of 5 CCGCTG repeats). The 
presence of CCG repeats were not investigated in DM1-UC1, but the RP-PCR 
data with CTG and CCGCTG repeat specific primers suggest that other 
repeats units are present between the CTG repeats at the 5'-end and the 
CCGCTG repeats. Future investigations will reveal the complete structure 
of DM1-UC1 and a better analysis will be performed. 
6.4.2 Somatic instability of imperfect CTG repeat alleles 
The CTG repeats at the 5'-end in the DM1+CMT++ allele in blood cells were 
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analysis of repeat blood samples from IV-21 with a time interval of 8 years 
revealed a statistically significant increase in the level of somatic variation 
(figure 4-14). However, no statistically significant differences were 
observed in repeat samples from III-9 and III-16 over 3 and 4 years, 
respectively. IV-21 was sampled at 22 and 30 years old; in contrast III-9 and 
III-16 were sampled after 50 years old. It could be possible that the effects 
were not as dramatic as IV-21 because of their age. To investigate this 
further, it would be interesting to analyse the instability of III-9 and III-16 
over a longer time period. Nevertheless, it could be postulated that the age 
effects are probably not as dramatic as in pure CTG repeats. This 
hypothesis could be further investigated if several repeat samples are 
obtained.  
To determine if the interrupted 3'-end affects the degree of somatic 
mosaicism of the CTG repeat at the 5'-end, the data from the DM1+CMT++ 
cases was compared with a previous study. Morales performed a study in 
more than one hundred DM1 patients and revealed that ~66% of the 
variation in the somatic mosaicism is caused by complex interactions 
between the progenitor allele length and the age at sampling (General 
Linear Model Anova, r = 0.81, p =0.005) (Morales 2006). The somatic 
mosaicism in the DM1+CMT++ was estimated using the model obtained by 
Morales. The values estimated were always higher than the values 
observed, except for IV-19 and IV-22 from whom a small decrease was 
obtained (table 4-3). These results suggested that the presence of 
interruptions at the 3'-end of the repeat array probably decreases the 
instability of the CTG repeats at the 5'-end.  
The level of somatic mosaicism in blood cells was investigated in DM1-UC2, 
DM1-UC3, DM1-UC4, DM1-UC5, DM1-UC6, DM1-UC8 and DM1-UC9. In all 
cases, the alleles were somatically unstable. However, it was not 
determined which part of the repeat tract was unstable. From the RP-PCR, 
it could be suggested that the interruptions seem to be quite stable since 
discrete bands are detected, while the CTG repeats at the 5'-end were 
detected as smears on bulk DNA consistent with somatic mosaicism. 
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DM1+CMT++ allele. This interpretation should be verified by using single 
molecule separated alleles and RP-PCR analysis.  
6.5 Possible mechanisms of genetic instability in 
imperfect CTG alleles  
The finding of a number of DM1 patients with imperfect CTG repeats alleles 
lead us to ask several questions. How do higher order repeats expand? How 
do pure CTG repeat arrays acquire novel repeat units and how do the novel 
repeats spread? Can the imperfect CTG repeat alleles be traced to an 
ancestral mutation, as is observed for the pure CTG repeat alleles, or have 
the interruptions arisen by multiple de novo mutations? 
The mechanisms of genetic instability of triplet repeats are not yet 
completely understood. Initially, it was proposed that the expanded 
repeats form unusual alternative structures, which may interfere with the 
normal cell processes such as replication, repair and transcription. The 
presence of these unusual structures in the DNA has been demonstrated in 
vitro, but there is still no evidence that these structures are formed in vivo 
(Wells 1996; McMurray 1999; Sinden, et al. 2002). Replication slippage was 
one of the favourites mechanism postulated. However the fact that cells 
that do not undergo replication (i.e. muscle and brain) present sometimes 
higher levels of instability lead to postulate that probably replication 
slippage was not the principal mechanism involved (Anvret, et al. 1993; 
Ashizawa, et al. 1993; Thornton, et al. 1994; Kennedy, et al. 2003). 
Subsequently, the mechanism of mismatch repair becomes the most 
plausible explanation. Investigations with knock-out mouse models revealed 
that indeed MSH2, MSH3 and PMS2, proteins involved in the mismatch 
repair might be directly involved in the generation of instability (Manley, et 
al. 1999; van den Broek, et al. 2002; Savouret, et al. 2003; Wheeler, et al. 
2003; Gomes-Pereira, et al. 2004b).  Mismatch repair is involved in 
repairing insertion-deletion loops outs up to 12-16 bp (Bellacosa 2001; 
Schofield and Hsieh 2003) and single base-base mismatches. However, 
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higher order repeats containing between 18 and 30 bp in DM1-UC2, DM1-
UC5, DM1-UC6, DM1-UC8 (figure 5-7). 
The size of the higher order repeats observed in the patients is comparable 
to minisatellites so probably we could infer that the mechanisms involved 
in the instability of minisatellites might cause the instability. Postulated 
mechanisms involved in genetic instability of minisatellites are: gene 
conversion and crossover events between sister chromatids (Jeffreys, et al. 
1994).  Studies on S. cerevisae have revealed that large loops mismatches 
are mainly repaired by a mechanism dependant on mismatch repair 
proteins (MSH2 and PMS1) (Clikeman, et al. 2001). In contrast studies on 
human nuclear extracts revealed that the mechanism is independent of 
mismatch repair and is directed by a single strand break at the 5'-end of 
the loop (Littman, et al. 1999). It is not clear if the loops are retained, lost 
or maybe is an equilibrium between the two. A polarity effect has been 
noticed in the instabilities of imperfect CTG repeat alleles, therefore the 
repair mechanism independent of mismatch repair directed by the 5'-end 
strand break seems a plausible mechanism to explain how the higher order 
repeats expand.  
It will be interesting to analyse how pure CTG repeats acquire novel 
repeats. In fragile X syndrome interruptions are present in normal alleles 
and then the interruptions are lost when the alleles expand. It was 
postulated that either a deletion or a transversion event could explain the 
loss of interruptions (Eichler, et al. 1994).  It could be postulated that a 
similar mechanism could explain the presence of novel repeats. A base 
substitution from T to C could be generated. Three possible mechanisms 
could cause base substitutions: a polymerase error during replication or 
during mismatch repair or by chemical damage. Long CTG repeats are 
probably more prone to errors than other regions because: are difficult 
regions for the polymerase to process, and can form secondary structures, 
which can be more sensitive to chemical damage. Another aspect of the 
instability is how can we explain the substitution spreading to generate 
several copies of the novel repeat units? Smith postulated that higher order 
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unequal crossover between sister chromatids (Smith 1976). Misalignment 
could occur between sister chromatids, via double-strand breaks, 
chromatid invasion, and intraallelic gene conversion. A series of these 
events could result in sequence homogenization, generating the spreading 
of the novel repeats detected in the patients (figure 6-1).  
 
Figure 6-1. Possible mechanism involved in the spreading of novel repeat units. A 
single base substitution must occur first. Subsequently, unequal crossover between sister 
chromatids could result with time in sequence homogenisation. A similar mechanism could 
be involved in generating the array of novel repeat units detected in the patients. 
The DM1 mutation is associated with a conserved haplotype. Nine 
polymorphic sites were investigated to define the haplotypes in III-9, IV-11, 
IV-12, III-16, IV-19, IV-20, III-17 and IV-21. It was revealed that the 
DM1+CMT++ allele was present on the DM1 classic conserved haplotype 
(figure 3-11).  Similarly, analysis revealed that the imperfect CTG repeat 
alleles of DM1-UC1, DM1-UC2, DM1-UC4, DM1-UC11, DM1-UC13 and DM1-
UC14 (data not shown) are also associated with the classic DM1 haplotype. 
There are two possibilities the imperfect CTG alleles and the pure CTG 
alleles diverged on two different haplotypes or on the same more recently 
evolved derived haplotype. An analysis of several distal polymorphisms will 
reveal if there is an extended haplotype or not (figure 6-2). Claudia Braida, 2008    Chapter 6, 158 
 
 
Figure 6-2. Two possible phylogenetic trees. Horizontal lines represent the size of the 
haplotypes, P (pure CTG repeats alleles), I (interrupted CTG repeat alleles) A. Interruptions 
are generated by de novo mutations, there are no extended conserved haplotypes. B. 
Interruptions evolving on a common haplotype, patients with interruptions will present more 
extended haplotypes than patients with pure CTG repeats. 
In this project two size ranges of imperfect CTG repeat alleles were 
identified: non-pathogenic alleles containing up to "40" triplet repeats and 
pathogenic alleles with more than "150" triplet repeats. How can we 
explain the formation of these two range of repeats? It could be postulated 
that the normal imperfect CTG repeat alleles expand to generate the 
expanded alleles or alternatively the expanded alleles suffer contractions 
originating the normal alleles. In pure CTG repeats, normal alleles expand 
in a process of multiple steps generating expanded alleles. In contrast, in 
imperfect CTG repeat alleles the most likely explanation seems to be a 
contraction. The structure of the normal imperfect allele consists of (CTG)5 
(CCGCTG)14 (CTG)5. The 5 CTG repeats at both ends are extremely stable 
and to date no expansions have been detected. The 14 CCGCTG repeats 
seem to be relatively stable, no changes were detected in the patients 
investigated in this project. Additionally, the stability of the complete 
structure was demonstrated to be comparable to a "27" pure repeat allele 
(Leeflang and Arnheim 1995). Taking into account all this, there is no 
reason to believe that this allele will be unstable. In the patients 
investigated the pathogenic alleles contain long CTG repeats at the 5'-end, 
so the most plausible explanation is that long alleles acquire interruptions 
at the 3'-end and subsequently the 5'-end suffer a contraction, as is has 
been described for pure CTG repeat alleles (Ashizawa, et al. 1994a). 
Therefore, the non-pathogenic imperfect alleles are most likely secondary 
products of long interrupted alleles. Claudia Braida, 2008    Chapter 6, 159 
 
6.6 Possible mechanisms of pathogenesis in the 
DM1+CMT++ family 
The molecular lesion causing the complex phenotype observed in the 
DM1+CMT++ family seems to be an imperfect CTG repeat allele. It could be 
argued that maybe the CMT is caused by a mutation in ARCMT2B locus or 
PRX or DNM2 genes associated with three forms of CMT also located in the 
chromosome 19. However, it will be extremely unlikely that 14 affected 
individuals carry an imperfect CTG allele together with a mutation in one 
of these loci. Additionally, a two-mutation model would not be able to 
explain the absence of symptoms in the first generation. Therefore, we are 
convinced that the only molecular lesion in the family is an imperfect CTG 
repeat allele. A confirmation of our theory will not be obtained unless a 
screen for mutations is performed in the whole linked region, but at the 
moment it will not be cost-effective.  
One of the questions that arise is how an imperfect CTG repeat allele could 
cause a complex symptomatology. It could be assumed that the expanded 
CTG repeats are responsible for the DM1 symptoms by an RNA gain-of-
function mechanism as in classic DM1 patients. However, how the presence 
of an imperfect CTG repeat allele could also be responsible for the CMT, 
hearing loss and acute encephalopathy symptoms is not known. Possible 
mechanisms include a novel RNA gain-of-function, and/or a novel effect on 
the downstream genes. 
The DM1+CMT++ allele contains an interrupted 3'-end containing GGC, CCG 
and CCGCTG repeats. The presence of these novels repeat units in the 
DMPK transcript probably alters its secondary structure and in consequence 
novel proteins may be trapped and a novel phenotype could be expressed 
by analogy to what happens in fragile-X associated tremor/ataxia syndrome 
(FXTAS). FXTAS is a neurodegenerative disorder caused by premutation 
alleles (55<CGG<200) in the FMR1 gene. The phenotype and the 
pathogenesis are completely different to fragile X syndrome (Hagerman, et 
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2003; Hagerman and Hagerman 2004). An RNA-gain of function model 
similar to the one postulated for DM1 and DM2 was postulated (Willemsen, 
et al. 2003). Investigations in FXTAS patients biopsies revealed the 
presence of ubiquitin-positive intranuclear inclusions containing FMR1 
mRNA in neurons and astrocytes of patients (Greco, et al. 2002; Tassone, 
et al. 2004). Proteins associated with different forms of CMT such as a 
number of neurofilaments and lamin A/C proteins were identified in the 
inclusions. In addition MBNL1 one of the RNA binding proteins interacting 
with the CNG repeat, which is recruited in DM1 and DM2 nuclear foci also 
co-localised in the intranuclear inclusions (Iwahashi, et al. 2006).  
In Drosophila it was shown that 90 CCG repeats or 90 CGG repeats cause a 
neurodegenerative phenotype with nuclear inclusions similar to the 
phenotype caused by CGG repeats in FXTAS (Sofola, et al. 2007). It could 
be postulated that the CCG repeats present in the DM1+CMT++ allele might 
recruit neurofilaments and lamin A/C proteins explaining the CMT 
symptoms observed in the DM1+CMT++ family.  However, the number of 
CCG repeats in the DM1+CMT++ allele is less than the threshold (55 CGGs) 
in FXTAS patients. So how can we explain that 20 CCGs will be sufficient to 
cause a phenotype? It is not known why at least 55 CGGs are required to 
have deleterious consequences in the cells, maybe this reflect a threshold 
for the transcript to be trapped in the nucleus. In DM1 it was demonstrated 
that the overexpression of the 3'-UTR of the DMPK transcript containing 11 
CTGs has a negative effect on myogenesis and in the presence of expanded 
CUG repeats the effect is enhanced (Sabourin, et al. 1997; Storbeck, et al. 
2004). Additionally, it was demonstrated that the overexpression of the 
3'UTR containing 5 CTGs repeats in mice was sufficient to reproduce 
myotonia, cardiac conduction defects and RNA splicing defects observed in 
DM1 (Mahadevan, et al. 2006). In the DM1+CMT++ family the transcripts will 
be retained in the nucleus for the large number of CTG repeats, so it could 
be that the presence of just 20 CCGs trapped in the nucleus is sufficient to 
cause a phenotype. 
The localisation and the composition of the nuclear foci in DM1 and FXTAS 
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of nuclear splicing speckles and containing mainly MBNL proteins and the 
mutant transcripts (Taneja, et al. 1995; Davis, et al. 1997; Miller, et al. 
2000; Fardaei, et al. 2001; Holt, et al. 2007). In FXTAS the foci are diffuse 
and contain the mutant transcripts with a number of proteins, at least 
more than 20 different proteins were identified (Greco, et al. 2002; 
Iwahashi, et al. 2006). The presence and characteristics of RNA nuclear foci 
will be investigated using a lymphoblast cell line from IV-21. Additionally, 
by imunohistochemistry the presence of neurofilaments and lamin A/C 
could be tested. 
In DM1 the RNA gain-of-function model proposed that the decrease of MBNL 
and the increase of CELF proteins cause a misregulation of the alternative 
splicing (Ho, et al. 2004). A number of pre-mRNAs were shown to present 
defects in the alternative splicing including: TNNT2 (Philips, et al. 1998), IR 
(Savkur, et al. 2001), CLCN1 (Charlet, et al. 2002; Mankodi, et al. 2002), 
brain microtubule-associated tau (Sergeant, et al. 2001) and MTMR1 (Buj-
Bello, et al. 2002). It will be interesting to investigate the localization of 
MBNL and CUGBP and investigate if the splicing defects observed with 
expanded pure CTG repeats are also reproduced in imperfect CTG repeat 
alleles. 
The symptoms of acute encephalopathy and migraine resemble symptoms 
observed in disorders such as: familial hemiplegic migraine type 1 (FHM1) 
and 2 (FHM2), cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) or acute confusional migraine 
(ACM). FHM1 can be caused by mutations in the calcium channel gene 
(CACNA1A) (Ophoff, et al. 1996), FHM2 by mutations in a gene encoding 
the alpha-2 subunit of the sodium/potassium pump (ATP1A2) (De Fusco, et 
al. 2003) and CADASIL by mutations in NOTCH3 (Joutel, et al. 1996). It 
could be postulated that these symptoms maybe caused by the loss of 
proteins, which are trapped in the nucleus or by defects in alternative 
splicing. However neither DM1 nor CMT patients present with migraine 
and/or acute encephalopathy. Three MBNL proteins have been described to 
co-localise in the DM1 loci (Fardaei, et al. 2002), it could be that the 
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MBNL proteins, and the levels are affected. Additionally, several CELFs 
have also been identified (Ladd, et al. 2001) and novel effects can also be 
caused by the combination of CUGs and CCGs trapped in the nucleus. This 
may have novel effects on the splicing of different premRNAs. 
Alternatively, the combination of both type of repeat might recruit novel 
proteins.  Further investigations of the characterisations of the nuclear foci 
could reveal the mechanism. It will be more difficult to explain how the 
patients developed hearing loss, since mutations associated with hearing 
loss have been identified in more than 20 different genes (Finsterer and 
Fellinger 2005). 
The second possible mechanism generating pathogenesis in the DM1+CMT++ 
family could be a novel effect on the downstream genes. It was postulated 
that the expansion of pure CTG repeats in the DM1 locus alters the 
adjacent chromatin structure establishing a region of condensed chromatin 
in consequence the transcription the DMPK gene and/or neighbouring genes 
might be repressed (Wang, et al. 1994; Otten and Tapscott 1995). The CTG 
repeats in the DM1 locus are inserted in a CpG island, which controls the 
activity of the downstream gene SIX5 (Boucher, et al. 1995). In DM1 
congenital cases the CpG island is hypermethylated and the expression of 
SIX5 is repressed. This repression might be a molecular explanation for the 
increase severity detected in congenital cases (Steinbach, et al. 1998). The 
interruptions in the DM1+CMT++ allele provide new CpG sites, of which at 
least some seemed to be methylated (section 4.2.6). It could be postulated 
that the pattern of methylation could be extended to the CpG island as in 
congenital DM1 cases; or alternatively, by analogy to the mechanism 
observed in FXTAS, the CpG island may remain unmethylated and the level 
of SIX5 transcription increased (Tassone, et al. 2000b). It could be argued 
that between these two possibilities the most likely explanation will be a 
increase in the levels of SIX5 since the DM1 symptoms in the DM1+CMT++ 
family are not as severe as in congenital cases. To test which mechanism is 
involved, the pattern of methylation within the interruptions and in the 
flanking DNA will be further investigated with other methylation sensitive 
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In the other unusual cases, the pattern of methylation at the 3'-end seemed 
to depend on the number and type of interruptions. Only one single site 
was investigated at the 3'-end, but differences were visualised, the 
expanded alleles of DM1-UC2, DM1-UC3, DM1-UC4, DM1-UC5 and DM1-UC6 
were methylated, whereas the expanded alleles of DM1-UC8 and DM1-UC9 
were unmethylated. Further investigations will be necessary to understand 
the possible effects of methylation on the activities of DMPK and SIX5. 
A correlation with the genotype and the clinical symptoms in the unusual 
cases would be extremely interesting to determine the effect of 
interruptions on the pathogenesis. It could be inferred that in the majority 
of the cases the presence of interruptions decreases the severity of the 
symptoms if we take into account that the progenitor allele is quite high 
for DM1 patients with the adult onset form. Additionally, it could be 
postulated that these unusual cases probably present a modified phenotype 
since the structure of the imperfect CTG repeat alleles resembles the 
DM1+CMT++ allele. Further analysis will be performed once our 
collaborators provide us with more details of the phenotype of the unusual 
cases. 
An increase in the severity of symptoms and a reduced age of onset was 
observed in the CMT phenotype through the generations in the DM1+CMT++ 
family. If CMT is caused by the presence of interruptions, the anticipation 
observed between the third and fourth generation could be explained by 
the small changes in the number of CTG repeats at the 5'-end. It could be 
possible that slight changes in the number of CTG repeats at the 5'-end are 
sufficient to enhance the effects of the CCG. Alternatively, it could be 
explained by a toxicity effect caused by the high concentration of mutant 
DMPK transcripts in the nucleus. It will be necessary to demonstrate first 
that the interruptions are definitely the cause of CMT to subsequently test 
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6.7 Concluding remarks 
In summary, this project has revealed that imperfect CTG repeat alleles 
are present in DM1 patients. Therefore, this fact should be taken into 
consideration when performing the molecular diagnosis of DM1, because 
false negatives obtained by PCRs and/or RP-PCR may be explained by 
imperfect CTG repeat alleles. A number of DM1 patients present with a 
disease that is not as severe as expected for the number of repeats, and 
the presence of imperfect CTG repeat alleles could be a possible 
explanation for this discrepancy. 
A better characterisation of the mutation in DM1 patients could lead in the 
future to the provision of more accurate prognosis. In addition to the 
considerable value of more accurate prognosis to individual families, these 
data will also facilitate clinical trials once therapies become available. 
More accurate genotype to phenotype data will reduce un-attributable 
variation within groups (treated versus placebo) and offer an enhanced 
ability to detect the effect of the drug. In particular, it will be necessary to 
investigate the presence of imperfect CTG repeat alleles in the DM1 
patients in order to achieve a better characterisation.  
Finally, the findings of this project can have more general implications. 
Imperfect alleles could also be present in other repeats diseases caused by 
dynamic mutations from which interruptions have not yet been considered. 
In those diseases such as fragile X syndrome, which are known to present 
interruptions, the interruptions are presented in the normal alleles. 
However, in a number of other diseases such as Huntington disease, only a 
small number of expanded alleles have been sequenced to date and no 
interruptions have been found, so it has been assumed that the expanded 
repeats are pure as is the case with DM1. The results from our project 
suggest that further investigation should be undertaken to test this 
assumption. Should interruptions be present in diseases such as HD, the 
presence of interruptions might have a modifier effect on the pathogenesis 
not only the severity of the symptoms but also in the age of onset, as it was 
demonstrated in SCA1, SCA2, SCA10, SCA17 and in our project (Chong, et Claudia Braida, 2008    Chapter 6, 165 
 
al. 1995; Zuhlke, et al. 2002; Matsuura, et al. 2006; Charles, et al. 2007; 
Gao, et al. 2008). Additionally, it could be possible that families with 
Charcot-Marie-Tooth disease with an unknown aetiology may be carriers of 
CCG or GGC expanded repeats as well. 166 
 
Appendices 
Appendix A: sequencing chromatogram showing a region of good sequence 
with little baseline noise and very strong peaks.  
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Appendix B: sequencing chromatogram showing a region with a noisy 
sequence.  
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